This book is protected by copyright. All rights including those regarding translation, reprinting and reproduction reserved. No part of this book covered by the copyright hereon may be processed, reproduced, and proliferated in any form or by any means (graphic, electronic, or mechanical, including photocopying, recording, taping, or via information storage and retrieval systems, and the Internet).
ISBN: 978-3-928383-96-7
Editorial
A rebound worth building on
Germany has reaffirmed its role as one of Europe’s strongest biopharma hubs in 2025, hosting over 3,800 companies across biotech, pharma, and medtech1. The industry’s momentum is remarkable: biotech firms raised nearly €2 billion in 20242 (a 78% yearon-year jump) and pharmaceutical sales surpassed €55 billion, marking a steady 8% annual growth. Just before we went to print with this report, Munich-based Tubulis announced a €308 million Series C round — the largest ever for a European biotech at that stage and the world’s biggest financing for a private ADC developer — further highlighting the investment confidence driving Germany’s biotech ecosystem.
Germany’s biopharma pipeline remains robust, with a record 169 biotech clinical trials underway in 2024/25, the most in the industry’s history. These include cutting-edge mRNA vaccines, cell therapies, and antibody drugs progressing through Phase II and III studies.
BioNTech also marked 2025 by acquiring its long rival CureVac for $1.25 billion, thereby uniting Germany’s mRNA pioneers. German pharma giant Merck KGaA also made headlines this year when it agreed to buy U.S. biotech company SpringWorks Therapeutics for $3.9 billion, in a move to strengthen its oncology portfolio ahead of looming patent expiries.
Germany’s biopharma manufacturing base continues to expand through strategic collaborations and investments. Ethris has joined forces with Thermo Fisher and Evonik to scale up its inhaled mRNA platform, while BioSpring GmbH is breaking ground on a new large-scale DNA/RNA manufacturing facility in Offenbach that will rank among the world’s biggest sites for oligonucleotide and mRNA production. Meanwhile, Evotec’s “Priority Reset” initiative, launched last year to increase profitability, is already yielding strong results in the first half of 2025.
The German biotech scene is thriving, but not everything is sunshine and roses. U.S. political volatility continues to unsettle the German biopharma sector, as shifting tariff threats and frequent reversals from Washington keep reshaping expectations for export costs and supply chains.
The overall outlook for 2026 is one of cautious optimism: Germany’s biopharma industry is balancing bold scientific progress and deal-making with a more challenging global political climate. The global biopharma story is still being written, and if you’re part of the German ecosystem, you’ll be right in the middle of what comes next.
Joachim
Eeckhout
CEO 1 Life Science Trend Analysis Germany 2025, Biotech Gate
2 German Biotechnology Report 2025, EY and BIO Deutschland
The German Biotechnology Sector 2025
Germany’s biotechnology sector demonstrates significant innovative potential. At the same time, it is facing considerable challenges in 2025, particularly in light of major upheavals in the United States – previously the sector’s most important global reference market. Germany has long been criticised for the comparatively slow pace at which innovations are translated into marketable products. The sector is also constrained by underfunding, excessive bureaucracy, and suboptimal political conditions, particularly for biotech investors. These structural issues have now been compounded by geopolitical disruptions following the end of the pandemic-driven biotech boom. Factors include the ongoing war in Ukraine, the conflict in Gaza, and new US-imposed tariffs on imports of prescription medicines and high-tech products – measures introduced in 2025 that are not compliant with World Trade Organization (WTO) rules. These developments have increased supply chain volatility and raised business risks for both SMEs and large enterprises.
Mounting pressure on German biotechnology sector
The US administration’s “Make America Great Again” (MAGA) policy and the associated isolation of the American biotech market from foreign players pose a direct threat to the value creation of German biotech firms – particularly in medical biotechnology, which ac -
counts for approximately 50% of sector activity in Germany. The sector relies heavily on financing, partnerships, and exit opportunities in the USA.
According to the 9th German Biotech Report 2025 by EY and BIO Deutschland, Germany is less resilient to growing international pressure than countries that have more advanced financing ecosystems. Moreover, potential industrial partners in Europe are themselves under considerable cost pressure due to the US import tariffs introduced in mid-2025 – 15% for EU-based imports and 39% for Swiss products – which are diminishing their margins. Unlike EU biopharma companies, medicines exported from Switzerland to the United States were not subject to the tariffs imposed on many sectors up to the end of September 2025, according to scienceindustries. A final ruling by the US Federal Court is expected in October 2025 on whether US$100bn in tariffs imposed by US President Donald Trump are lawful or must be reimbursed.
In addition, structural changes in the global biopharmaceutical value chain are expected during the second term of US President Donald Trump, which began in January 2025. In particular, Trump’s announced significant reduction in drug prices in the US threatens revenues and, consequently, the long-term investment planning of ex-US pharmaceutical companies, which
Key figures of the biotech sector in Germany
currently generate more than 50% of their global revenue from prescription medicines in the US. Due to uncertainty over whether the existing value chain will remain intact, the major economic blocs – the US, China and the EU, with Germany as its strongest economy – are working intensively to strengthen their economic resilience, particularly in strategic key technologies such as biotechnology. However, Europe and Germany are less competitive than the US and China, especially in terms of technology transfer.
Despite retaining a world-class scientific foundation, Germany continues to lose talent, intellectual property, and high-potential developments to other countries, especially the US, due to comparatively poor domestic conditions for financing, development, commercialisation, and exit.
R&D investment
The number of German biotech companies (excluding their 216 international subsidiaries, first reported in 2004) rose by 2.2% to 804 in 2024. Including subsidiaries, the total stands at 1,020. New company foundations increased significantly, with 39 recorded in 2024 compared to 24 the previous year (+63%). Domestic R&D investment rose to €4.316bn in 2024, an increase
of 3.5% from €4.17bn in 2023. Including subsidiaries, the increase was 4%.
Workforce
After years of continuous employment growth, the domestic biotech workforce declined in 2024, falling from 47,140 to 43,845 employees (–7%). In contrast, employment at foreign subsidiaries rose from 11,872 in 2023 to 12,248 (+3.1%).
Revenues
German biotech companies – both private and publicly listed – generated €9.976bn in revenue in 2024. Including subsidiaries, the total was €10.8bn, down 8% from €10.979bn in 2023. However, this remains twice the level recorded before the COVID-19 pandemic. Globally, revenues of publicly listed companies in Europe and the US each grew by 7%, totalling US$205bn.
Financing
External financing of German biotech companies rose by 78% to €1.9bn in 2024 compared to the previous year – double the amount recorded in the pre-pandemic year 2019 (€896m). Higher values were only achieved during the COVID years of 2020 and 2021.
Venture capital investment in SMEs rose markedly to €898m (2023: €533m). Publicly listed companies secured €999m (+€546m), largely driven by a convertible bond issued by Qiagen worth €453m and the Initial Public Offering of Eckert & Ziegler spin out company Pentixapharm, which raised €20m. The largest VC round in Europe was secured by Garching-based radioisotope specialist ITM (€188m), followed by cancer immunotherapy firm CatalYM (€137.8m) in fourth place, and ADC developer Tubulis GmbH (€128m) in seventh.
Medical biotech raised most VC
Of the €898m in venture capital, 71% (€640m) was directed to medical biotechnology. As other biotechnology markets are also maturing, about 23% (€207m) went to agri-, food, and industrial biotech applications – a 345% increase over 2023 (€60m). Most money flew into the industrial and food biotech sector as of mid-2025, while novel agribiotech applications remain blocked in Europe due to regulatory constraints. Contract research and manufacturing organisations as well as life science research companies received €40m (4.4%), while diagnostics companies raised €11m (1.2%).
Fragmentation
In contrast to the US, China, the UK and Switzerland, Germany has no internationally visible biotech cluster. The resulting fragmentation makes it more difficult for investors to identify profitable opportunities in Germany. Bavarian
SMEs accounted for 68% (€613m) of the total VC funding, followed by firms in Berlin-Brandenburg and Hamburg. By contrast, in clinical development, companies based in Rhineland-Palatinate were in the lead with 49 studies, followed by Bavaria (38) and Baden-Württemberg (33).
Competitiveness
Despite improvements, German biotech companies attracted relatively low VC funding in international terms – amounting to just 0.02% of Germany’s GDP in 2024 (2023: 0.01%). This placed Germany fifth in Europe, behind Switzerland (0.08%), Denmark (0.07%), the UK (0.05%), and Belgium. In the US, biotech firms raised €14.7bn in venture capital in 2024, four times the amount raised in Europe (€3.7bn), equivalent to 0.07% of US GDP. The median deal size in the US was €10.8m –higher than Germany’s €6.8m. EY did not publish comparable figures for China. The Chinese biotech sector is primarily funded through its 2021–2025 Five-Year Plan and regional government budgets. Nonetheless, China’s biotech sector raised US$2.1bn in VC funding, equivalent to 0.01% of GDP.
Crash in Q1/2025
EY reports that the financing boom of 2024 came to an abrupt end in Q1 2025, likely a reflection of market uncertainty arising from changes to research funding (NIH, USDA), drug pricing, and trade protectionism under the current US administration. German biotech
Fig. 2: Share of Venture Capital on GDP in 2024
companies raised just €130m in Q1 2025, a 78% drop from Q1 2024 (€591m).
Clinical trials and market approvals
The number of clinical trials initiated by German biotech firms increased by 4% in 2024, from 169 to 176, despite the acquisitions of Cardior by Novo Nordisk and MorphoSys by Novartis. Twelve programmes were transferred abroad. The pipeline showed growth, with 98 Phase II and 21 Phase III trials (10 more than the previous year). By Q1 2025, five marketing approvals had been granted – three for biologics (Lindis Biotech/Catumaxomab; InflaRx/Vilobelimab; Allecra Therapeutics/ Cefepime+Enmetazobactam) and two biosimilars (Formycon: FYB203 [Aflibercept] and FYB202 [Ustekinumab]). According to the 2025 annual report by the German Association of Research-Based Pharmaceuti-
cal Companies (VFA), there were 39 biologics approvals in 2024 (+64%), bringing biologics’ market share to 35% (+1.3%). The number of biologics development programmes among the 144 pharma companies involved in medical biotechnology rose slightly to 677 (2023: 674). Sector revenues increased from €18.8bn to €21.4bn.
Both EY and the VFA criticise the protracted start-up times for clinical trials in Germany, which are reportedly twice as long as in the UK or US. According to EFPIA, China is six months faster than the US in initiating trials. The German government has pledged to cut red tape, and the adoption of new standard contract clauses by the Bundesrat in July 2025 is expected to shorten negotiations between sponsors and clinics. EY notes that current delays undermine the attractiveness of German start-ups for investors, particularly as
Fig. 3: Number of clinical studies across different indication areas
only 12.5% of follow-on financing for domestic drug developers comes from German investors, compared to 87.5% from abroad.
Value chain orientation
The alignment between German biotech firms and the interests of the pharmaceutical industry becomes clear when comparing VC allocations, pharma R&D investment, and innovation pipelines. According to EY, 80% of the largest VC financings were directed toward oncology. The VFA reports that oncology accounts for 32% of pharmaceutical revenues in Germany. Of the 26 new approvals in 2024, 12 were in oncology, and 301 of 667 active clinical development programmes are in the oncology space. However, the limited availability of IPOs – only four in Europe in 2024 versus 21 on Nasdaq –means that mergers and acquisitions remain the pri -
mary exit route for German biotech firms. As a result, disruptions to the value chain, such as US tariffs or price cuts, could significantly affect M&A activity. EY concludes that geopolitical risk now requires more rigorous political due diligence. Beyond market size, production costs, and timelines, partnership decisions must increasingly factor in reliability across R&D, manufacturing, supply chains, and distribution.
According to EY’s 2025 Firepower report, around 65% of total revenue among leading biopharma firms is generated from products acquired via M&A or developed through alliances and joint ventures. As external innovation becomes more central and global dealmaking expands, exposure to geopolitical risk is rising. The longer-term implications for German biotech firms remain to be seen.
Prefaces
Germany in the race for global leadership in biotechnology
Dr. Kai Joachimsen, General Manager BPI e.V.
Germany has set itself ambitious goals. In their 2025 coalition agreement, the ruling parties, the Christian Democratic Union and the Social Democratic Party, pledged to make the country the most innovative global hub for chemistry, pharmaceuticals, and biotechnology. Biotech has been explicitly defined as a key industry. Genomic techniques, novel therapies from molecular and pharmaceutical research, and innovations in precision and personalised medicine lie at the heart of this strategy. For pharmaceutical companies, this signals strong political intent: Germany wants to move faster in creating the right conditions for biotech research, development, and market access. Yet ambition alone will not be enough. Germany must act decisively to compete with the rest of Europe and the United States. The investment climate illustrates this challenge.
Germany – the investment climate
The financial performance of the German biotech sector paints a mixed picture. According to recent reports, the German biotech sector showed modest growth in 2024, with a 2% increase in the number of companies and a 4% rise in research and development (R&D) spending. However, falling revenues (-8%) and declining employment (-5%) reveal structural weaknesses. Financing surged to €1.9bn in 2024 but dropped sharply in early 2025.
Compared to the United States, where investment volumes are four times higher, Germany still lags behind. US biotech companies are supported by a highly risktolerant investor base and a flexible regulator, the US Food and Drug Administration (FDA), which recently accelerated approval processes.
Despite this lack of incentives in Germany, oncology remains a magnet for investors. Antibody-drug conjugates dominated financing rounds in 2024, with radiopharmaceuticals and immuno-oncology approaches also gaining traction. This shows that innovation continues to attract capital where medical needs are high.
Europe – moving towards a stronger framework
While Germany struggles with uneven performance, Europe is moving forward. The European Commission launched a new Biotech and Biomanufacturing Platform in January 2025 to help companies navigate funding, infrastructure, intellectual prop -
erty, and regulatory processes. In July, the European Commission presented its Strategy for European Life Sciences with the goal of making Europe the most attractive life sciences hub worldwide by 2030. The strategy includes €300m in new targeted investments, support for clinical trials and Advanced Therapy Medicinal Products, and efforts to harmonise regulations and shorten market access times. These steps are crucial in strengthening competitiveness, and they resonate strongly with the BPI’s long-standing calls for better market conditions and faster access to innovation.
The Biotech Act, currently under public consultation, represents another decisive milestone. It aims to simplify frameworks, accelerate market entry, and create conditions for sustained growth in biotech. The BPI has already submitted its input and continues to engage in Brussels to ensure that companies’ needs are heard.
At the same time, Denmark and other member states are pushing for a strong European Life Science Strategy, focusing on funding, clinical research, and regulatory reform. These initiatives offer a chance to close the gap with the US, but they require consistent follow-through.
BPI – shaping the future of biotech
Germany now faces a critical choice. To remain competitive, policymakers must strengthen start-ups and scale-ups, close financing gaps through targeted funds, and create incentives for high-risk R&D. They must also use European synergies more effectively. The BPI works tirelessly to shape these frameworks. Our teams in Berlin and Brussels contribute expertise to policy debates, support our members in navigating regulatory hurdles, and advocate for efficient and innovation-friendly rules.
The German biotech sector has enormous potential. Nearly 800 companies now operate within the field, with strong momentum in therapeutic development, oncology, and advanced therapies. With the right mix of innovation, capital, and political support, Germany can become a global leader in biotechnology. The BPI is committed to ensuring that companies have the right conditions to bring new medicines and therapies to patients – quickly, safely, and competitively.
Biotechnology is the foundation for future healthcare and a driver of Europe’s competitiveness. Together with our members, we will make sure that Germany and Europe seize this opportunity. With strong political frameworks, robust investment, and the dedication of their companies, both Germany and Europe can succeed.
Bundesverband der Pharmazeutischen Industrie e.V. (BPI) Friedrichstraße 148
10117 Berlin
Tel.: +49 (0) 30 2 79 09 0
E-Mail: info@bpi.de
www.bpi.de
Biotechnology and Biopharmaceuticals in Germany Germany remains one of the most important biotech locations worldwide. Even after overcoming the COVID-19 pandemic, the biotechnology industry in Germany has continued to grow. According to BIOCOM, sales fell to €12.57bn; however, biopharmaceuticals now account for more than a third of total sales. Around 38,120 people were employed by 79 biotech companies based in Germany. R&D expenditure in 2023 amounted to more than €3.74bn.
Prefaces
Speak up for biotech
Dr. Kathrin Rübberdt, Head of Division Science & Industry at DECHEMA e.V.
Do you listen to podcasts? Have you noticed that all podcasts about politics, economy and other current topics these days bear a timestamp? The hosts do not only mention the day of publication, but the exact time of recording – and for a reason: Between recording a podcast and its appearance in your playlist, things may already have changed fundamentally.
If we have been speaking about an “era of transformation” in the last decades, we’ve had to learn that despite all the uncertainties we were facing, this was nothing compared to what we are experiencing today.
This holds true for the biotechnology industry as well. Investing in a pilot plant for bio-based plastics? At present a difficult decision as large parts of the world (and not without sympathy from some European players) increase the exploitation of fossil resources. Building a precision fermentation plant for whey proteins? That depends on your expectations for the development of the regulatory framework. Even the research for new vaccines is put in question despite the experiences with COVID as cultural clashes are being transferred to the field of health policy.
Transformation always goes hand in hand with a certain degree of uncertainty. But usually there is a goal in sight and a strategic direction discernible. Currently, identifying this direction can be difficult. Our industries – and with them research – are lacking a reliable framework and strategic orientation. For technologies with large investments at an early development stage, long time to markets and subject to tight regulation, mid- to long-term reliability of political and regulatory frameworks is essential; otherwise, innovation will be stifled before it even comes close to reaching the market.
What can we, the biotech community, do? Sure, we cannot set the exterior frameworks on our own. But we can contribute by giving a strong voice to our visions, our solutions, but also our expectations and requirements. To do this, we need to shape our ideas and develop a joint voice. More than ever, we need an open and ongoing dialogue and exchange in our community and also across disciplines.
Over the past years, we have seen an increasing integration of biotechnology and chemistry. As the most relevant interdisciplinary platform and bridge between industry and academia, DECHEMA has fostered this development by bringing experts from all sides together in its working groups, at events and in workshops. A striking exam-
ple that we have to combine our knowledge is the circular economy: From mechanical recycling to the syngas route, from the recovery of metals from electronic waste to the management of water cycles, a plethora of technologies is used – and available! Biotechnology goes hand in hand with chemistry, whether by including enzymatic steps in synthetic pathways, using bio-based feedstock in chemical plants or employing microorganisms in recycling processes.
Interdisciplinary exchange is the basis to identify the best routes and methods and to develop seamless interfaces between the different approaches – a task DECHEMA has been committed to from its very beginnings almost 100 years ago. Bridging the gap from the development of a promising synthetic pathway to scale-up and application is the next big step. With a unique network both in academia and different industries, DECHEMA can help to find the right partners and shape co-operation to turn invention into innovation. The benefits of a trust-based exchange, however, apply not only to research and technology, but also cover opportunities to share the challenges of a heavily regulated environment, exchange best practices and formulate joint points of view that can be brought to the attention of policymakers.
But bringing together our expertise is only the first step. We have to showcase our findings, take part in political and societal discussions and provide our point of view and advice. In dialogue with Federal Ministries, regional clusters and other stakeholders, we outline the opportunities biotechnology offers and the required prerequisites.
Last but not least, Germany and Europe are facing a transformation of the workforce. With the “baby-boomers” on the verge of retirement and dwindling numbers of MINT students, our research groups and industries have to follow diverse strategies: Increasing process efficiency, attracting foreign talent and raising awareness of the attractiveness and potential of a career in biotech. With our twofold approach of addressing high-school students by our student competition DECHEMAX and making sure that academic curricula remain aligned and relevant to the requirements of future employers, we aim to ensure that a skilled and motivated workforce is ready to tackle the challenges of tomorrow.
But in the end, organisations like DECHEMA are facilitators – the most important actors are you! Make use of the manifold opportunities to support your research and business – join networks, bring in your expertise and ideas and raise your voice in political and societal dialogues. Promote our industries and explain why we need reliable frameworks. Share your enthusiasm not only with your business partners or fellow researchers, but also at a school event, within your recreational club or at the family convention. Biotechnology has so much to offer – let the world know!
DECHEMA Gesellschaft für Chemische Technik und Biotechnologie e.V. Theodor-Heuss-Allee 25 60486 Frankfurt am Main Germany
Tel. +49 69 7564-0 info@dechema.de
Prefaces
VDGH: Innovation for Health and Beyond
Dr. Martin Walger VDGH – Association of the Diagnostics Industry
We are delighted to welcome the 27th edition of the Guide to German Biotech Companies. This reference work has become a key point of reference for the German biotechnology and life sciences industry. Not only does it offer a comprehensive overview of companies and players, it also serves as an important showcase for international partners. It thus makes a decisive contribution to strengthening the visibility and attractiveness of Germany as a location for innovation.
Biotechnology is a key industry for the future. It makes an important contribution to healthcare and food security as well as to sustainable solutions. The Association of the Diagnostics Industry (VDGH) represents both the in vitro diagnostics (IVD) industry and companies in the field of life science research (LSR). We thus unite two industries closely linked to biotechnology, which have a significant impact on Germany as a location for research and innovation and contribute to Europe’s competitiveness.
The interaction between biotechnology, diagnostics and LSR is a decisive factor for success. Start-ups from the biotech sector are developing into important players in diagnostics. The IVD industry provides indispensable tools for prevention, early detection and precision medicine. The LSR industry, in turn, provides the basis for groundbreaking developments such as cell and gene therapies. This networking makes it clear that progress in healthcare is always the result of collaboration between many disciplines – and that diagnostics and research play a key role in this.
The VDGH sees itself as a strong voice for these industries. In Germany, associations play a central role in the political process, and we are actively involved as mediators between business, politics and society. We are regularly consulted in legislative procedures at ministries, authorities and in the Bundestag. In our current position paper, “10 points for a better healthcare system”, we highlight how laboratory diagnostics and life science research can improve care, accelerate access to innovations and drive forward digitalisation in healthcare. Prevention, securing skilled workers and sustainability are also on our agenda.
The Life Science Research department ensures that the innovative strength of this industry is visible. Exclusive offers such as our FundFinder, which bundles research funding from Germany and other European countries, facilitate access to projects and markets. Market and product surveys provide valuable data for strategic decisions with a level of detail that no commercial report can offer. This information is a
unique selling point of membership and strengthens the position of companies in a dynamic environment.
Regulatory and health policy issues are at the forefront for the IVD industry. The VDGH is committed to the further development of the European IVD Regulation, which enables innovation while ensuring patient safety. We also call for fair remuneration structures that reflect the value of diagnostic procedures, as well as accelerated access to standard care for laboratory innovations. After all, new tests can only realise their potential if they find their way into practice in a timely manner. Through our involvement in European networks such as MedTech Europe, we ensure that German interests are also heard in the European context and lead to practical solutions.
In addition, the VDGH creates platforms for exchange, knowledge transfer and visibility. With formats such as the Diagnostica Forum, the Summer Academy and the LSR Spotlight Forum at analytica, we bring together industry, science, politics and the media. We also offer seminars, workshops and digital information services that provide our members with guidance and a knowledge advantage. Our association’s communications play a special role in this. Through publications, newsletters and social media activities, they ensure that the contributions of our member companies are visible both to the professional public and to society at large. In this way, we position the industry in public debates, communicate its importance for research and healthcare, and contribute to its attractiveness as an employer.
The heart of the association’s work continues to be its committees, i.e. the specialist departments, committees and working groups that are open to all members. In more than 30 committees, knowledge is shared, positions are coordinated and joint solutions are developed. This is where the industry’s expertise is pooled and ideas are generated that go far beyond the work of individual companies.
We invite all companies to take advantage of the benefits of VDGH membership. It provides access to exclusive market and research data, political decision-making processes and a unique network that builds trust and enables synergies. Together, we can further develop Germany as a centre for research and healthcare, accelerate innovation and highlight the contribution of our industries – for the benefit of society and patients.
VDGH – Verband der Diagnostica-Industrie e.V.
Neustädtische Kirchstr. 8 10117 Berlin
Tel. +49 30-2005 99-40
Germany
www.vdgh.de
Profiles of German Biotech Companies
Name ›
4base lab GmbH advanced molecular analysis
Address/P.O. Box › Postal Code/City › State ›
Contact Person › Telephone › Email
Website ›
Founded (year) › Type of Laboratory
Areas of Activity ›
Aspenhaustr. 25
72770 Reutlingen
Baden-Wuerttemberg
Dr. Johannes Ries
+49-7121-317878-0
pharma@4base-lab.com
https://en.4base-lab.com/pharma/ 1995
GMP, S1/L2
| Identity/quality assessment of mRNA/ DNA vaccines
| Contamination analysis of residual DNA/RNA
| Vaccine quality analysis by Nanopore direct RNA-sequencing
| DNA/cDNA-sequencing by Sanger
| Determination of mRNA poly(A) tail length
| Sequencing the CDS in mRNA
| Direct colony full-length sequencing
| Contract research/outsourcing
| Viral- and microbial detection
The Experts
For almost three decades, 4base lab has been at the forefront of molecular analysis, maintaining GMP-compliant laboratories that consistently meet the highest industry standards. As a reliable partner of mRNA/DNA vaccine manufacturers including leading pharmaceutical companies, 4base lab offers safety at every stage of the manufacturing process.
Excellence through collaboration is our guiding principle. Our team of experienced scientists and qualified technicians partners closely with you to comprehend your unique objectives. We leverage this understanding to develop customized assays and validation methods that are tailored to your specific requirements and ensure optimal results.
Customized advice and flexible adaptation of our test systems are our strengths.
The services
DNA sequencing: The confirmation of sequence identity is an essential part of the production of therapeutic nucleic acids. 4base lab offers reliable non-GMP and GMP sequencing services according to Sanger, covering all steps necessary for the determination of complete DNA sequences. Even samples with ultra-low DNA concentrations, limited volume or colonies can be sequenced in full-length using validated Rolling Circle Amplification (RCA) methods.
RNA sequencing: The assessment of therapeutic mRNA vaccines directly, without reliance on intermediate molecules, is increasingly in focus of regulatory quality control requirements regarding the sequence coding identity, modifications, and structural motifs. 4base lab offers a qualified analysis pipeline to address these issues directly on the RNA.
Determination of poly(A) tail length: for determination of poly(A) length of mRNA vaccines, qualified sequencing strategies utilizing Sanger adapter sequencing as well as Oxford Nanopore Technologies (ONT) direct RNA sequencing are available.
Residual nucleic acid analysis: Detection of residual DNA contamination. Safety at every step of your manufacturing process of mRNA vaccines. Various validated qPCR/RT-PCR protocols are established for the detection of residual E. coli genomic DNA, RNA and plasmid DNA contaminant in mRNA vaccines.
Development and Validation: New detection systems can be developed at any time according to customer requirements and validated in accordance with ICH Q2.
Viral and microbial detection: Please inquire for available systems.
Quality assurance
4base lab has been maintaining GMP compliant laboratories for molecular analysis for almost three decades. Furthermore, 4base lab is certified according to DIN EN ISO 9001, DIN EN ISO 14001 and accredited according to DIN EN ISO 17025.
Name ›
Address/P.O. Box › Postal Code/City › State
Contact Person
Telephone
Email
Website
Social Media
Number of Employees
Founded (year) › Areas of Activity
ABclonal Germany GmbH
Emanuel-Leutze-Straße 8 40547 Dusseldorf North Rhine-Westphalia
Dr. Jing Lu +49-211-1584-9841 info@eu-abclonal.com abclonal.com
F I I
500
2011
| Develop and manufacture high quality reagents, including antibodies, recombinant proteins, molecular enzymes and NGS library preparation kits for research, IVD, CRO, and CDMO.
| CRO service for antibody discovery, engineering, and production using hybridoma, single B cell, or phage display strategies.
| CRO service for recombinant protein expression and peptide synthesis
ABclonal Germany GmbH –Your European Partner in Global Life Sciences Innovation
ABclonal is an innovative growth company aiming to provide reliable and cost-effective products and services for both basic and translational research in cutting edge biomedical science. Innovation is our DNA, with worldwide R&D centres focusing on technical innovation and product development for protein science and molecular biology.
ABclonal Germany GmbH, a strategic branch of ABclonal Technology Co., Ltd., embodies the global vision and scientific excellence of its parent company while delivering localised expertise to researchers, biotech companies, and healthcare institutions across Europe. As part of ABclonal’s international network – supported by R&D, production, and commercial hubs spanning North America, Asia, and Europe – we are committed to advancing life sciences innovation worldwide.
Global Strength, Local Precision
External › Collaborations
| The Michael J.Fox Foundation | YCharOS
| mAb3D Atlas; | Histologix Ltd
Leveraging ABclonal’s global infrastructure, ABclonal Germany provides European clients with direct access to cutting-edge solutions in biological reagents, molecular enzymes, NGS automation, and antibody discovery services.
Why Partner with ABclonal Germany?
› Trusted Globally, Rooted Locally: Join 100,000+ international customers who rely on ABclonal’s products, backed by our German team’s commitment to responsiveness and regulatory excellence.
› End-to-End Solutions: From research antibodies to diagnostic materials, we provide products validated for global reproducibility, with logistics optimised for European timelines.
› Sustainability & Compliance: Aligned with EU regulations and sustainability goals, we prioritise ethical practices and eco-friendly innovation.
Our Milestones
› Antibody Production Services
ABclonal was founded with a strong focus on providing customised antibody production services. Our mission has always been to enhance life science research by delivering better, high-quality antibodies.
› Every Protein Should Have an Antibody
We launched the Human Genome Antibody Project, aiming to document and generate an antibody for every protein encoded in the human genome. By utilising recombinant protein antigens, we have successfully developed over 20,000 rabbit polyclonal and monoclonal antibodies.
› Next-Generation Sequencing (NGS)
Leveraging the expertise of our molecular biologists and geneticists, we are developing cutting-edge NGS technology. Our goal is to produce innovative NGS library preparation kits while integrating advanced bioinformatics platforms. This will accelerate biomedical research and aid in the discovery of biomarkers for genetic and epigenetic diseases.
Our Mission
To become a global leader in biomolecular solutions. Our Values:
› Customers Come First – We prioritise our customers’ needs and success.
› Collaboration Over Individualism – We believe in teamwork and shared achievements.
› Embracing Challenges – We see obstacles as opportunities for growth.
Name ›
Address/P.O. Box ›
Postal Code/City › State
Contact Person
Telephone
Email
Website
Social Media
Number of Employees
Founded (year)
Areas of Activity
Absea Biotechnology
Building D85, Robert-Roessle-Str. 10 13125 Berlin Berlin
Philip Loessl
+49-30-94893560 info@abseabio.com www.absea.bio I
200+ 2020
Comprehensive catalog: 40K+ mAbs, 14K+ human proteins, 13K+ isotopelabeled protein standards, 2K+ antibody pairs and IP-beads.
High-throughput services: AI-guided protein construct design+production, mAb development+pairing+selective conjugation
Large-scale data: multiplex IHC/IF/IP/ WB/FACS/ELISA, unique mass spec pipelines for pharma and AI
Proteome-scale reagent libraries and profiling technologies to advance biomedicine, pharma, and AI
Absea Biotechnology provides a proteome-scale infrastructure for academic and industry partners worldwide. Our strong commitment to innovation, scalability and customization, we address critical gaps in the protein biotechnology market.
Our vast biomolecule portfolio comprises >14,000 soluble human proteins, covering 70% of the human proteome. Over 90% of these proteins are readily producible as 15N-labeled standards, enabling biomarker detection with attomole sensitivity as well as multiplexed absolute protein quantification by MS. Our portfolio of >40,000 monoclonal antibodies (mAbs) is validated for applications such as ELISA, western blot, immunohistochemistry, immunofluorescence, immunoprecipitation, and flow cytometry. The mAbs are sequenced and ready to be engineered and recombinantly produced in our CHO cell platform.
Our bespoke protein and antibody development benefits from AI- and data-driven technologies. Our proprietary SIEVE® algorithm allows us to achieve a >75% success rate in soluble protein expression, setting a new benchmark for efficiency and scalability in protein production. With InformAb™️ and SpeedyDate™️, we are able to produce and validate mAbs for up to 300 new targets each month. All these mAbs can be selectively functionalized with Absea’s USB® coupling chemistry.
Our MS-based Architectomics™️ pipelines provide a holistic view of protein behavior, empowering drug discovery and biomedical research with actionable molecular insights. We offer three complementary programs:
› Drug-centric: Proteome-wide profiling of on/off-targets and binding sites to better understand drug mechanisms.
› Protein-centric: Mapping targeted interactomes, epitopes, paratopes, and disulfide bonds for in-depth characterization of protein therapeutics and disease markers.
› Cell-wide: Discovering health and disease-related protein interaction networks, binding sites, structures, and localizations directly in intact human cells and microbes.
Key application areas of our reagent and data solutions are
› Early-stage drug discovery (e.g. E3ome panel with >200 mAbs for targeted degrader research)
› Generation of ground-truth data for AI (e.g. biomolecular interaction networks with matched affinities)
› Neurobiology (e.g., >50 Tau phospho-isoform specific antibodies, APOE4-specific antibodies)
› Immunology (e.g. comprehensive cytokine protein panel, Ig-subclass specific mAbs)
Name
Address/P.O. Box ›
Postal Code/City
State
Contact Person
Telephone
Email
Website
Social Media
Number of Employees
Founded (year)
Type of Laboratory
ACILA Dr. Weidner GmbH
Opelstr. 14 64546 Mörfelden-Walldorf Hesse
Mustafa Mentes
+49-6105-9301-0 info@acila.com acila.com/en I < 50 1986
Contract Laboratory, S1/S2, Clean Room Areas A/B/C, GMP, ISO 9001:2015, DIN EN ISO/IEC 17025:2018
Areas of Activity
External
Collaborations
| Bacterial Endotoxin Test Reagents & Accessory Products
| Sterile & Endotoxin-free Sample Vials
| Pharmaceutical Primary Packaging Material
| Animal Blood & Derivatives
| Microbiological and physico-chemical testing of medical devices, pharmaceuticals and active ingredients
International Distribution Partnerships
ACILA Dr. Weidner GmbH specialises in endotoxin-free and sterile laboratory products, pharmaceutical primary packaging materials, and animal blood and derivatives for use in pharmaceutical, biotechnological, and medical-device industries.
Founded by Dr. Peter Weidner in 1986 in MörfeldenWalldorf near Frankfurt am Main, the company combines in-house production and an ISO 17025-accredited, GMP-regulated contract laboratory for microbiological and physico-chemical analysis under one roof, ensuring full traceability and compliance with Ph. Eur., USP, ISO and GMP standards.
Sample Vials, Bacterial Endotoxin Test Reagents & Accessory Products
With decades of expertise, ACILA produces high-quality reagents and consumables for Bacterial Endotoxin Test (LAL Test) and aseptic applications.
PYROKONTROL® stands for endotoxin-free sample vials, test tubes and high-purity diluents suitable for endotoxin and pyrogen testing.
STERICERT® represents ACILA’s line of sample vials certified endotoxin-free and sterile, achieving a Sterility Assurance Level (SAL) of 10 -6
Complementary products such as TrisSol® Tris Buffer, ACILA® LAL Reagent Water (LRW), and PYROCERT® LPS are produced under validated conditions and ensure consistent quality and reliability.
Pharmaceutical Primary Packaging Materials
Ready-to-use, sterile, and depyrogenated glass vials for pharmaceutical use.
PYROVAC ® Vials have been specifically developed for the automated preparation of radiopharmaceuticals and can also serve as containers for drugs or diagnostic solutions, ensuring the highest standards of quality and safety.
Animal Blood and Derivatives
ACILA® supplies fresh sheep blood collected weekly from veterinarian-controlled donor animals via aseptic venipuncture.
The blood is processed under aseptic conditions – either gently defibrinated or treated with an anticoagulant such as heparin, sodium citrate, or EDTA. No preservatives or antibiotics are added.
This high-quality sheep blood is ideal for microbiological applications, including as an additive for culture media (e.g., blood agar), for the preparation of viable erythrocytes, simulation of contamination of e.g. surgical instruments, disinfectant efficacy testing and other diagnostic or research uses.
Contract Laboratory
ACILA operates an ISO 17025-accredited and GMPregulated laboratory performing microbiological and physico-chemical testing of medical devices, pharmaceuticals and active ingredients in accordance with the European Pharmacopoeia (Ph. Eur.), the United States Pharmacopoeia (USP) and DIN EN ISO standards.
Among others, the following tests are routinely performed:
› Sterility Test
› Examination of Non-Sterile Products
› Bacterial Endotoxin Test (LAL Test)
› Particulate Contamination
› Determination of Chlorides
These services complement ACILA’s in-house production – in full compliance with international standards – from a single source.
Research solutions for preclinical and clinical development with a focus on nucleic acid therapeutics (NAT), including bioinformatics-guided sequence selection, high quality oligonucleotide manufacturing, analytics (GMP), bioanalytics (GLP, GCP), lead molecule identification, and in vitro and in vivo pharmacology
External
Collaborations
Axolabs collaborates with research groups around the world in the field of oligonucleotide therapeutics, including > 15 Big Pharma enterprises, > 200 biotech companies, and > 30 academic research institutes
Your complete nucleic acid therapeutics journey. From discovery to commercialisation.
Axolabs is the leading custom research organisation focused on the discovery, development and manufacture of oligonucleotide and nucleic acid therapeutics.
Founded firmly on our world-leading know-how and more than 20 years of experience, we provide high-end preclinical and clinical development solutions tailored to our clients’ needs.
From discovery hubs to GMP-certified production sites, Axolabs’ facilities are built to support nucleic acid therapeutics development. Our global presence includes state-of-the-art sites in Kulmbach and Berlin, Germany and Petaluma, US, with each site specialising in a specific phase of your drug development journey.
Research and early development services
We offer a comprehensive suite of research and early development services, starting from in silico analyses to late-stage preclinical testing including:
› Lead Identification
› Safety and Toxicity Analyses
› Cell-Based Assays for Efficacy, Viability, and Toxicity Efficacy Assays
› Viability and Toxicity Monitoring
› Cell Differentiation and Characterisation
› Protein Quantification and Analysis
› Functional and Mechanistic Studies
› Sequencing (NGS, Oxford Nanopore)
› CRISPR/Cas Technologies: gRNA Design and Validation
› GLP/GCP Bioanalytical Services
› DMPK Services
Manufacturing services
From early-stage research to commercial-scale cGMP production, facilitating a smooth handover from research to production.
› Preclinical screening synthesis
› Chemically modified RNA therapeutics and their conjugates
› Synthesis of long (oligonucleotide) entities
› Organic synthesis laboratory
› Lipid nanoparticle (LNP) formulation and manufacturing
Our integrated platforms provide quality assurance and seamless transitions between development and commercialisation
› Streamlined Data Flow from research to manufacturing
› Technology Transfer and Scale-Up Efficiency
› Regulatory and Quality Considerations
Start your Axolabs journey. Visit axolabs.com or email info@axolabs.com
Name ›
Address/P.O. Box › Postal Code/City › State › Contact Person
Telephone
Email
Website
Social Media
Number of Employees
Founded (year) ›
Areas of Activity ›
BAG Health Care GmbH
Amtsgerichtsstrasse 1-5
35423 Lich Hesse
Dr. Klaus Dörre
+49 170 9048457
k.doerre@bag-healthcare.com www.bag-healthcare.com I 100 1947
| Aseptic Filling and lyophilisation in vials from small to mid-size batches
| Analytical services for drug substance, drug product, and stability programmes
| Packaging, labelling, and serialisation
| QP-release
BAG Health Care GmbH is a privately held, familyowned CDMO located in Lich, Germany, with over five decades of experience in aseptic fill & finish of parenteral drug products. We focus on small to mid-sized batches and have permission to produce for clinical and commercial setting.
Renowned for its precision, compliance, and clientfocused approach, BAG is a trusted manufacturing partner for pharmaceutical and biotech companies worldwide.
BAG specialises in the aseptic filling of vials ranging from 2R to 50H and offers a robust track record in handling biologics, peptides, nucleotides, and small molecules. The company also supports adjacent areas such as sterile solutions regulated as medical device components and raw materials for ATMP production. This breadth of experience, coupled with technical depth, ensures reliable support across a wide spectrum of formulation types and regulatory requirements.
As an end-to-end service provider, BAG offers comprehensive support from technology transfer and process development through aseptic filling, lyophilisation, and secondary packaging. In-house analytical services, QP release, ICH-compliant storage, and stability programmes round out a full-service package designed for clinical and commercial needs. The manufacturing infrastructure is fully GMP-certified and Annex 1 compliant, with a proven track record in terminal sterilisation and aseptic processing. More than 80 % of our batches are released for commercial supply – highlighting BAG’s maturity in managing market-ready products.
With the particular focus on small to mid-sized batch production, BAG is ideally positioned for biologics companies seeking flexible, responsive, and highquality fill & finish solutions. The company’s ability to scale efficiently, meet complex handling requirements, and maintain high compliance standards makes it an optimal partner for early-phase through commercial launches – especially for products that require careful process control and a high degree of aseptic assurance. At BAG Health Care, we empower our customers’ success through scientifically grounded precision, empathetic collaboration, and passionate dedication.
Our collaborative spirit drives our core promise – to lead our clients to success. Whether for pilot-scale programmes or commercial supply, BAG Health Care offers the experience, infrastructure, and commitment needed for sustainable partnerships in sterile drug manufacturing.
Name ›
Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Fax
Email
Website
Social Media › Number of Employees › Founded (year) › Type of Laboratory
Service provider for biomolecular interaction analysis using SPR Biacore technology; supplier of recombinant proteins and reagents for kinase research and signal transduction
Company overview
External › Collaborations
Request for › Further Collaborations
Collaborations with academic research groups and industrial partners
Biaffin is looking for strategic partners interested in complementing their analytical portfolio with SPR Biacore technology.
Biaffin GmbH & Co KG is an ISO 9001:2015 certified bioanalytical service provider specialised in the application of biosensors based on surface plasmon resonance (SPR) for biomolecular interaction analysis (BIA). BIA technology is ideally suited for highly accurate kinetic characterisation of any interacting molecules in real time in a label-free state. Biaffin has extensive knowledge and many years of experience in various application areas and supports biopharmaceutical drug development programme of pharma, biotech, and generic drug companies as well as scientific institutions worldwide as a competent partner. Our services are performed by a highly specialised team (PhD level scientists) in a laboratory well equipped with several state-of-the art SPR instruments (5x Biacore T200, 1x Biacore 8K+, 1x Biacore 1S+). Sufficient capacity of SPR instruments allows Biaffin to start interaction studies on short notice, quickly run multiple projects in parallel, and receive results in a timely manner. A qualified Biacore T200 instrument is available for SPR assay validation and GMP-like SPR analysis. The company’s expertise is documented by many peer-reviewed publications in renowned scientific journals.
Analytical services for biopharmaceutical development
For the development of therapeutic antibodies, biopharmaceuticals, and biosimilars, Biaffin offers reliable SPR services for a highly accurate, quantitative kinetic characterisation, semi-quantitative kinetic ranking, or rapid qualitative screening of drug candidates. SPR assays have already been established for many target proteins and can be developed quickly by application of established protocols for reversible and site-directed coupling of biomolecules using specific capture surfaces. These assays can be applied for comparability and stability studies and batch-to-batch comparison during process optimisation. Available assay formats include dual-potency assays, pair-wise epitope mapping, and determination of active concentration based on binding activity (calibration-free methods). Assays can be validated and conducted under GMP-like conditions on a qualified Biacore instrument.
ADCC SPR assays
ADCC SPR assays are established for interaction analysis of antibodies with Fc gamma receptors (CD16, CD32, CD64) including receptor variants and different species, neonatal Fc receptor (FcRn), and complement C1q binding.
Small molecule drug development
Biaffin’s services in small molecule drug development comprise customised SPR assay development for defined target proteins, fragment screening, hit validation, secondary screening, kinetic profiling, competition analy sis, and lead optimisation of compounds to improve specificity, selectivity, and potency. Early ADME studies (serum protein binding) and studies on mode of action, cofactor requirements, and thermodynamic binding analysis further support the drug development process.
Catalogue products
Apart from analytical services, Biaffin offers a range of products serving customers’ needs in kinase research and exploring cellular signal transduction pathways. Biaffin’s product portfolio, available from the online shop www.Proteinkinase.biz, comprises recombinant proteins (kinases, cytokines, receptors, CD antigens), peptide substrates, specific inhibitors, and a biochemical ATP determination assay for customers’ in-house research.
Quality statement
Biaffin has successfully implemented and maintains a Quality Management System certified according to the ISO 9001:2015 international standard, enhancing our ability to supply high-quality products and provide reliable, innovative services according to the highest quality standards, which consistently meet the needs and expectations of our clients.
BIDECO Bio- und Pharmasysteme GmbH
Engineering Excellence for Pharma and Biotech
Address/P.O. Box
Postal Code/City
State
Contact Person
Telephone
Email
Website
Social Media
Number of Employees
Founded (year)
Clara-Schumann-Straße 3
88400 Biberach an der Riß
Baden-Württemberg
Steffen Schnabel
+49-7351-30-230-11 info@bideco.de www.bideco.com I
70 (worldwide) 1995
BIDECO is a specialised consulting and engineering company focused on the design, engineering and realisation of projects of all sizes for the pharmaceutical and biotech industries. Whether designing a new production site or upgrading existing infrastructure, BIDECO brings strategic insight, technical expertise and unwavering commitment to every project.
Through its offices in Germany and Switzerland, BIDECO combines local expertise with global project experience, offering tailored solutions that meet the highest industry standards.
Comprehensive Services
As an EPCMQ contractor, BIDECO covers all project phases:
› Concepts: Master plans, feasibility studies, conceptual designs, regulatory and building permit support
› Design & Engineering: Basic and detail design, BIM coordination and integration
BIDECO’s interdisciplinary team includes experienced process and mechanical engineers, building engineers, validation and GMP specialists and project managers who work collaboratively to deliver efficient, compliant and state-of-the-art facilities. This blend of technical depth and practical expertise makes BIDECO a trusted partner in the industry. Name
Regulatory Expertise and Industry Know-How
In a highly regulated environment, BIDECO ensures that every aspect of facility engineering complies with current Good Manufacturing Practices (cGMP) and satisfy the regulatory frameworks set by international bodies, including EMA, Swissmedic and FDA. Through robust planning, thorough risk assessment and precise execution, BIDECO supports clients in achieving audit-ready facilities that stand the test of time.
In biotechnology, BIDECO supports, among others, the development of facilities for bacterial fermentation, mammalian and plant cell cultures, viruses and viral vector production and antibody-drug conjugates (ADCs). Each project is customised to the specific process and scale, ensuring seamless integration of upstream (USP) and downstream (DSP) operations.
In the pharmaceutical sector, BIDECO excels in the design and execution of sterile manufacturing facilities, including sterile filling, compounding for aseptic products, lyophilisation, assembly, labelling and packaging. Plasma processing plants and containment facilities for high potency drugs or highly active pharmaceutical ingredients (APIs) complete the portfolio.
With more than 30 years of experience, BIDECO is a key partner in the engineering and design of biotech and pharmaceutical facilities. Its firm commitment to quality, innovation and customer satisfaction ensures that BIDECO remains a trusted partner for the development of state-of-the-art life science facilities.
Name ›
Address/P.O. Box › Postal Code/City › State › Contact Person
Bio-Techne empowers scientists and clinicians by providing high-quality reagents, analytical instruments, and precision diagnostics.
$1.2B (FY25)
8% of Revenue
Member of
Bio-Techne is a global developer, manufacturer and supplier of high-quality reagents, analytical instruments, and precision diagnostics.
It has an extensive catalogue of over 500,000 products. Since its incorporation in 1981 as R&D Systems growth has been accelerated through acquisitions, organic investments, diversification of our customer base and expansion into new markets. In 2014 we became Bio-Techne. In fiscal year 2025, Bio-Techne delivered net sales of over $1.2 billion. Bio-Techne includes the following brands: ACD, Asuragen®, Lunaphore, Novus Biologicals, ProteinSimple, R&D Systems and Tocris Bioscience.
Together, we unlock the possibilities of science
Through our premier R&D Systems brand we develop and manufacture products and services cover a wide range of solutions to accelerate basic scientific understanding, translational research, and diagnostics.
› We develop and manufacture high-quality proteins, antibodies, small molecules, and immunoassays, as well as arrays, stem cell products, cell culture reagents, and other cell biology tools. If you are looking to minimise variability in your research, scale up processes, or transition to GMP-grade raw materials, we can assist you on your journey and make a difference in your research workflows.
› Our protein detection and analytic instruments help reveal new insights into the true nature of proteins and simplify your lab life. With our comprehensive portfolio of tools, which includes Simple Western™️ and Simple Plex™️ systems that quantify protein expression and Biologics systems that probe the structure and purity of protein-based therapeutics.
› In spatial biology, we bring sensitive and specific innovation to researchers, helping them to understanding the spatial basis of gene expression and provide automation solutions that simplify technology adoption for translational research laboratories. Both individually and in partnership our RNAscope™️ technology and COMET ™️ systems make multiomic
spatial biology solutions, accessible to researchers.
› We support the genetic and molecular oncology diagnostic fields with our easily adopted kits that through proprietary chemistry and software that expands lab test menus. In addition we develop and manufacture controls, calibrators and assays for regulated diagnostics.
› Through extensive experience in developing, manufacturing,and commercialising innovative pro ucts and services, we welcome partnerships of shared expertise and resources through business development and in-licensing new technologies with a shared goal of positively impacting research and clinical applications.
Our 2025 sustainability report highlights our commitment to environmental responsibility by accelerating the shift to renewable energy sources across our operations and aligning with science-based targets aimed at reducing greenhouse gas emissions. In addition to climate-related goals, Bio-Techne is focused on driving innovation within the life sciences sector and promoting diversity and inclusion within its workforce.
Whether you’re at the cutting edge of academic research, translating basic discoveries to therapeutic leads, or at a facility that requires the highest level of diagnostic testing, our award-winning tools and solutions empower scientists and clinicians to achieve reproducible and consistent results.
Trusting Bio-Techne means choosing confidence that every solution you use will help move you toward better answers.
Name ›
Address/P.O. Box › Postal Code/City › Country › Contact Persons › Email › Website › Social media › Number of Employees ›
Areas of Activity ›
BioCopy AG
Hochbergerstrasse 60F
CH-4057 Basel
Switzerland
Dr. Matthias Wiedenfels, CEO info@biocopy.com Biocopy.com I 40
Drug Discovery and Development
Immuno-oncology
TCR-like Antibody Engineering
Development of next-generation Cancer Drug Candidates AI-powered closed-loop Platform pHLA complexes
The BioCopy Group
BioCopy is a German-Swiss biotech company headquartered in Switzerland with one R&D site in the south of Germany. BioCopy is breaking new ground in the development of next generation cancer drugs with its proprietary technologies joined in a unique AI-powered engineering platform.
The BioCopy platform
The BioCopy platform is designed to streamline and optimise the drug discovery and development process. It combines AI-powered workflows with wet-lab data in a closed-loop feedback system.
Streamlining Drug Discovery and Development
One of the most promising strategies in fighting cancer is the development of drugs that target specific markers typically concealed within cancer cells. While this approach holds great potential for therapeutic breakthroughs, it also presents significant challenges in identifying the ideal antibody and developing the optimal drug.
BioCopy focuses on the target class of so-called pHLA complexes. These are intracellular proteins presented as peptide fragments via HLA complexes on cell surfaces. Certain pHLA complexes are only found on cancer cells, making them ideal targets for cancer treatment – however, the difference to healthy cells is very small.
The engineering of therapeutic antibodies that target pHLA (so-called TCR-like antibodies) has been challenging and high-risk due to toxicity issues and the difficulties in the later manufacturing process.
BioCopy unlocks the transformative potential of TCRlike antibodies with a unique solution. We combine expertise in the pHLA space with high-throughput screening technologies, advanced protein engineering, and cutting-edge cell culture. This wet lab framework is integrated with databases and artificial intelligence, enabling accelerated learning through a closed-loop feedback system.
The generated proprietary data is fed into BioCopy AI-powered engineering workflows which identify the most promising antibody candidates for a particular kind of cancer.
The combination of bioinformatic workflows and advanced AI tools broadens the scope of off-target sequences, ensuring comprehensive coverage and precise analysis. This minimises off-target toxicity, which is one of the biggest challenges in the development of such drugs.
Parallel Assessment and Development
The BioCopy approach ensures exceptional efficacy and safety. Our platform allows us to work on multiple tasks and processes in parallel.
This paves the way for a streamlined, efficient and highly effective path from molecular concepts to drug candidates that are not only ready for clinical trials, but have a high probability of success.
At BioCopy, we herald a revolution in the discovery and development of drugs with pHLA targeting, and we are redefining the benchmark for time to market.
Name ›
Boehringer Ingelheim Biopharmaceuticals GmbH
Address/P.O. Box › Postal Code/City › Country
Contact Person
Telephone
Fax
Email
Website
Number of Employees
Founded (year)
Type of Laboratory
Areas of Activity › Net Sales › Relevant R&D Budget › Request for › Further Collaborations
Focus on human pharmaceuticals, animal health and biopharmaceutical contract manufacturing
26.8 billion EUR in 2024
6.2 billion EUR in 2024
Boehringer Ingelheim BioXcellence™ is a dedicated partner for biopharma companies, providing comprehensive development and GMP manufacturing services. Renowned for its reliability, the company supports clients throughout the lifecycle of their products, thus transforming biologic innovations into commercial realities.
Company profile
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow.
Boehringer Ingelheim BioXcellence™️ is a leading biopharmaceutical contract manufacturer – a reliable partner that accompanies customers throughout the life cycle of their products. We provide E2E biopharmaceutical manufacturing based on mammalian cell culture and microbial fermentation.
We have extensive experience with a variety of different host cells, producing a broad range of molecules in accordance with cGMP manufacturing guidelines and covering all stages of development, including aseptic filling. Our focus is on creating value for our customers through robust processes, effective preparation for launch, and global clinical and commercial supplies of high-quality biopharmaceuticals.
We are committed to maintaining high-quality standards in all operations, with robust systems designed to meet stringent regulatory requirements, and strong quality control capabilities that ensure product quality at every manufacturing stage. Our team’s extensive regulatory experience and impressive inspection track record demonstrate our ability to navigate complex regulations and integrate in-depth technological knowledge into our operations.
World-Class Expertise
With over 40 years of biotechnology experience and a team of dedicated and highly trained employees, we have helped our customers bring more than 45 biopharmaceutical medicines to the market, serving patients all
over the world. Our expertise spans across various host cells, enabling us to produce a wide array of molecules. Our commercial portfolio comprises monoclonal antibodies, recombinant proteins, antibody fragments, and recombinant vaccines, and is complemented by intensive experience in bi- and multispecific antibodies, Fc fusion proteins, scaffolds, peptide hormones, and pDNA.
World-class Facilities
Our network of manufacturing facilities spans the globe, from Fremont, California in the United States to Biberach in Germany, Vienna in Austria, and Shanghai in China. With around 430 kL for mammalian cell culture and 12 kL for microbial fermentation in fully licensed multiproduct facilities we are your right partner for high-quality global supplies of biopharmaceuticals to patients. This is evidenced by our regulatory excellence. Our operations are based on fully licensed multi-product facilities for all major markets. One-quality, one-compliance, and oneregulatory form the foundation of our global network.
Your World-class Production Partner
For many of our customers, we are the preferred partner for reliable supplies. Seven of the top 10 pharmaceutical companies already trust us due to our extensive commercialisation experience. At Boehringer Ingelheim, we are deeply invested in the success of your product. Our shared passion is reflected in our commitment to providing the highest quality services and solutions to ensure your product reaches its full potential. Aside from our extensive experience and technical expertise, which complements yours, there are several other compelling reasons to choose us as your trusted contract manufacturing partner. At Boehringer Ingelheim, we have learned over the generations that the challenging path towards health innovation requires long-term commitment, resilience, and transformative action.
Let’s build a future together based on our history. We have capabilities to complement your expertise and are committed to turning your biologic innovation into commercial reality.
Name ›
Address/P.O. Box › Postal Code/City › State
Telephone
Email
Website
Social Media
Number of Employees
Founded (year)
Type of Laboratory
Areas of Activity ›
BRAIN Biotech AG
Zwingenberger Straße 34 – 36 64673 Zwingenberg Hesse
We’re looking for partners in the food, feed, chemicals, cosmetics and pharmaceutical industries to work with us to develop innovative, biobased solutions.
Custom enzymes. High-performing production strains. Scalable bioprocesses.
BRAIN Biotech AG (BRAIN Biotech Group) is a leading partner in industrial biotechnology, driving innovation through enzyme technology, microbial strain development, and advanced bioprocess design. The group supports companies in the food and beverage, chemical and life sciences industries, as well as businesses facing environmental challenges.
BRAIN Biotech is renowned for its wide-ranging biotechnology portfolio and customised R&D services. Customers value the company for its creative and reliable solutions, even for highly demanding projects.
R&D services are complemented by enzyme and protein manufacturing services at the group’s fermentation facilities in the United Kingdom.
R&D and manufacturing services:
› Enzyme discovery & engineering: We identify and develop enzymes through our proprietary screening platforms, rational design combining bioinformatics with AI predictions, as well as directed evolution. Clients benefit from unique metagenomic sequence resources and our broad range of microbial strains for gene expression.
› Microbial strain development: Industrial production strains (bacteria, yeast, fungi) are designed to produce enzymes, proteins and biomolecules in high yields. The group offers strain engineering using genome editing or classical methods as well as biosynthetic pathway engineering.
› Bioprocess development & scale-up: Customised bioprocess design helps customers to advance the production of microbial enzymes and proteins. The production of microbial biomass supports those with lacking in-house microbiology expertise and production capabilities.
Member of
› Manufacturing: Our production site in Cardiff, Wales has production capabilities of up to 2 x 10,000 litres, as well as full downstream processing capabilities. Facilities are food-grade, kosher, and halal-certified, ensuring compliance with global markets.
End-to-end solutions for enzymes
Under the BRAINBiocatalysts brand, the group leverages its extensive infrastructure and in-depth vertical expertise to offer end-to-end solutions. Enzyme discovery and engineering, strain development and production in industry scale are all part of the service.
Variation of cooperation models
The modular project architecture allows for a variety of cooperation models, ranging from fee-for-service contracts to strategic joint development agreements. Pilot scale-up and regulatory consulting services are also available to ensure the feasibility of biotechnological applications on an industrial scale.
Commitment to sustainability and innovation
BRAIN Biotech’s mission is to use nature’s toolkit to enable a circular and sustainable bioeconomy. Its R&D strategy supports environmental and economic sustainability goals by helping clients reduce their reliance on petrochemical processes and enhance process efficiency through innovative biological solutions.
Name ›
Address/P.O. Box › Postal Code/City › State › Telephone › Fax › Email › Website › Social Media ›
Number of Employees › Founded (year) ›
Areas of Activity ›
CeGaT GmbH
Paul-Ehrlich-Strasse 23
72076 Tübingen
Baden-Wuerttemberg
+49-7071-565-44-55
+49-7071-565-44-56 info@cegat.com www.cegat.com I F ~ 200 2009
CeGaT is a global provider of genetic analyses for a wide range of medical, research, and pharmaceutical applications.
Founded in 2009 in Tübingen, Germany, the company combines state-of-the-art sequencing technology with medical expertise – with the aim of identifying the genetic causes of diseases and supporting patient care. For researchers and pharmaceutical companies, CeGaT offers a broad portfolio of sequencing services and tumour analyses. CeGaT generates the data basis for clinical studies and medical innovations and drives science forward with its own insights.
The owner-managed company stands for independence, comprehensive personal customer service, and outstanding quality. CeGaT’s laboratory is accredited according to CAP/CLIA, DIN EN ISO 15189, and DIN EN ISO/IEC 17025 and thus meets the highest international standards.
Your true partner for next-generation sequencing (NGS)
Our vision is to make next-generation sequencing available to all life scientists and bring diagnostic knowledge into sequencing service.
We are your true partner for next-generation sequencing. Being pioneers in NGS-based genetic diagnostics, we have a profound understanding of the underlying technology. Based on this, we offer practical applications for research and medicine. Consistently high quality is our maxim: We perform all projects in-house and automate processes whenever possible.
We strongly believe that teamwork is key. Our interdisciplinary team consists of specialists from various disciplines who contribute their specific know-how. A dedicated project manager supports you from beginning to completion and will be your individual contact. Together, we realise smart sequencing solutions to address your research questions.
A comprehensive product portfolio to match your project’s requirements
To support scientists in accomplishing projects of any scope, we offer a broad product portfolio. You can choose from a wide range of sequencing services, such as:
› Whole Genome Sequencing
› Whole Exome Sequencing
› Transcriptome Sequencing
› Ready to Load Sequencing
The portfolio is complemented by analyses suited for microbiome, immunology, translational oncology, and epigenomics studies. We are also your partner of choice for NGS services within clinical studies. All our services can be tailored to your requirements, be it the isolation of nucleic acids, data output format, or further bioinformatic analyses.
High throughput technology meets outstanding scientific expertise
The rapid advancement of technology is constantly increasing the potential of genetic analyses. Therefore, CeGaT continuously invests in the latest equipment. We constantly improve sequencing quality and data analysis by using the most advanced technologies and pipelines available. In-house, we run three Illumina NovaSeq™️ 6000, four NovaSeq™️ X Plus, and two MiSeq™️ systems for high-throughput short-read sequencing. In addition, our PacBio Sequel IIe and Revio platforms enable high-quality long-read sequencing. Together, this setup provides a very large sequencing capacity, allowing the rapid processing of genetic material.
For consistently high quality as well as time and cost savings, we rely on the automation of processes. At the same time, human expertise is indispensable to us and an essential pillar of our company. The entire process is supervised by a dedicated project manager who provides advice and support from project design to the final report. We also adopt the strict requirements of genetic diagnostics for research projects.
Name ›
Address/P.O. Box › Postal Code/City
State
Contact
Telephone
Email
Website
Social Media
Number of Employees
Founded (year)
Cellex Cell Professionals GmbH
Melli-Beese-Str. 9-11
50829 Cologne North Rhine-Westphalia Business Development
+49-221-2509-0 businessdevelopment@cellex.me www.cellex.me/en I
380+
Company founded in 2001
Active in ATMP manufacturing since 2016
2018 opening of the Cellex Cell
Manufacturing Plant in Cologne
Type of Laboratory
| 27,000 sq ft GMP-compliant manufacturing area
| Quality control laboratories
| Cryostorage area
Areas of Activity
External
Collaborations
Full service CDMO partner for Cell and Gene Therapy (CGT) and provider for human starting materials FROM BENCH TO BEDSIDE
| Regulatory strategy support and consultancy
| GMP manufacturing and QP release
| Quality Control System
| Cryostorage
| Coordination, product labeling and logistics
| Technology transfer from preclinical to commercial scale
Pharmaceutical companies, large, mid-size and small Biotech as well as academia.
Your CDMO partner for cell and gene therapy
Cellex has a strong expertise in manufacturing final drug products & intermediate drug products for Cell and Gene Therapy. Benefit from our comprehensive solutions to get your innovative drug products from early preclinical stage to clinic and commercialisation. As a reliable and trusted partner of international pharma and biotech companies and with extensive knowledge in autologous and allogenic development and manufacturing, Cellex is a true full-service CDMO partner.
Manufacturing of CGT products / ATMPs
Our state-of-the-art facility offers GMP-compliant services across the entire product lifecycle – from process development to clinical and commercial manufacturing.
› 10+ manufacturing licenses for autologous and allogenic CGT products
› 5,800+ manufactured ATMP batches
› In-house QC labs, cryostorage and QP release
› 100% of requested products were manufactured
› Experienced team including highly qualified operators, project managers and a consistent leadership
›
Why partner with Cellex?
› Expertise in manufacturing cellular intermediates and final drug products
› State-of-the-art facilities with increased production capacity and flexibility
› Laboratories with a broad portfolio of analytical methods to ensure product quality
› Manufacturing process development and optimisation
› GDP-compliant, customised logistics & transport solutions
› End-to-end support related to CGT products: Project Management, QP Services, and Product Labelling
› Full regulatory compliance (e.g. EMA, ICH, GMP)
› Regulatory consultancy and audit capabilities
Human Starting Materials
Cellex offers high-quality starting materials from healthy donors and patients affected by specific conditions for R&D, clinical and commercial use. With >50,000 collections performed, Cellex has deep expertise in collecting allogenic and autologous cellular blood products.
Why choose Cellex as a supplier?
› Highly diverse donor database and large network of partners for international donor access
› Healthy & diseased donor material
› Donor prescreenings and recallable donors available
› Specialised collection centre for CGT collections
› Customised cell products according to client specific needs (donor and product requirements)
› Autologous patient collections for clinical use
› Located in Cologne with direct access to highways, high-speed trains and several airports for fast delivery worldwide.
Name › Address/P.O. Box › Postal Code/City › State
Contact Person
Telephone
Email
Website
Social Media
Number of Employees
Founded (year)
Key competencies
CG Pharma & Biotech
Business Unit of CG Chemikalien GmbH & Co. KG
Ulmer Straße 1 30880 Laatzen
Lower Saxony
Dr. Frank Velte, Head of CG Pharma & Biotech +49-511-87803-0 info@cg-chemikalien.de www.cg-pharma-biotech.com
65 dedicated CG Pharma & Biotech 1962
| Custom manufacturing of sterilefiltered process solutions and excipients for biopharmaceutical applications.
| Ready-to-use sterile-filtered solutions in single-use bags
| Expertise in processing hazardous substances in cleanrooms
| In-house production of Water for Injection (WfI) and Purified Water (AP
| Pharmacopoeia-compliant raw materials for further use in production of DS and DP
| Scalable production capacity enables us to meet your needs flexibly
| “Made in Germany”
Innovative products and › solutions
| C-Made, customised formulations
| PharmProve ®, bioprocessing chemicals and excipients
| Buffer solutions
| Cleaning in place solutions
| High quality water
| Vaccine - raw materials
| Plasma fractionation - raw materials
As a trusted partner to manufacturers of plasma-derived therapeutics and biologic drugs, CG Pharma & Biotech serves as a preferred partner for major (bio)pharma companies, supporting the industry’s growing trend toward outsourcing buffers, process solutions as well as critical raw materials. Our mission is to enable European biopharma companies to strengthen and localize their supply chains.
“Our journey began with a vision for innovation and quality. Today, thanks to our dedicated team and strong partnerships, we are a trusted partner for the global (bio)pharma industry –delivering tailored solutions and setting new standards for the future.”
Dr. Velte, Head of CG Pharma & Biotech
Our core markets
Biotechnology-based drug substances and drug products, e.g. Vaccines (mRNA, recombinant DNA, ATMPs, Cell culture media, Monoclonal antibodies (mAbs) and Biosimilars
Biological medicinal products, e.g. Plasma-derived medicinal products (PDMP), Enzymes and Heparins Classic pharmaceuticals, e.g. Solid, liquid and semisolid oral formulations, Inhalation formulations, Ophthalmic formulations and Dialysis formulations
Tailored
solution
We offer tailored solutions through agile project management, consulting, and planning, as well as the development and production of customized formulations, supported by our in-house research and development department. We accompany our partners on the path from the development stage to commercial production.
Service & products
C-MADE
Manufacturing and development of customised formulations for the (bio)pharma production process – upstream, down-stream and final formulation steps acid solutions, acids and caustics blends, alcohols & solvents blends, buffer solutions, caustic solutions, detergent solutions, high quality water (ap/wfi), salt solutions
PHARMPROVE®:
Multi-compendial bioprocessing chemicals for use as raw material and excipient for manufacturing of (bio) pharmaceuticals acetates, amino acids, buffers, carbohydrates, carbonates, chlorides, citrates, cleaning in place solutions, hydroxides/oxides, phosphates, specialty components, sulphates
Quality
› Manufacturing authorisation according to the German Medicinal Products Act AMG §13
› EU GMP certified acc. to Part 1+2
› Risk management system acc. to ICH Q9
› IPEC-GMP for Excipients certified by EXCiPACT standard
› 800 m2 cleanroom area, divided into two areas: liquid and solid
› Production facility free of animal components (AOF)
› Weighing of raw materials; compounding and filling in cleanroom class C&D
› Automatic transport conveyor system with integrated weighing technology
› SIP/CIP system for sanitisation and cleaning with validated cleaning processes
› 2,000 L and 5,000 L stainless steel vessels
› 2,000 L and 5,000 L plastic vessels (PVDF)
› 1,000 L mobile single use mixer for small scale batch production
Name ›
Address/P.O. Box › Postal Code/City › State › Contact Person › Email › Website › Social Media › Number of Employees › Founded (year) › Type of Laboratory › Areas of Activity ›
Coriolis Pharma Research GmbH
Fraunhofer Straße 18b 82152 Martinsried/Munich
Bavaria
Bettina von Klitzing-Stückle
Bettina.klitzing@coriolis-pharma.com www.coriolis-pharma.com I 200+ 2008
Contract research and development
Formulation excellence for biopharmaceuticals, incl.: | Drug Product Development | Analytical Services under R&D and GMP | Manufacturing Services
Coriolis Pharma – Drug Development, Analytical and Manufacturing Services
Coriolis Pharma is a global contract research and development organization (CRDO) and the premier partner for the development of liquid and lyophilized drug products, analytical services, and manufacturing services across a vast array of therapeutic modalities, including biologics, gene and cell therapies and vaccines.
Our expert scientists design and execute platform and custom services to accelerate and derisk your program right from the start and throughout the entire product lifecycle.
Partner with us − Right from the start Accelerate Preclinical Development
We help you establish a robust formulation foundation from the outset, reducing risks and avoiding costly delays later in development. Our collaborative approach and deep scientific expertise ensure that your formulations are optimized for stability and efficacy from day one.
Reliable Early-Phase Support
Transitioning through the mid-phases of drug development involves complex analytical and validation requirements. We provide consistent, reliable support through these critical stages, delivering robust analytical methods that streamline development and ensure compliance.
Efficient Late-Phase Solutions
As your drug approaches commercialization, managing the complexities of process development and regulatory submission becomes paramount. Our development support in this phase provides the necessary insight and expertise to navigate these challenges efficiently.
Commercial Services
We support your drug’s journey to market with proven GMP processes and meticulous attention to detail. We excel at process optimization and release testing alike, providing comprehensive support throughout the final stages of development.
CORIOLIS PHARMA
Expert Guidance Throughout
Navigating biologics development can be daunting, particularly when faced with unique formulation challenges or complex regulatory landscapes. Coriolis acts as a knowledgeable guide, providing specialized insights and collaborative support to address these issues effectively.
Our Services
Drug Product Development
› Developability assessment
› Pre-formulation screening
› Formulation development, optimization and robustness
› Stability studies
› Primary packaging and container closure selection
› Forced degradation studies
› Clinical/commercial in-use and compatibility studies
› Life cycle management and reformulation
Manufacturing Services
› Tox study manufacturing
› Filing of reference material
› Lead lot stability material
› Lyophilization process development, optimisation, transfer and scale-up
› Comparability, pump, headspace & CCIT studies
› Process development
› Manufacturing troubleshooting
Analytical Services under R&D and GMP
› Method development, qualification, and transfer
› Phase-appropriate method validation
› Compendial method verification
› Release testing / Tech transfer support
› Fast track analytics
› Particle characterisation
Coriolis at a Glance
› Established in 2008
› Headquartered in Martinsried, Germany with 6,900+ sqm lab and office space
› R&D and GMP labs under biosafety levels 1 and 2
› Commercial Organization in Michigan, USA
› GMP certified and regularly audited since 2012
Name ›
Address/P.O. Box › Postal Code/City › State › Contact › Telephone › Fax › Email › Website › Social Media › Number of Employees › Founded (year) › Areas of Activity › External › Collaborations
Research and development of transformative medicines based on messenger RNA (mRNA)
Selected CureVac collaborations: | The University of Texas MD Anderson Cancer Center | myNEO | CRISPR Therapeutics
CureVac’s profile
CureVac is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. CureVac’s mRNA platform incorporates a series of novel technologies, designed to improve the efficacy, safety and cost-effectiveness of mRNA therapeutics aimed at resulting in enhanced immune responses at lower doses. It has developed LNPs, which have been optimized for indication specific use across infectious diseases and oncology. CureVac is leveraging mRNA technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized cancer vaccine product candidates. It also develops programs in prophylactic vaccines and in treatments that aim to enable the human body to produce its own therapeutic proteins.
Headquartered in Tübingen, Germany, CureVac also operates sites in the Netherlands, Belgium, Switzerland, and the United States.
CureVac’s mRNA technology
The CureVac technology builds on more than 25 years of scientific excellence in harnessing mRNA as a universal template for protein synthesis. It is based on a targeted approach to create and optimize mRNA constructs that encode functional proteins that either induce a desired immune response or replace defective or missing proteins. By mimicking human biology, CureVac utilize mRNA to prevent infections and treat diseases through the synthesis of encoded proteins. These new mRNA constructs represent a highly flexible, novel class of medicine that have the potential to address limitations of conventional treatment modalities.
CureVac’s pipeline
CureVac’s proprietary second-generation mRNA back bone serves as the foundation of the company’s current clinical and pre-clinical development programs. CureVac’s mission to develop potentially transformative medicines for people and patients focuses on oncology and infectious diseases, where mRNA technology shows immense promise, as well as on other areas with significant unmet medical needs.
In its oncology area, CureVac combines cutting-edge omics and computational tools for antigen discovery to design and develop the next generation of mRNA cancer vaccines. The initial focus is on the development of off-the-shelf cancer vaccines, targeting tumour antigens shared across different patient populations and/or tumour types. In this area, CureVac entered a collaboration with the University of Texas MD Anderson Cancer Centre, one of the world’s leading oncology centres. A Phase 1 study assessing the shared antigen approach is currently ongoing in glioblastoma. It is complemented by the development of fully personalized cancer vaccines based on a patient’s individual tumour genomic profile.
In prophylactic vaccines, CureVac joined forces with GSK in 2020. Developments exclusively based on CureVac’s second-generation mRNA backbone yielded promising candidates for seasonal influenza, avian influenza, and COVID-19. These vaccine candidates are currently in Phase 2 clinical trials and show potential to become best-in-class. Under a new licensing agreement between CureVac and GSK, GSK has taken control of developing and manufacturing as well as globally commercializing these candidates. This new agreement is a landmark achievement for CureVac, which validates the company’s proprietary mRNA platform. CureVac is poised to make substantial strides in both the prevention and treatment of diseases, reaffirming its role as a leader in mRNA technology.
Name
Address/P.O. Box
Postal Code/City
State
Contact Person
Telephone
Email
Website
Social Media
Number of Employees
Founded (year)
Areas of Activity
Dr. Paul Lohmann GmbH & Co. KGaA
Hauptstrasse 2
31860 Emmerthal
Lower Saxony
Dr. Joswin Kattoor
+49-5155-630 sales@lohmann-minerals.com www.lohmann-minerals.com I
Approx. 650 1886
Raw materials for biopharma, biotech food, Industrial biotech processes
Dr. Paul Lohmann® is a manufacturer and developer of high quality Mineral and Metal Salts for food, food supplements, pharma, biopharma, cosmetics and industrial applications.
Since 1886, a high level of flexibility and an innovative spirit enables Dr. Paul Lohmann® to respond to changing needs. Customers profit from the broadest portfolio available of high value Minerals. Our strength lies in customised solutions tailored to your exact needs. We work closely with you to develop and optimise products to meet your specific requirements. This personalised approach ensures that you receive the perfect solution for your application – giving you a distinct competitive advantage through innovation, reliability, and superior performance.
Salts for Biopharma
We are experts in high quality Salt manufacturing and provide DPL-BioPharm Salts for upstream, downstream and fill & finish processes of biopharmaceutical industry. Our Salts are an indispensable part of bioproduction and act as nutrients, processing aids or excipients in the final formulation. Our multi-compendial DPL-BioPharm grade convinces with a constant and high-quality including Bioburden and heavy metal profile according to ICH Q3D.
Minerals for Food Biotech
Biotechnology is one of our forward-looking segments, transforming renewable resources into valuable products in novel ways. Among the various techniques used, fermentation plays a crucial role in the food industry. Biomass fermentation and precision fermentation are biotechnological processes for producing a wide range of foods and food ingredients, including cultured meats, plant proteins and flavourings.
In this context, Minerals can fulfil multiple roles, including:
› Macronutrients such as Magnesium, Calcium, or Ammonium
› Micronutrients such as Iron, Manganese, or Copper
› Buffering agents such as Acetates, Formates, and Phosphates
We offer high value Salts specifically designed for food biotechnological applications creating an optimal environment for microorganism to grow robustly. Made in Germany through carefully defined processes, our Salts meet the highest quality standards and can be tailored to customers specifications.
Lohtragon ® BT Portfolio for Industrial Biotechnology
The increasing role of Biotechnology (BT) is linked to the sustainable approach of producing value-added products from renewable sources with reduced waste, energy consumption and greenhouse gas emission, avoiding fossil resources and hazardous intermediates.
The Lohtragon® BT product range for industrial biotechnology focuses on large-scale fermentation processes considering all steps along the biotechnological valuechain. We thereby permanently support the formulation of defined synthetic fermentation media. Our experts are keen to adjust our inorganic components and their blends according to your requirements. Our range of metal salts combined with our expertise in product modification contribute to a properly defined culture media.
Salts From Your Trusted Partner
At our ISO- and GMP-certified production sites in Germany we use state-of-the-art equipment and this, combined with our many years of extensive high-level manufacturing experience, ensures the highest and reliable quality. Our commitment to supply chain stability, along with full transparency and traceability, ensures that you benefit from a dependable partnership. Let’s shape the future together and develop innovative solutions for your challenges.
L1/L2/S1/S2, | CDMO, Microbial Fermentation | Manufacturing: cGMP, FSSC 22000, EFfCI, ISO 9001, FAMI-QS | Strain and process development | Piloting and Scale-up
A global precision fermentation leader from strain development to large-scale production
The Business Line Health Care at Evonik operates a global network of biotechnological production sites at different scales with up to 250 m³ fermentors. This network includes a versatile multi-product site in Slovakia, designed for process scale-up and market launch of new and innovative products, which is available to our industrial partners.
External › Collaborations
CDMO, Joint Development, Supply Agreements, Joint Venture, Venture Capital
Request for › Further Collaborations
Long-term business orientation
Evonik has leveraged its expertise in fermentation and biocatalysis technologies, including strain development, process optimisation, piloting, and large-scale manufacturing to bring a wide range of products to market. These products span various application fields, such as APIs, pharma intermediates, biomaterials, food ingredients, excipients, and cosmetics. With a total CDMO fermentation capacity exceeding 4,000 m³, Evonik’s network of sites in the U.S. and Europe is well positioned to support customer projects and products, regardless of scale or process complexity.
Evonik CDMO services – a one-stop shop
In addition to development and production services, Evonik can support customers in techno-economical assessments (TEA) and life cycle assessments (LCA). Leveraging Evonik’s extensive engineering experience, Evonik can also facilitate the realisation of brownfield or greenfield concepts in case the volume demand should exceed current capacities.
As such, Evonik positions itself as a comprehensive, one-stop shop and full-service provider.
Member of
Sustainability as a growth driver for biotechnology services
Industrial biotechnology is a crucial driver for growth and innovation, enabling the development of novel, natureinspired products that are inaccessible through chemical synthesis, thereby complementing Evonik’s existing technologies and services. Advances in synthetic biology and a shift towards sustainable manufacturing methods are increasing the demand for Contract Development and Manufacturing Organizations (CDMOs) with bestin-class microbial fermentation capabilities. For over four decades, Evonik has been a dependable partner to pharmaceutical companies and other innovators aiming to industrialise disruptive biofabrication technologies.
The Evonik biotechnology platform
The Evonik Biotech Hub serves as a central hub for various scientific disciplines within the global biotechnological network. With more than 100 scientists at three international sites, the Biotech Hub is the competence centre for industrial biotechnology at Evonik, providing everything from groundbreaking ideas to industrial bioprocesses, facilitating the transformation of business opportunities into commercially feasible processes.
The profound understanding of biological systems, like the interactions in different target systems or the elucidation of the mode of action, as well as the differentiating capability in designing and operating efficient and sustainable manufacturing processes for biomolecules and microbial solutions, enables the Biotech Hub to develop tailored and competitive solutions allowing its customers to assume a leading position in their respective markets.
Address/P.O. Box › Postal Code/City › State › Contact Person
Full service CRO for conduct of clinical studies, offering support in | Regulatory Affairs | Project Management/Monitoring | Medical Safety | Data Management/Biostatistics | Medical Writing | eSolutions | Quality Assurance all over Europe.
Our daughter companies create special added value for our clients:
| “FGK Representative Service”: EU Representation Services which are legally required for non-European sponsors conducting clinical studies in the EU (EEA).
| “FGK Pharmacovigilance”: Post-Market PV services including QPPV and PMSF.
External › Collaborations
Company overview
› Feasibility, site management, monitoring, etc. Name ›
Request for › Further Collaborations
BVMA - Federal Association of Contract Research Organisations
Small to mid-sized biotech, device or pharmaceutic seeking flexible support in their clinical development
FGK Clinical Research is an owner-managed CRO of an ideal size for cooperation with smaller and mid-sized biotech, medical device or pharmaceutical companies. Covering all phases and areas of clinical development in Europe, we have experience in every major medical indication, including oncology, cardiology, neurology, dermatology, and gastroenterology. Broad knowledge in rare diseases, ATMPs and Cell Therapy completes our expertise.
Most staff is located in our headquarters in Munich and our branch office in Berlin, Germany. We have operational subsidiaries in Czech Republic, Hungary, Poland, United Kingdom as well as US (Boston).
Our approach to a project
The main philosophy for FGK is to prepare and conduct studies in close cooperation with the sponsor. Our operational team works hand-in-hand with all other departments involved. This also applies for the project manager, who is the central contact person delivering all required information to the sponsor.
Timely approvals and efficient troubleshooting are achieved through a combination of centralized project management and local monitoring, as well as local expertise and regulatory submissions within the country of study conduct.
Services
Clinical Operations
› Project management, primary liaison for sponsor communication, status reports, etc.
Regulatory Affairs
› Consulting on regulatory topics
› Review of study documents (e.g. protocol, informed consent form, labels)
› Clinical Trial Application with submission to EU and non-EU regulatory bodies
› Legal representative – also visit www.fgk-rs.com
Medical Safety/Pharmacovigilance
› Adverse Event Management and assessment/reporting
› Drug safety, medical monitoring and coding of medical terms
› Pharmacovigilance – also visit www.fgk-pv.com
Medical Writing
› Investigator’s brochures, study protocols, ICF and subject information
› Clinical expert reports, clinical publications, IMP and submission dossiers
Data Management
› CRF design and review, clinical trial databases
› Data validation, processing and cleaning, external data handling, CDISC SDTM
Biostatistics and Programming
› Study design, sample size calculations
› Statistical consultancy, analysis plan, programming and reporting
› CDISC ADaM
Quality Assurance
› Audits of investigator site, database and system audits, internal audits
› SOP composition and implementation
eSolutions
› eCRF/ePRO, RTSM, eTMF, CTMS, DCT elements
Address/P.O. Box
Postal Code/City
State
Social Media
Number of Employees
Founded (year)
Areas of Activity
GENEWIZ Germany GmbH
Bahnhofstrasse 86
04158 Leipzig, Germany
Saxony
www.genewiz.com
Next generation sequencing (NGS)
Plasmid sequencing and PCR Services
Gene synthesis and gene editing
Full-length plasmid sequencing
RNA / transcriptome sequencing
Whole genome sequencing
Microbiome and metagenomics
Proteomics and spatial biology
Oligo synthesis
Plasmid preparation services
Custom antibodies
Viral packaging
Pre-clinical and clinical services
GENEWIZ, a world-leading genomics service provider, is a trusted partner for academic, biotech and pharma researchers requiring multiomics and synthesis services. With a global network of laboratories supporting you locally, we deliver integrated genomics and analytical solutions that accelerate discoveries with greater confidence.
At the heart of Europe, our laboratory in Leipzig, Germany, is a 1,500 m² high-tech facility equipped with cutting-edge sequencing technologies. Our experienced project management team and advanced automation, enables us to deliver scalable solutions – from single samples to complex studies involving thousands of samples – often within very short turnaround times and great support in many European languages, including German.
Next Generation Sequencing (NGS)
In Leipzig, we provide a comprehensive portfolio of NGS services, supporting transcriptomic and genome sequencing focusing on human, animal and microbial samples. We also have an expert team experienced in extracting and processing complex samples including plant, bacterial, fungal, and viral. With a large-scale expert extraction capacity and accreditation to process infectious and genetically modified organisms, our facility is prepared to handle projects of all sizes and complexities. To enable deeper insights, we also offer advanced multiomics capabilities such as single-cell sequencing (10x Genomics), spatial transcriptomics (Nanostring), and Olink proteomics.
Sanger Sequencing
Sanger sequencing services in Leipzig, including plasmid, PCR and colony sequencing, are designed to provide fast, reliable, and cost-efficient results. We can process a wide variety of sample types and complexities, from single tubes to high-throughput projects. Leveraging the newest long-read NGS technologies, we also provide complete plasmid sequencing without the need to design or supply primers. All samples are proName
cessed in a highly automated laboratory with barcodebased tracking, ensuring precision and reliability. With flexible logistics, including customised sample pick-up across Europe, we deliver sequencing results quickly, often overnight or within one business day in Europe.
Gene Synthesis and More
While gene synthesis is performed through the global GENEWIZ network, customers in Europe benefit from seamless access to high-quality synthetic DNA (oligos, DNA fragments, cloned constructs, mRNAs, ssDNAs, and others) supported by our local team of experts. In addition, the network provides plasmid prep services, viral packaging, antibody expression, as well as GLPand CLIA-compliant solutions for pre-clinical and clinical studies. Our specialist Leipzig team ensures smooth project coordination, helping researchers integrate these services with their local sequencing workflows.
Part of Azenta Life Sciences
GENEWIZ Germany GmbH is part of Azenta Life Sciences, a global leader in life sciences solutions. Azenta supports innovators across drug development, clinical research, and advanced cell therapies with a comprehensive portfolio of multiomics services and trusted cold-chain sample management. Together, we help bring scientific breakthroughs to market faster.
For additional information, please visit www.genewiz.com.
High Performance Glycoanalytical & (Glyco)Proteinanalytical Services & Products
glyXera GmbH is a Max Planck Society spin-off, specialised in high performance glycoanalysis. We are utilising separation- and mass-spectrometry-based glycoanalytical tools and have substantial experience in providing glycoanalytical products & services tailored to the specific needs of our customers. Worldwide exclusively glyXera provides the high-performance glycoanalysis system glyXboxTM
Our clients include leading pharmaceutical, biotechnology and food companies throughout the world. We offer you our sophisticated technology platforms and our expertise with respect to glycoanalytical services, tailored to your specific needs. We guide you for better decisions and help you to perform better and faster during discovery phase, R&D, (clinical) trials and approval of your innovative products (biopharmaceuticals (originators & biosimilars), vaccines, food additives, functional food, etc.), and QA/QC in your production stages.
Expertise & pace
glyXera GmbH is specialised in glycoanalysis, utilising state-of-the-art separation- and mass-spectrometrybased glycoanalytical tools and has a strong background in providing glycoanalytical services. We run modern analytical and synthesis labs, equipped with state-of-the-art instrumentation.
glyXera offers high performance glycoanalysis to its clients, providing sophisticated technology platforms and expertise with respect to glycoanalytical services, tailored to the specific needs of the variety of its customers from academia, clinics, pharmaceutical and food industries. We have substantial experience in glycomics, glycoproteomics and proteomics of biotechnological (e.g. recombinant glycoproteins (mAbs, fusion proteins, factors, hormones, etc) or viral membrane glycoproteins) and clinical (blood, milk and other body fluids) samples.
High-performance glycoanalysis
glyXera provides exclusively worldwide fast and reliable glycoanalysis utilising a “real” high-throughput system (method/software/database) with superior performance and capacity compared to other glycoanalysis tools available on the market.
Our patented system glyXboxTM, based on multiplexed capillary gelelectrophoresis with laser induced fluorescence detection (xCGE-LIF) enables generation and comparison of glyco-fingerprints from large sets of samples and structural analysis of glycans within these samples.
High throughput, high resolution, high sensitivity, high reproducibility, high reliability:
› Up to 96 capillaries in parallel enable “real” high throughput
› Up to 3500x more sensitive and 450x faster, compared to LC
› An order of magnitude higher separation power, compared to LC
› Standard Glycoprofiling: Identification of glycans in complex mixtures via database matching
› Extended Glycoprofiling: Extended structural analysis of glycans in complex mixtures using exoglycosidase sequencing in combination with repeated glycoprofiling.
Our services
› Glycofingerprinting & Glycoprofiling by xCGE-LIF & HILIC-FLR
› MALDI-MS based Glycoprofiling
› LC-MS based profiling of N- and/or O-glycans
› Monosaccharide (Composition) Analysis
› Site Occupancy Analysis
› Proteomics
› N- & O-Glycopeptide Mapping
› Intact Mass Protein Analysis (Glycoform Determination)
› General (Glyco)-Protein Characterisation by Protein Gel Electrophoresis Pattern Analysis
Our products
› glyXbox CE : High performance glycoanalysis system based on xCGE-LIF (incl. glyXtoolCE software)
› glyXprep: Sample preparation kit for glycoanalysis
› Tailored standards & kits for glycoanalysis
Name ›
Hamilton Germany GmbH a subsidiary of Hamilton Company
Address/P.O. Box › Postal Code/City › State › Telephone › Email › Website › Social Media ›
Automated liquid handling, automated sample management systems, sensors for process analytics, syringes, needles and HPLC columns
Request for › Further collaborations ›
In addition to our direct offer to customers, we partner with kit manufacturers to automate their methods under various collaboration and partnership models, including OEM
Hamilton Company
Hamilton Company specializes in the development, manufacturing, and customization of precision measurement devices, automated liquid handling workstations, and sample management systems. The company’s history dates back to the late 1940s, when chemical engineer Clark Hamilton developed the microliter syringe, an innovation that quickly became a global best-seller. Today, Hamilton employs more than 3,000 people and is managed by Clark Hamilton’s sons and grandchildren.
The company’s headquarters are located in Reno, Nevada; Franklin, Massachusetts; Bonaduz, Switzerland; and Timisoara, Romania, with subsidiary offices worldwide, including in Germany.
Hamilton Automated Liquid Handling Solutions
Hamilton offers a wide array of solutions for the life sciences community. Within the pharmaceutical and biotech industries, its automated liquid handling systems are particularly prominent.
Three platform categories cover a broad spectrum of throughput and integration requirements:
› Microlab ® VANTAGE: Designed for high-throughput assays (35 to 60 SBS plates) with 360° integration capabilities, including Hamilton’s Logistic and Rear Integration Cabinets.
› Microlab ® STAR™️ and STAR V: Tailored for mediumto-high-throughput applications (25 to 60 SBS plates) with 180 to 270° integration.
› Microlab ® NIMBUS and Microlab ® Prep™️: Ideal for entry-level and lower-throughput labs (7 to 20 SBS plates).
In addition, the BioSpot ® platform family is engineered specifically for ultra-low volume dispensing in the picoliter to nanoliter range.
Member of
Hamilton’s philosophy is to provide customers with a broad range of options, including solutions with standardized hardware and software packages, as well as customized solutions designed to fulfill the needs of each specific project. Standardized solutions, referred to as Assay-Ready Workstations, are available for
applications such as NGS library preparation, LC-MS sample preparation, blood fractionation, bioprocessing and cell maintenance.
Customized solutions include the integration of proprietary on-deck modules for heating, shaking, cooling, capping, decapping, media management, centrifugation, pH measurement, filtration, solid phase extraction, or image analysis. Integration with third-party instruments such as plate readers, washers, incubators, and imaging systems is frequently incorporated for pharmaceutical applications.
Hamilton systems provide the flexibility and scalability required to support a wide range of applications.
Hamilton Pipetting Technologies
At the core of every Hamilton liquid handler is advanced pipetting technology:
› Compressed O-Ring Expansion (CO-RE®): Ensures precise tip attachment and alignment.
› Liquid Level Detection (LLD): Accurately identifies liquid surfaces in tubes and plates.
› Monitored Air Displacement (MAD): Detects clots or empty wells in real time during aspiration.
› Total Aspiration and Dispense Monitoring (TADM™️ ): Enables traceable digital auditing of pipetting performance.
› Anti-Droplet Control (ADC™️ ): Optimized for volatile organic solvents.
Additional automation tools, such as Autoload for barcode-based labware detection, CO-RE gripper and plate gripper for plate transport, and DeckWatch for activity monitoring, ensure complete traceability without compromising flexibility.
For more than 70 years, Hamilton has been recognized worldwide for innovation, precision, and reliability in automated liquid handling, consistently delivering reproducible results and upholding rigorous standards with an unwavering commitment to quality.
126 (Staff reductions planned until mid-2026) 1997
ADC technology | Takeda | Binghamton University
Unique. Like every patient
Heidelberg Pharma is a publicly listed clinical-stage company working on a unique treatment approach in oncology and developing innovative Antibody Drug Conjugates (ADCs) for the targeted and highly effective treatment of cancer. ADCs combine the specificity of antibodies with the efficacy of toxins to fight cancer. Selected antibodies are loaded with cytotoxic compounds, the so-called payloads, which are transported into diseased cells. Inside the cells, the toxins then unleash their effect and kill the diseased cells.
First to use compound Amanitin
Heidelberg Pharma is pioneering the payload Amanitin from the green death cap mushroom in cancer therapy. The biological mechanism of action of the toxin represents a new therapeutic modality and is used as a compound in the Amanitin-based ADC technology, the so-called ATAC technology. Amanitin is crosslinked to different antibodies designed to transport the compound to the cancer cell, where it is absorbed, the Amanitin is released and results in programmed cell death, or apoptosis. RNA polymerase inhibition is a novel principle in cancer therapy and offers the possibility of breaking through drug resistance and destroying dormant tumour cells.
Strategic and operational focus
In September 2025, the company decided to focus on its lead programme with the ATAC candidate HDP-101, which is currently in a Phase I/IIa clinical trial. At the same time, early-stage research activities and operating costs, including a significant reduction in workforce by approximately 75%, were significantly reduced to extend the Company’s cash reach.
Unique. Like every patient
Every patient is unique. Just like our novel ADC technology, with which we are pioneering targeted and highly effective cancer treatment. With a novel mechanism of action we address various types of cancer and overcome tumor resistance by also killing dormant tumor cells.
Two Amanitin-based candidates in clinical testing
The lead Amanitin-based candidate, HDP-101, is being tested for multiple myeloma, the second most common blood cancer worldwide. The initial clinical results are promising, with objective response rates up to 50%. In some patients, HDP-101 achieved a partial response and thus an objective improvement in the disease, with one patient even achieving complete remission. HDP-101 has been well tolerated to date with a favourable safety profile.
A second ATAC candidate, HDP-102, is being developed for non-Hodgkin lymphoma (NHL) and is tested in a Phase I study. This multicenter, multinational, openlabel study is designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of HDP-102 in patients with relapsed or refractory B-cell malignancies, and to determine the recommended dose for future studies. Preliminary signs of biological activity have already been observed at the very low dose of Cohort 1. Due to cost-cutting measures, the clinical trial is currently put on a temporary hold.
Third ATAC candidate ready to start
A third ATAC candidate, HDP-103, was planned to be developed for the treatment of metastatic castrationresistant prostate cancer (mCRPC). Preclinical studies on in vitro and in vivo efficacy, tolerability and pharmacokinetics have shown that HDP-103 has a promising therapeutic window. Clinical Trial Application for HDP-103 is beeing prepared for submission.
Mission
Heidelberg Pharma is striving to eradicate cancer through its ATAC pipeline driven by a unique payload technology. Amanitin offers the chance to break through therapy resistance and also eliminate dormant tumour cells. For patients who no longer respond to any other treatment, this would represent a significant advance in treatment.
Name ›
Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Email › Website › Social Media › Number of Employees › Founded (year) › Areas of Activity ›
IDT Biologika
Am Pharmapark
06861 Dessau-Rosslau
Saxony-Anhalt
Antje Seidler
+49-34901-8850
info@idt-biologika.com www.idt-biologika.com
I
1,600 1921
End-to-End Services in Contract
Development and Manufacturing of Cell Culture & Microbial Proteins, Monoclonal Antibodies, Vaccines, Gene & Immune Therapeutics, Biosimilars and other Sterile Injectables
About IDT Biologika
IDT Biologika, as part of SK bioscience, is a globally operating biopharmaceutical contract development and manufacturing organization (CDMO) specializing in cell culture and microbial-based proteins, monoclonal antibodies, vaccines, gene and immune therapeutics, biosimilars and other sterile injectables. With more than a century of expertise in biopharmaceutical manufacturing, we provide solutions that combine maximum flexibility, uncompromising quality, and complete regulatory compliance. Beyond delivering technical reliability and scalability, we understand the unique requirements of our customers—from early clinical phases through to commercial supply. Our dedicated teams ensure seamless process development and efficient product transfer, always upholding the highest regulatory standards.
Our services
We offer our clients a one-stop shop, with seamless end-to-end solutions and the ability to nimbly scale projects from development through to commercialisation. This includes process development and validation, drug substance manufacturing up to BSL-2, fill-finish, labelling & packaging, quality control & analytics for clinical and commercial batches. At our clients’ request we supply their products in vials, pre-filled syringes (with and without safety devices), autoinjectors, or as combination products.
Our site
At our headquarters in Germany, IDT Biologika operates one of Europe’s premier integrated facilities, providing true end-to-end services for both clinical and commercial manufacturing. With state-of-the-art infrastructure, strict quality systems, and experienced teams, we ensure flexibility, reliability, and full compliance with international regulatory standards - helping our clients bring their products to market efficiently and with confidence.
Proven expertise and strong track record
Our fully integrated services are underscored by our commitment to quality and the operational excellence that flows through our best-in-class process and cGMP (up to BSL-2) manufacturing capabilities, meeting FDA, EMA, and ANVISA standards.
IDT Biologika has made a significant contribution to global health by manufacturing products for international biopharma companies that are used in the fight against infectious diseases. In the rapidly emerging area of oncolytic virus-based therapies, we have established ourselves as a trusted partner by manufacturing one of the first commercial oncolytic virus products approved by EMA and FDA.
Furthermore, with more than 35 years of proven expertise, we have earned the trust of clients worldwide as a reliable supplier of the fill-finish of sterile injectables.These achievements reflect the dedication, quality, and longstanding commitment of our company and its people.
Our Technology Excellence
Our industry-leading knowledge of bacterial and viral manufacturing and our next-generation platforms build on years of successful partnerships with our clients and continue to drive innovation in biopharmaceutical manufacturing. Our broad technology portfolio includes proprietary cell lines as well as deep expertise with a variety of other cell lines. In addition, we have extensive know-how in handling and manufacturing bacterial strains and viral vectors across diverse production platforms. This covers the entire value chain—from drug substance upstream and downstream processing to final drug product manufacturing. Complementing these capabilities, we also provide our own well-characterized seed and cell banks, ensuring reliability, consistency, and flexibility for our customers’ projects. To further support our partners, we offer a full range of in-house analytical services, enabling seamless integration, highest quality standards, and efficient project execution.
Please contact us for further information.
Name ›
Address/P.O. Box › Postal Code/City › State ›
Contact Person
Telephone
Email
Website
Social Media
Number of Employees › Founded (year)
Areas of Activity › External › Collaborations
Immunic Therapeutics
Lochhamer Schlag 21 82166 Gräfelfing
Bavaria
Headquarter: New York City, USA
Jessica Breu (Vice President Investor Relations and Communications)
+49-89-2080477-09 info@imux.com www.imux.com
F I Q
90 2016
| Immunology
| Chronic inflammatory and autoimmune diseases
| University Hospital Frankfurt, Germany: Institute for Infectiology
| Ludwig-Maximilians-University (LMU) Munich, Germany: Department of Pharmacy
| City of Hope, California, USA: Beckman Research Institute, Dept. of Immunology & Theranostics
| Charité – Berlin University of Medicine, Germany: Dept. of Gastroenterology, Infectious Diseases & Rheumatology
| University of Turin, Italy: Neuroscience Institute Cavalieri Ottolenghi
| Kyoto University, Japan: Institute for Life and Medical Sciences
Immunic (Nasdaq: IMUX) is developing a clinical pipeline of oral, small molecule therapies for chronic inflammatory and autoimmune diseases. The company’s lead asset, vidofludimus calcium (IMU-838), is being developed as a next-generation oral treatment option for patients with relapsing and progressive forms of multiple sclerosis (MS). Immunic’s second clinical-stage asset, IMU-856, has demonstrated clinical proof-of-concept in celiac disease patients and may represent a completely new treatment approach for a variety of gastrointestinal disorders. IMU-381, currently in preclinical testing, is a next generation molecule specifically addressing the needs of gastrointestinal diseases.
Vidofludimus Calcium: Addressing Multiple Drivers of Neurodegeneration in Multiple Sclerosis
Vidofludimus calcium is an orally available, next-generation selective immune modulator that acts as a potent, first-in-class nuclear receptor related 1 (Nurr1) activator and as a dihydroorotate dehydrogenase (DHODH) inhibitor. Nurr1 is a neuroprotective transcription factor and an emerging target in neurodegenerative diseases.
Vidofludimus calcium is currently being investigated in the twin phase 3 clinical ENSURE trials in relapsing MS (RMS). Immunic announced a positive outcome of an interim analysis, confirming the trials can continue as planned without a need for potential upsizing. Top-line data for both ENSURE trials is expected by the end of 2026.
For progressive MS (PMS), Immunic announced positive results from its phase 2 CALLIPER trial of vidofludimus calcium. The drug showed consistent reductions in disability progression in the overall PMS and all subpopulations, including primary and non-active secondary PMS – both areas with high unmet medical needs. Meaningful benefits were also observed in patients without active inflammatory lesions at baseline, along with reduced thalamic brain volume loss. Safety and tolerability remained favourable, with no new safety signals identified.
Neuroprotective, Anti-Inflammatory, and Anti-Viral Effects
Immunic believes that vidofludimus calcium has the potential to demonstrate important advantages over approved MS treatments through its combined neuroprotective, anti-inflammatory, and anti-viral effects, potentially making it a unique treatment option for all forms of MS. The collective findings support the concept that Nurr1 activation may represent a novel mechanism to prevent neurodegeneration in MS. To date, vidofludimus calcium has shown consistent clinical effects and favourable safety/tolerability in approximately 2,700 patients across trials and formulations.
The molecule selectively targets hyperactive immune cells without suppressing normal immune function. In phase 2 clinical testing, it demonstrated strong suppression of MRI lesions, showed encouraging signs of reducing confirmed disability worsening, and lowered serum neurofilament light chain (NfL) levels. In addition, vidofludimus calcium’s broad-spectrum anti-viral activity may support lowering the rate of viral infections and reactivations, including Epstein-Barr virus (EBV), potentially resulting in slowing EBV-related neurodegenerative processes.
IMU-856: Targeted to Restore a Healthy Gut by Renewal of the Gut Wall
IMU-856 is an orally available and systemically acting small molecule modulator that targets Sirtuin 6 (SIRT6), a protein which serves as a transcriptional regulator of intestinal barrier function and regeneration of bowel epithelium. Immunic announced positive phase 1b trial results in celiac disease, with IMU-856 showing benefits across histology, symptoms, biomarkers, and nutrient absorption, while being safe and well tolerated.
Additionally, in a post hoc analysis of this trial, IMU-856 demonstrated a dose-dependent increase of endogenous glucagon-like peptide-1 (GLP-1) levels and, in preclinical testing, showed a dose-dependent reduction of body weight gain and food consumption, indicating potential as an oral treatment option for weight management. Further clinical testing is in preperation.
Name ›
Address/P.O. Box ›
Postal Code/City › State
Contact Persons
Telephone
Fax
Email
Website
Social Media
Number of Employees
Founded (year) › Type of Laboratory
Areas of Activity
Indivumed GmbH
Falkenried 88 | Bldg. D
20251 Hamburg
Hamburg
Prof. Dr. Hartmut Juhl (CEO)
+49-40-4133-83-0
+49-40-4133-83-14 info@indivumed.com www.indivumed.com I ~100 2002 S2, S1
Patient-centric R&D approach
| Data-driven target discovery
| Target validation
| AI-driven drug discovery
Innovative pipeline
| Therapeutically novel targets
| Small molecules and biologic modalities
| CRC and other solid tumours
Partnering opportunities
| Partner on novel therapeutic targets
| Collaborate on the development of innovative therapeutics
| Co-create new pipelines
Clinical cooperations and scientific collaborators
| Clinical network of leading cancer clinics in Europe, US and Asia
| Scientific collaborators, such as
| University of Rochester
Medical Center, US
| Salk Institute, US
| Georgetown University Medical Center, US
| A*Star Institute of Molecular and Cell Biology, Singapore
The world needs novel therapies against cancer. We find them.
Indivumed is a biotech company focused on precision oncology. Our patient-centric, data-driven R&D approach enables the discovery of therapeutically novel targets for the development of first-in-class therapeutics. With over 20 years of experience in collecting tissue and data of unmatched quality and variety, we have built a unique multi-omics database that connects molecular and clinical data, unlocking a deep understanding of cancer. Our translational pipeline is strategically focused on colorectal cancer (CRC) and other solid tumours with high unmet clinical needs, advancing differentiated therapeutic programmes across small molecule inhibitors, monoclonal antibodies, and other biologic modalities.
A patient-centric R&D approach driving targets into first-in-class therapeutics
Grounded in a uniquely strong foundation that enables transformative insights into cancer biology, our R&D strategy is built around an end-to-end ecosystem: from the surgical suite, to our biobank and database, to the lab, and back to the clinic - with many partners supporting each stage. This ensures effective and meaningful therapeutic development.
We start with meticulously collected and curated patient samples, both tumour and matched normal tissue, prioritising a cold ischaemia time of under 12 minutes. This ensures exceptional tissue quality and preserves molecular integrity, which is critical for accurate disease characterisation.
Leveraging this high-quality material, we deploy a comprehensive multi-omics approach, including wholegenome sequencing, transcriptomics, proteomics, and phospho-proteomics. What differentiates us further is the integration of these molecular datasets with over 300 clinically relevant data points, creating a powerful platform for identifying novel, therapeutically actionable targets.
To de-risk and validate these targets, we use patientderived 3D tumour models generated from the same tissue used for molecular profiling, offering superior
translational relevance compared to conventional 2D cell lines. Early-stage development is further strengthened through in-house-developed functional assays in both cell-free and cell-based systems. These patient-centric insights drive the identification and validation of novel cancer targets, accelerate drug discovery and development, and enable precise stratification of patient populations for targeted therapies.
Our focus: Surfaceome targets in CRC and pipeline building
We are advancing a dynamic pipeline of innovative targets and modalities, including both small molecules and biologics. Our decision framework for selecting targets and progressing novel therapeutics is based on strong disease association, high therapeutic relevance, robust biological validation, and expected patient impact, as well as market potential.
We are focused on colorectal cancer, a high-impact disease with limited treatment options. Our biobank also includes extensive patient cases in non-small cell lung cancer (NSCLC) and other solid tumours, providing a strong foundation for future innovation across multiple cancer types.
We partner with ambitious teams to develop first-inclass cancer therapeutics.
› Partner on novel therapeutic targets: intracellular and surface-bound targets (functional, locator targets for ADCs, bispecifics)
› Co-develop innovative therapeutics: small molecules and antibody-based modalities
› Co-create new pipelines: addressing unmet medical needs in solid tumours
Name ›
Address/P.O. Box ›
Postal Code/City › State ›
Contact Person › Telephone › Email › Website › Social Media ›
Number of Employees › Founded (year) ›
Areas of Activity ›
iOmx Therapeutics AG
Fraunhoferstr. 22 82152 Martinsried Bavaria
Dr. Apollon Papadimitriou +49-89-8999-7090-0 info@iomx.com www.iomx.com I 45 2016 | Next-generation cancer immunotherapies | Drug development | Immuno-oncology
iOmx is a clinical-stage biotech company that harnesses deep tumour immunology insights to generate novel treatments for the most prevalent solid tumour indications.
The company is translating unexplored immune evasion biology into a growing pipeline of biomarker-enabled drug programs. Focused on developing drugs with single-agent activity and multimodal mechanisms of action, iOmx is creating potential new backbone therapies. By applying its comprehensive drug discovery and development expertise iOmx is committed to shaping the future of cancer therapy.
Next Generation Immuno-Oncology Programs
Cancer immunotherapy has revolutionized cancer treatment, led by anti-PD-1/PD-L1 monoclonal antibodies. Furthermore, T cell engagers and bispecific antibodies have gained substantial momentum and relevance as therapeutic option for solid tumour indications over the past years. Yet, despite their success, most patients currently do not benefit from existing drugs, highlighting the need for next-generation cancer immuno-therapies.
iOmx follows a route of new immune-evasion biology discovery and drug development. In a modality-open fashion, the company is developing first-in-class therapies with single-agent efficacy, focusing on targets that are biologically distinguished and orthogonal to the PD-1/PD-L1 suppression pathway. With promising novel targets identified, the company is now advancing their clinical and biomarker-guided development to deliver transformative treatments for patients.
iOmx’s pipeline
OMX- 0407 is an orally available, first- in - class, spectrum-selective inhibitor of SIK (salt-inducible kinase) and other oncology-relevant tyrosine kinases. The mode of action of OMX- 0407 combines immune sensitisation and modulation of the tumour microenvironment with direct tumour cell cycle arrest, thereby driving tumour eradication.
In a Phase Ia clinical trial, it showed a favourable safety profile and signs of anti-tumour activity. This clinical data has led to the initiation of a Phase Ib expansion study in kidney cancer and angiosarcoma, evaluating safety and single-agent activity.
IOMX- 0675, is a best- in - class antibody targeting the immunosuppressive receptors LILRB1 and LILRB2, part of the leukocyte immunoglobulin-like receptor (LILR) family – an evolving target class with cumulating clinical validation. This receptor family is expressed on myeloid and immune cells. The fully human, crossspecific, high-affinity antibody neutralises these potent immuno - suppressive receptors, while sparing closely related immune-activating members of the LILR family, such as LILRA1 and LILRA3. IOMX- 0675 has received CTA approval and is preparing for a first-in-human trial.
IOMX 0235 is a humanised antibody designed to treat inflammatory bowel disease, including Ulcerative Colitis and Crohn’s Disease. It has been engineered to effectively target and reduce CCR9-positive cells and shows strong potential within a clinically validated class of therapies.
In addition, iOmx is driving discovery programs to add to its pipeline of next-generation immune-oncology drugs, e.g. a tri-functional bispecific antibody synergistically blocking multiple immunosuppressive pathways, as well as several T cell engager programmes against novel undisclosed tumor-specific targets.
iOmx’s mission
The team at iOmx Therapeutics is driven by a shared purpose: to transform cancer treatment with courage, clarity, and commitment. The company is dedicated to discovering and developing innovative therapies that target previously unexplored biology - for science, for patients, and for a better future.
Name ›
Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Email › Website › Social Media ›
Number of Employees › Founded (year) › Type of Laboratory ›
Radiopharmaceutical biotech company | Oncology | Precision Medicine | Targeted Radionuclide Therapy | Nuclear Medicine
Targeted radiodiagnostics and therapeutics for cancer treatment
ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hardto-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including two phase III studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life.
Targeted Radionuclide Therapy or Radiopharmaceutical Therapy (RPT) is an emerging class of cancer therapeutics, which seeks to deliver radiation directly to the tumor while minimizing radiation exposure to normal tissue. In contrast to conventional external radiotherapy, Targeted Radionuclide Therapy is defined by the intravenous infusion of a radiopharmaceutical. Targeted radiopharmaceuticals are created by linking a therapeutic radioisotope to a targeting molecule (e.g., peptide, antibody, small molecule) that can precisely recognize tumor cells and bind to tumor-specific characteristics, like receptors on the tumor cell surface. As a result, the radioisotope accumulates at the tumor site and decays, releasing a small amount of ionizing radiation, thereby destroying the tumor. The highly precise localization enables targeted treatment with minimal impact to healthy surrounding tissue.
Often, the targeting molecule can be used in a “theranostic” approach for both therapeutics and diagnostics. For diagnosis, the targeting molecule is linked with a diagnostic radioisotope, for therapy with a therapeutic radioisotope. This allows tumors and metastases to be both precisely localized at an early stage, and subsequently treated following the same mechanism.
ITM is developing a proprietary portfolio and precision oncology pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine tumors, glioblastoma, prostate cancer, as well as folate receptor α positive tumors like lung, ovarian or clear-cell renal cell carcinoma (“ccRCC”) cancer. To validate the Targeted Radionuclide Therapy approach, efficacy and safety of the lead candidate n.c.a. 177Lu-edotreotide is currently being compared to standard treatments for patients with neuroendocrine tumors of gastroenteric or pancreatic origin in two Phase III clinical trials, COMPETE & COMPOSE.
The unique combination of ITM’s longstanding expertise, high-quality radioisotopes and global supply network enables ITM to develop new Targeted Radionuclide Therapy based treatment options for hard-to-treat cancer indications. ITM strives to positively impact the treatment algorithm currently in place for solid tumors and make a tangible impact in improving the treatment outcomes and lives of cancer patients.
For more information about ITM, please visit: www.itm-radiopharma.com
Name ›
Address/P.O. Box › Postal Code/City › State ›
Contact Person › Telephone
Email
Website ›
Social Media › Number of Employees ›
Founded (year) ›
Areas of Activity › External › Collaborations
KUPANDO GmbH
Willy-Brandt-Platz 2 12529 Schönefeld
Brandenburg
Dr. Johanna Holldack (CEO), Angelika Leppert (CFO) +49-30-5200586020 contact@kupando.com www.kupando.com I
| University of Bochum (oncology); | Undisclosed Partner (innovative vaccine research)
| BMBF-funded pathogen-agnostic therapy and prophylaxis against AMR
Request for › Further Collaborations
Kupando is pioneering a new era in cancer and infectious disease prevention and treatment through the power of innate immune activation and trained innate immunity. The innovative dual TLR agonist approach has the potential to transform the way of fighting these diseases.
We’re seeking partners who share our vision for transforming patient care. We are currently open to codevelopment partnerships for solid tumors, either as single agent or combination therapies.
Partner with Kupando and help us develop innovative therapies for cancer and infectious diseases.
KUPANDO
is a pioneering biotech company developing disruptive therapies to address critical unmet medical needs with significant market potential in cancer and infectious diseases.
Kupando’s disruptive approach harnesses the power of innate immune stimulation and induction of trained innate immunity by dual Toll-Like Receptor (TLR) agonists.
Our lead candidate, KUP101, is a differentiated and competitive dual TLR agonist with a robust preclinical profile and a clear path to the clinic with a pipeline of multiple programmes targeting oncology and infectious disease indications.
Drug candiates: TLR4/7 agonists
Toll-Like Receptors (TLRs) are key components of the immune system responsible for detection of cancer and infection signature molecules. When they detect a threat, such as a virus or a tumour cell, they activate the immune system to fight back. TLR4 and TLR7 are two important TLRs, each with unique roles in recognising and responding to different threats.
Kupando develops innovative drug candidates which activate both TLR4 and TLR7 simultaneously, unleashing a powerful immune response, both harnessing innate immunity and inducing trained immunity.
Kupando’s lead compound, KUP101, is formulated to provide a multitude of options for administration routes and applications.
A unique tool to fight cancer and infectious diseases
Our proprietary drug candidates are ideally suited for the systemic treatment of solid tumours (tissue agnostic), and the prevention and treatment of infectious diseases. Kupando is focusing on critical unmet medical needs, such as treatment-resistant cancers and antimicrobial-resistant infections.
A game-changer
Kupando’s drug candidates are first-in-class, differentiated and competitive small molecules with the potential to transform the management of cancer and infectious diseases. The innate immune system is highly conserved. As such, its efficacy treating cancer or treating/ preventing infections is tumour/ pathogen agnostic.
Hope for cancer patients facing difficult-to-treat conditions
In cancer, Kupando’s lead drug candidate, KUP101 may extend therapeutic options for those who do not respond to checkpoint inhibitors.
Promising new approach to combat infectious diseases
As a host-directed agent – unlike antibiotics – KUP101 has the potential for highly effective therapeutic as well as prophylactic applications, while mitigating the risk of pathogen resistance; especially in antimicrobialresistant infections.
Advantageous features
› TLR4 and TLR7 are validated targets
› High specificity for target
› No relevant off-targets
› The only therapy in development that combines both TLR4 and TLR7 agonists
› Effective as single agent or in combination (synergistic in combination with checkpoint inhibitors)
› Host-directed agent, no induction of drug resistance when used to treat or prevent infectious diseases
Management
With over 100 drug development projects and a huge variety of transactions under its belt, our team brings extensive expertise in business and drug development including in manufacturing, non-clinical and clinical development of vaccines and drugs, as well as regulatory pathways in Europe, the US and Asia.
+49-89-899-363-0 info@metabion.com www.metabion.com I 70 1997
Small-, mid- and large-scale oligonucleotides and components for in vitro diagnostics (IVD)/analytespecific reagents (ASRs), as well as small-/mid-/large-scale oligos for R&D and therapeutic applications (GMP grade).
Custom Third Party and OEM Services: Contract Manufacturing & Kitting in the Diagnostics and RUO space.
metabion is a biotechnology company headquartered in the greater Munich area, and globally renowned as a “boutique” and best-in-class provider of custom high-quality oligos. With three decades of experience, metabion specialises in the production of a wide range of synthetic DNA and RNA oligonucleotides tailored to customers’ requirements, alongside the supply of standard life science products.
metabion’s state-of-the-art production facility in Kirchheim b. München is specifically designed for high-quality manufacturing, from small-scale R&D oligonucleotides and oligo components for diagnostic/IVD/ASRs, to mid-/ large-scale oligos for R&D/therapeutic applications. metabion is certified according to DIN EN ISO 9001:2015, ISO 13485:2016, aligned with GMP standards.
Successfully translating the highest quality standards into everyday practice is at the core of metabion’s corporate philosophy and the key to its popularity at the same time. We are dedicated to enhance scientific excellence and to support diagnostic and therapeutic solutions. Quality to trust!
Custom Synthesis of High-Quality Diagnostic/IVD Oligonucleotides
› Small-, mid- and large-scale production of diagnostic/IVD oligos – from nmoles to mmoles
› ISO 13485 and cGMP compliant manufacturing
› Unmodified and modified primers – a wide range of modifications available
› qPCR and dPCR probes (DLPs and DQPs) including an extensive portfolio of reporters and quenchers
› nGS oligonucleotides for diagnostic applications
› Hybridisation probes for FISH applications.
Custom Synthesis of High-Quality Therapeutic Oligonucleotides
› From R&D to GMP grade manufacturing of small-, mid- & large-scale oligos, oligonucleotide-based vaccine adjuvants and APIs
• Lead Discovery and Optimisation
• Preclinical Development
• Clinical Trials (phase I and II)
› Support and Services:
• Design of Experiment (DOE)
• Process Characterisation, Development and Validation
• Scale-up and Process Transfer
• IND & NDA Filing support
› Therapeutic oligonucleotide portfolio includes:
• Immune-stimulating CpG oligonucleotides
• Antisense oligonucleotides (ASOs)
• siRNAs, miRNAs, sgRNA
• Gapmers/RNA-DNA Chimeras
• Aptamers
• Oligonucleotide-peptide/lipid/sugar conjugates for tissue-specific API delivery
› Exhaustive panel of QC Analytical methods and services
› Custom formulation, Fill & Finish support and services
Custom Synthesis of High-Quality R&D Oligonucleotides and Gene Fragments
› Oligonucleotide “boutique” with most complete standard portfolio (ss and ds DNA/RNA, single tube plates, low/medium/high throughput, modifications)
› Highly customised oligo manufacturing capabilities upon inquiry
› ds gene fragments and gene fragment libraries (m-blocks) up to 2 kb
Custom Third Party/Contract Manufacturing and OEM Services
› Formulations and aliquotation/replication in tubes or plates
› Filling of diagnostic assay components including third party reagents and components
› Complete assay/kit assembly and labelling
› Logistics including drop-shipping to customers
› Application programming interface for ordering and billing systems integration
Manufacturer and marketer of precision instruments and services for many applications in research and development, quality control, production, logistics, and retail to customers around the world.
Advanced solutions to optimise every step of your life science workflow
OneDrop UV/VIS Spectrophotometry: The Life Sciences Specialist UV5Nano micro-volume spectrophotometer from METTLER TOLEDO stands out with its innovative technology and intuitive usability coupled with modern design. FastTrack™️ technology combines a long-lasting light source with state-of-the-art array technology and enables very fast, accurate, and precise measurements.
Real-time cell counting without staining
CytoDirect’s intuitive operation makes cell counting seamless, accelerating your workflow and reducing time to results. Powered by digital holographic microscopy and machine learning, CytoDirect delivers stain-free viability measurements, eliminating the need for dyes or reagents.
Viability Map offers a deep dive into cell health, helping you fine-tune experimental conditions and ensure continuity with existing protocols. Compact and fully portable, CytoDirect fits effortlessly into any lab environment – even under the hood – giving you the flexibility to work wherever science takes you.
RAININ liquid handling solutions by METTLER TOLEDO
Rainin by METTLER TOLEDO delivers precision liquid handling solutions tailored for life sciences. From ergonomic pipettes with Lite Touch System (LTS) technology to BioClean Ultra tips and expert pipette services, the Pipetting 360° concept ensures accuracy, comfort, and reliability across the lab.
PipetteX 4.0 software streamlines asset management with real-time tracking, calibration alerts, and instant access to service records and certificates – making compliance effortless and efficient.
Rainin MicroPro 20 and 300 are the smallest 96-channel benchtop pipetting systems available. MicroPro delivers precision and speed for 96- and 384-well plate workflows. Compact, powerful, and designed for high-throughput efficiency, MicroPro offers wireless control and intuitive
functions like aliquoting, dilution, and mixing – enhancing reproducibility and reducing errors.
And more...
› Precise pH and conductivity measurements from small sample volumes with a single keypress for fast and reliable results
› Analytical balances deliver consistent, high-precision weighing with durable, easy-to-use tools that support efficient lab routines
› Excellent workflow support with PlateDirect – an intuitive microplate reader designed for smooth, userfriendly operation
› Seamless workflows and secure data management with our software systems LabX and PipetteX
Process analytical solutions for pH, dissolved oxygen and carbon dioxide
Control of pH and dissolved oxygen during the fermentation process is essential for quality, yield, and batch-tobatch consistency. The concentration of dissolved carbon dioxide has become another important parameter and can now be measured in situ directly in the bioreactor instead of in the off-gas with a BGA, thus providing the exact activity of CO2 in the media.
Our digital online sensors using ISM (Intelligent Sensor Management) technology provide correct measurements as well as sophisticated diagnostics information about sensor performance, such as DLI (Dynamic Lifetime Indicator), ACT (Adaptive Calibration Timer), TTM (Time to Maintenance), SIP/CIP counter, and hours of operation. With the iSense software tool the registration, maintenance, and calibration of a sensor is easily documented for quality purposes.
All sensors can be integrated in controllers for benchtop bioreactors in the R&D environment, used in combination with modern transmitters in the scale-up process, and finally used in large-scale fermenters in the production area. Sensors for O2 are available with classic amperometric technology or with modern optical technology based on fluorescence quenching.
Name ›
Address/P.O. Box › Postal Code/City › State
Contact Person
Telephone
Fax
Email
Website
Social Media
Number of Employees
Founded (year)
Type of Laboratory
Microcoat Biotechnologie GmbH
Am Neuland 3
82347 Bernried Bavaria
Dr. Ingrid Wanninger (Business Development)
Dr. Michael Kroder (Business Development)
+49-8158-9981-0
+49-8158-9981-10 info@microcoat.de www.microcoat.de I > 200 1992
S1/S2, GLP, GCP, GMP, ISO 9001, EN ISO 13485
ISO 14001
Areas of Activity
External › Collaborations Request for › Further Collaborations
| Contract manufacturing | Custom development | Laboratory services | Endotoxin and pyrogen testing service
Business-to-business with industrial partners in the pharmaceutical industry, diagnostic industry and life science industry
Microcoat seeks joint projects and service partnership with pharmaceutical, biotech and diagnostic companies, as well as with players in the field of food safety testing, crop science and instrumentation (medical devices).
Company profile
Microcoat offers a wide range of individual and specialised services for the diagnostic and pharmaceutical industry. In close cooperation with our customers, we aim for best performance, building on a complete range of advanced technologies and uncompromised quality standards.
For pharmaceutical companies, we leverage our profound expertise in in-vitro diagnostics and assay development in order to become a preferred partner in early development, pre-clinical and clinical phases of drug development and patient sample testing. For food safety, environmental testing and other specialised diagnostic fields, Microcoat aims to be the preferred OEM-partner for the development and manufacturing of reliable test components and kits.
Contract manufacturing diagnostics
Microcoat is an approved original equipment manufacturer (OEM) for diagnostic test kits, bulk and finished components. We manufacture according to ISO and IVD standards. Since all critical test components are produced and modified in house, we are able to control quality at all stages of the production process.
Production technologies:
› Fermentation (30 litre scale)
› Downstream processing
› Protein chemistry
› Microplate and particle coating
› Dispensing/filling/labelling
› Freeze-drying
› Kit assembly
Product categories:
› Coated microplates
› Lateral flow test strips
› Recombinant proteins/antigens
› Antibody/protein conjugates
› Liquid components
› Dried/lyophilized components
› Diagnostic kits
B2B Diagnostics
Custom development diagnostics
Microcoat offers unique expertise in diagnostic assay and product development. A broad spectrum of methods, skilled staff and intensive communication with the customer are the cornerstones of successful project execution.
Development projects are based on detailed milestone plans and follow standardised development guidelines through the five project phases (feasibility, development, verification, validation and manufacturing).
We develop for you:
› Immunological assays
› Molecular assays
› Sample and matrix preparation protocols
› Depletion protocols
Functional Service Provider Laboratory services
In our certified facilities, we conduct a broad spectrum of GLP/GCP services to support drug development starting from early discovery to post-marketing surveillance. As an independent contract research organisation and preferred provider we serve pharma and life science industries worldwide. Based on long lasting experience in endotoxin and pyrogen testing, Microcoat offers a set of proprietary methods and skilled scientific personnel for GMP release testing as well as non-routine projects. Services are run as flexible customer-specified projects including the search for root causes, exploration of realization alternatives, development of product-specific adaptions and GMP compliant validation of newly established methods.
Our services include:
› Assay development and validation
› Biomarker testing
› Immunogenicity/PK assays
› Endotoxin and pyrogen testing
Business model
Microcoat is focused on business-to-business with industry customers, seeking a reliable and long-lasting partnership for outsourcing projects such as contract manufacturing (OEM), assay and product development, and bioanalytical testing in the context of pre-clinical and clinical studies.
Name ›
Address/P.O. Box
Postal Code/City
State
Contact Person
Telephone
Fax
Email
Website
Number of Employees › Founded (year) › Type of Laboratory ›
Miltenyi Biotec
Friedrich-Ebert-Straße 68 51429 Bergisch Gladbach North Rhine-Westphalia
Svea Lübcke
+49-2204-8306-0
+49-2204-85197
MACSsales@miltenyi.com
www.miltenyibiotec.com
www.miltenyibioindustry.com
4,700 worldwide 1989
| S1/S2
| L1/L2
| cGMP
| clean room facilities A/B/C/ | fully automated laboratory (collaboration with Tecan® Group Limited)
Areas of Activity
| Sample preparation
| Cell separation
| Flow cytometry
| Cell sorting
| Cell culture and stimulation
| Spatial biology
| Imaging and microscopy
| Lentiviral vector transduction
| Cell analysis
| Cell processing
| Therapeutic apheresis
| Cryopreservation
| Cellular therapy
| Lab automation
External › Collaborations
Customised Applications
Check out our collaborations on our website www.miltenyibiotec.com/ grant-management-and-collaboration
Miltenyi Biotec is a global provider of products and services that empower biomedical discovery and advance cellular therapy. Our innovative portfolio enables scientists and clinicians to obtain, analyse, and utilise the cell. Our technologies offer solutions for cellular research, cell therapy, and cell manufacturing. With over 35 years of expertise, we cover research ares including immunology, stem cell biology, neuroscience, cancer, hematology, and graft engineering. In our commitment to the scientific community, we also offer comprehensive scientific support and expert training. Today, Miltenyi Biotec has 4,700 employees in 24 countries.
MACS ® Sample Preparation
Start smart with innovative solutions for your tissue preparation. gentleMACS™️ Dissociators and MACS ® Tissue Dissociation Kits enable standardised sample preparation from almost any tissue source.
MACS ® Cell Separation
With over 52,000 citations, the MACS Cell Separation portfolio is the most trusted technology for isolating target cells. Combining proven magnetic isolation with flexible workflows, it supports manual to fully automated processing. Our MicroBeads and instruments provide reliable solutions tailored to your research needs.
MACS ® Flow Cytometry
The MACSQuant ® Instruments include ultra-compact flow cytometers and the MACSQuant ® Tyto ®, a microchip-based cell sorter, and provide unrivalled ease of use for multisampling and multiparameter analysis and sorting. Our large portfolio of antibodies, including REAfinity ® Recombinant Antibodies and Vio ® Dyes, comprise a family of conjugates with high fluorescence intensities and stain indices.
MACS ® Imaging and Spatial Biology
The MACSima™️ Platform, powered by MICS (MACSima Imaging Cyclic Staining) technology, enables researchers to fully explore spatial biology with its advanced protein multiplexing capabilities. The UltraMicroscope Blaze™️ Platform allows automated 3D imaging at a cellular level, from rodent organs or organoids to samples as big as a human kidney or whole mouse models. To complement these technologies, we offer a growing collection of recombinant antibodies that have been pre-tested for fluorescence microscopy.
MACS ® Cell Culture and Stimulation
Our cell culture media, cytokines, growth factors, and reagents for stimulation, expansion, and differentiation of a variety of mammalian cells are also available up to GMP grade, thus enabling GMP-compliant, cellular product manufacturing.
Clinical products and services
Miltenyi Biotec’s comprehensive portfolio for advancing translational research and therapy includes the FDA approved CliniMACS CD34 Reagent System as well as a range of CliniMACS Reagents for cell separation and processing and MACS GMP products for cell culture and stimulation. The CliniMACS Prodigy ® platform is a unique cell processing solution that enables the fully automated and integrated manufacture of a GMPcompliant cell product in a closed environment. Miltenyi Bioindustry is our global CDMO service department helping biopharmaceutical companies and advanced clinical centres from process development into commercial scale, GMP-compliant manufacturing of viral vectors and cell and gene therapies. The CliniMACS Cell Factory ® facilities are located across North America, Europe, and China and in close proximity to customers.
Name ›
Address/P.O. Box › Postal Code/City › State
Contact Person
Telephone
Email
Website
Social Media
Number of Employees
Founded (year)
Areas of Activity
Molecular Devices
Sauerbruchstr. 50 81377 Munich Bavaria
Janet Graystone +49-173-5386574
janet.graystone@moldev.com https://www.moleculardevices.com/ I
Exploring complex biology together Empowering Scientific Discoveries to Improve Quality of Life Everywhere
Molecular Devices provides high-performance bioanalytical systems, software, and consumables for life science research and biotherapeutic development. Our platforms support high-throughput screening, genomic and cellular analysis, colony selection, and microplate detection– helping scientists accelerate research and therapeutic discovery.
Molecular Devices is a life-science technology innovator
Our integrated hardware and software solutions enable automated workflows – from start to finish – for any research application. Whether its cell line development, 3D biology, drug screening – or a combination of the three – our technology maximizes throughput and reproducibility to give researchers more time and greater insights. Together with Danaher’s global businesses, we drive innovation to improve lives worldwide.
Dedicated solutions for clone screening and singlecell isolation.
Our clone screening solutions enable researchers to confidently verify monoclonality, efficiently pick colonies, and automate workflows to streamline cell line development. With precise image-based documentation, automation, and advanced robotics, these systems provide scalable, efficient solutions for antibody discovery and synthetic biology.
The QPix® FLEX™️ goes beyond colony picking, bringing together plating, streaking, liquid handling, and highresolution color imaging into one compact, chambercompatible system. As a fully integrated workcell, it transforms traditionally manual, error-prone steps into a seamless, automated workflow that boosts throughput, traceability, and reproducibility.
Accelerate cell line development with a range of Molecular Devices platform
ClonePix 2 Mammalian Colony Picker automatically screen more clones in less time than conventional techniques, select cells with optimal expression levels, and pick colonies with accuracy. ClonePix systems are now used in over 100 laboratories around the world to increase workflow productivity, leaving more time to better characterize target proteins and run new projects.
Exploring
Complex Biology Together
Unlocking the full potential of complex biology to revolutionize research.
We’re ready for what’s next. Are you?
CloneSelect Imager – standard and fluorescence, provides high quality imaging and intelligent image analysis. CloneSelect Imager allows you to assess cell confluence objectively and quantitatively. Cell growth is viewed and tracked in every well in every plate.
Unlock the Potential of Complex Biology with Cutting Edge Microplate Readers
For over 40 years, our SpectraMax® readers and SoftPro software have supported protein and cell biology research. These flexible, user-friendly tools support ELISAs, nucleic acid and protein quantitation, and more.
Unlock the full potential of 3D biology
We support researchers transitioning to or scaling 3D bio logy. Our CellXpress.ai ® system automates cell culture with AI-driven monitoring and scheduling. 3D Ready™️ Organoids and Expansion Services deliver scalable, quality-controlled PDOs. We also offer bioprinters, imagers, and AI-powered analysis tools.
Explore our portfolio of high-content imaging systems and AI-Powered High-Content Screening
Our ImageXpress ® systems and MetaXpress/IN Carta software enable high-throughput, scalable imaging and analysis. With flexible modules and AI tools, they support diverse applications and accelerate discovery.
| Microbial DNA isolation (manual and automated solutions)
| DNA-free PCR reagents, assays, and polymerases
| Customised master mixes | OEM business
Request for › further collaborations
Molzym is interested in the following partnerships or collaborations: | Development and production of individualised, pre-analytical, and analytical solutions, including automation | Service providers and companies in the field of Next Generation
Sequencing, e.g. to establish and improve NGS-based workflows for pathogen identification directly from clinical samples
Scientific Rigor Driving Innovation
Since 2003
Nucleic acid extraction is an important step in molecular microbiological processes as it significantly influences the entire downstream workflow. Molzym focuses on culture-free detection of infectious agents that can cause severe diseases and developed a unique technology for targeted enrichment and extraction of microbial DNA from clinical samples.
Since 2003, Molzym’s sole aim has been to avoid the GIGO effect and to provide laboratories with solutions for highly sensitive and broad detection of pathogens.
Molzym relies on 2 processes that ensure the most efficient extraction: (1) the depletion of non-target human DNA from clinical samples and (2) the production of ultra-pure reagents.
Based on these special characteristics, various highquality products for molecular microbial analysis by PCR- and NGS-based methods are available in over 30 countries.
Products & Automation
From CE IVD-marked broad-range molecular diagnostic kits, host DNA depletion technology, MolYsis™️, to ultra-clean PCR reagents and assays, Molzym is one of the leading providers of culture-independent molecular solutions.
Our technology enables the detection of microbes directly from body fluids, tissues, and swabs using PCR or NGS-based methods. Pathogens can be identified within hours, significantly improving the management of patients with rapid, pathogen-targeted antimicrobial therapy.
MolYsis™️ is Molzym’s proprietary technology of host DNA depletion allowing targeted isolation of microbial DNA from a great variety of samples. Ultra-pure,
DNA-free PCR reagents and master mixes allow for the precise detection of microbes from human samples and animal models. Complete assays for the broad-range amplification of selected regions of the 16S and 18S rRNA genes of bacteria and fungi are available. Basic and dye master mixes can be used with custom primers for PCR and Real-Time PCR analysis.
The latest development is a walk-away robotic system, SelectNA™️plus, for the fully automated host DNA depletion and extraction of microbial DNA from clinical and other material. SelectNA™️plus conveys utmost technical advances to the demands for contamination-free and low-hands-on processing of samples.
With SepsiTest™️-UMD and Micro-Dx™️, Molzym offers two CE-marked in vitro diagnostic solutions for the culture-independent detection of pathogens causing various diseases. Both kits include reagents for the depletion of human DNA and the targeted isolation of microbial DNA from a variety of clinical samples, e.g. whole blood, CSF, BAL, joint aspirates, tissue biopsies, abscesses and other specimens. Manual DNA isolation can be accomplished with SepsiTest™️-UMD and with Micro-Dx™️ the process is fully automated on the SelectNA™️ plus robot. Precise detection is performed with broad-range 16S/18S PCR and sequencing analysis to identify the pathogens down to the species level. Both assays are especially applicable for samples which were negative after culturing, e.g. due to prior antibiotic treatment or fastidious growth requirements.
With the MolYsis-SNplus™️ IVD we offer our first IVDR compliant kit for fully automated human DNA depletion and isolation of bacterial and fungal DNA. The kit is specially tailored for modern diagnostic procedures based on NGS or PCR directly from samples.
The Molzym team appreciates your interest and is at your disposal for further information about our products and developmental projects. Please call at: +49-42169-61-62-0 or send your inquiries to info@molzym.com.
Name ›
NanoEntek Europe (mts med-tech supplies GmbH)
NanoEntek: Revolutionising Life Sciences with Lab-on-a-Chip Technology
Over 100 cell therapy research institutes and companies globally, plus leading pharmaceutical organisations worldwide
L’Oréal Groupe – Cell BioPrint Technology
Company Overview
NanoEntek, founded in 2000 in Seoul, South Korea, has established itself as a global leader in Bio-MEMS (Biological Micro-Electro-Mechanical Systems) technology and developed the world’s first automated cell counter. The company specialises in lab-on-a-chip solutions that integrate biotechnology with microfluidics to create innovative equipment for life sciences research. With more than 100 employees and holding about 100 patents, NanoEntek has achieved a remarkable 30% global market share in automated cell counters. In Europe, NanoEntek operates through mts med-tech supplies GmbH in Martinsried, Germany, serving the European market.
Revolutionary Technology Platform
NanoEntek’s core technology combines MEMS and microfluidics to create disposable microfluidic chips that perform multiple laboratory analyses with minimal sample volumes in dramatically reduced time frames. This lab-on-a-chip platform integrates laboratory operations such as mixing, reaction, separation, and quantitative analysis onto chips the size of a fingernail.
Life Sciences Product Portfolio
Cell Counter Series
EVE Plus: The world’s fastest cell counter delivering results in <1 second using Trypan Blue or Erythrosin B staining.
ADAM MC2: An automated fluorescence cell counter, performs viability and cell counting measurements using the AO (Acridine Orange) or PI (Propidium Iodide) staining method of combined with advanced image analysis in just 25 seconds.
ADAM MC Plus: New standard automated fluorescence cell counter with bright field and dual fluorescence
channels (AO/DAPI). Features 15 μL sample volume, 4 tests per slide, 40-second analysis, total cell counting with viability, and aggregation analysis using disposable microfluidic chips for simple, accurate operation. ADAM-CellT Plus is the version with 21 CFR Part 11 compliance.
ADAM II LS: Benchtop image-based fluorescence cell analyser with bright field and three fluorescence channels (GFP/RFP/DAPI). Provides flow-cytometer-like accuracy for transfection efficiency, protein expression, cell cycle, apoptosis analysis, and total cell counting with dot plot visualisation. Features 21 CFR Part 11 GMP compliance.
EVE HT (FL): High-throughput automated fluorescence cell counter equipped with bright field (Trypan Blue/ Ery. B) or two fluorescence channels (AO/DAPI). In just three minutes, up to 48 samples can be counted and analysed. EVE™️ HT (FL) delivers brilliant precision and accuracy, making it the optimal choice for both cell lines and primary cell analysis in a variety of applications.
JuLI Stage Live-Cell Imaging
A compact, real-time imaging system compatible with standard CO 2 incubators. Features a fully automated X-Y-Z stage, multi-channel fluorescence (GFP, RFP, DAPI, bright field), and supports a wide range of plate formats from 6 to 384 wells. Typical applications include cell proliferation and wound healing assays, real-time transfection efficiency checks, and numerous other kinetic and endpoint cell biology studies.
ExTransfection Electroporation System
Pipette-style electroporation with gold-coated electrodes and 300 pre-set protocols. Achieves high transfection of cell lines, primary cells, stem cells, and haematopoietic cells.
C-Chip Disposable Hemocytometers
NanoEntek’s famous C-Chip products are precision disposable plastic haemocytometers developed to solve common issues with conventional glass models.
Name ›
Navigo Proteins GmbH
Business Unit: Navigo Precision
Address/P.O. Box › Postal Code/City › State
Contact Person
Telephone
Email
Website
Social Media
Number of Employees › Founded (year)
Type of Laboratory
Areas of Activity
Biological patent
External collaborations
Heinrich-Damerow-Straße 1
06120 Halle/Saale
Saxony-Anhalt
Michael Hamm (Head of Business Development Navigo Precision) +49 345 27996-330 info@navigo-proteins.com www.navigo-proteins.com
I
80-90 2017 S1
Precision Medicine, Oncology, Ophthalmology
Extensive patent portfolio in proprietary affinity ligand technology
Navigo Precision, part of the Navigo Proteins Group, is a German, fast-growing, near-clinical stage biopharmaceutical company developing next-generation targeted therapies for Precision Medicine. We have a proprietary AI-driven platform with strong IP protection for therapeutic proteins called Affilins®. These are a novel class of target-binding therapeutic proteins, combining the advantages of antibodies and peptides with a smaller size, better tumour penetration, excellent stability and a robust, scalable production process.
We have a growing portfolio of targets directly available for partnering and have existing collaborations in the pharmaceutical industry with strong players such as ITM, SCK CEN, GAIASO Theranostics, or Oncodesign Precision Medicine (OPM) for the development of targeted therapies in oncology.
Our Mission
By leveraging the unique features of Affilin® technology, Navigo Precision is redefining targeted therapeutics, advancing these innovations from the laboratory to clinical development, and ultimately delivering transformative therapies to patients worldwide.
AI-Driven Innovation and Advanced Collaborations
Navigo Precision is at the forefront of integrating artificial intelligence with wet-lab capabilities, dramatically enhancing the accuracy and applicability of our research. Collaborations with partners such as AIDT, Nostrum, and the University of Leipzig further accelerate innovation and discovery.
Targeted Therapeutics Powered by
Affilin ®
Target-Binding Proteins
Precision Medicine is built on the ability to accurately target specific molecular structures, such as TumourAssociated Antigens (TAAs) and checkpoint signalling pathways. At Navigo Precision, we combine deep
expertise in protein engineering and drug design with an unwavering commitment to developing innovative targeted therapeutics and diagnostics.
The Power of Affilin ® Design
Affilins® can be precisely customised as mono-, bi-, or multi-specific ligands, allowing for tailored therapeutic strategies. They can be seamlessly conjugated with functional moieties, such as cytotoxic payloads or radioactive isotopes, to create highly targeted and potent anti-cancer therapeutics.
These therapies address both Tumour-Associated Antigens and immuno-oncology (I/O) targets, offering a versatile platform for advanced cancer treatment. Our expanding portfolio of Affilin® assets demonstrates exceptional pre-clinical results, tackling key challenges in targeted therapy, such as:
› Optimising biodistribution for maximum efficacy.
› Effectively targeting low- or medium-expressing tumours with high and sustained tumour-specific accumulation, outperforming current benchmarks.
Through these innovations, Navigo Precision is driving the development of best-in-class therapies designed to meet unmet medical needs and improve patient outcomes
Expanding Partnerships for Breakthrough Research
To advance cutting-edge science, Navigo Precision is rapidly expanding its network of partnerships. These include collaborations with other leading innovators such as Veraxa, and research institutions like SCK CEN, both of which are dedicated to highly innovative, nextgeneration cancer research.
A key strength of our platform is its application in radiotheranostics, a field where we have co-founded a new venture, GAIASO Theranostics, focused on developing next-generation therapies for female cancers , which remain among the most pressing areas of unmet medical need in oncology.
Name
Address/P.O. Box
Postal Code/City
Contact Person
Navigo Proteins GmbH
Business Unit: Navigo Pure
Heinrich-Damerow-Straße 1
06120 Halle/Saale
Saxony-Anhalt
Joséphine Hammerlindl (Business Development Manager Navigo Pure)
Precision Capturing ® is Navigo Proteins’ pioneering affinity chromatography platform within the Navigo Pure business unit that redefines the way biologics are purified. Traditional downstream processing often requires multiple sequential chromatography steps, each of which adds time, cost, and complexity to biologics manufacturing. Precision Capturing ® addresses these challenges by consolidating purification into a single, highly efficient capture step . This streamlined approach significantly accelerates process development, improves product quality, and enhances manufacturing efficiency across a wide spectrum of biologics.
Downstream processing
Custom affinity ligand and resin development
Extensive patent portfolio around proprietary affinity ligand technology
At the heart of the platform are proprietary, engineered scaffold ligands, derived from artificial Protein A scaffolds. These ligands are small, robust, and highly specific, designed to selectively bind even the most challenging biologic molecules. Unlike conventional technologies, which are often limited to antibodies with Fc regions, Precision Capturing ® enables purification of a diverse range of therapeutic modalities, including antibodies, enzymes, blood factors, vaccines, viral vectors, and non-Fc proteins. This flexibility makes it a truly universal solution for next-generation bioprocessing.
Navigo Pure: From Innovation to Implementation
Precision Capturing® ligands and resins are already applied in EMA- and FDA-approved bioprocesses, proving their regulatory acceptance and industrial reliability. These products are used throughout the entire value chain, from preclinical development to clinical supply and large-scale commercial manufacturing.
To bring this platform to market on an industrial scale, Navigo has established Navigo Pure, the dedicated business unit focused on delivering custom ligands and resins for use under GMP standards. Navigo Pure ensures that customers benefit from:
› Simplicity & Speed: Fewer purification steps mean shorter timelines, reduced process complexity, and accelerated time-to-market for novel therapies.
› Robustness & Yield: The high specificity of Navigo’s ligands enables excellent product quality, improved yields, and more predictable performance under industrial conditions.
› Scalability & Regulatory Readiness: With GMPcompliant production and extensive regulatory expertise, solutions are designed to seamlessly support clinical and commercial manufacturing.
› Cutting-edge Ligands & Resins: Advanced affinity tools are created for drug classes most in need of efficient chromatographic processes, helping overcome current bottlenecks in biologics production.
25+ Years of Experience
Backed by over 25 years of experience in bioprocessing innovation, Navigo Proteins has become a trusted global partner for affinity purification . Today, the company proudly supports more than 40 organisations, from fast-moving biotech start-ups to established Top-10 global pharmaceutical leaders, in developing and commercialising life-changing therapies. With the Navigo Pure business unit, Navigo Proteins is shaping the future of biologics manufacturing by delivering smarter, faster, and more reliable purification solutions.
Name ›
Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Fax › Email
BioStoffV S3** cGMP certified production facilities, EU (Annex 1 EU-MP guideline) up to grade A respectively ISO5 (according to EN-ISO 14644-1)
The company
The company Neovii Biotech GmbH – as part of the Neovii Group – is dedicated to delivering targeted biopharmaceutical treatment options in transplantation medicine and haematological oncology. The focus of its activities is the development and commercialisation of immunologically active biopharmaceutical therapeutics based on innovative antibody technologies. All the manu facturing activities are located in Gräfelfing/ Germany.
Neovii has a presence in more than 40 countries worldwide.
For further details please visit: www.neovii.com
Research and Development
Areas of Activity › External › Collaborations
| Transplantation Medicine | Haematological Oncology
Academic research institutions and other companies
Neovii supports research and development activities in the fields of solid organ transplantation, stem cell transplantation, and immune and haemato-oncological disorders. Neovii actively seeks in-licensing and acquisitions opportunities. We are looking to expand our portfolio of products with novel life-transforming therapies that address severe unmet medical needs, in particular in the areas of transplantation, haemato-oncology, and immune disorders.
Areas of interest
Since its inauguration Neovii Biotech has been manufacturing and commercialising a medicinal product for the prevention of graft-versus-host-disease after stem cell transplantation and prevention/treatment of acute organ rejection following solid organ transplantation.
ATLGs are antibody-based medicines for the targeted suppression of immune responses (immunosuppressants).
They suppress immune responses by multiple mechanisms, such as immune cell depletion, inhibition of T-cell function, and induction of regulatory immune cells. Their immunosuppressive properties are used mainly in solid organ transplantation and stem cell transplantation. In stem cell transplantation (SCT) polyclonal antibodies are indicated for the prevention of graft-versus-hostdisease (GVHD).
GVHD is recognised as a severe complication following SCT that negatively impacts on the patient’s quality of life and is a major cause of morbidity and mortality. In GVHD, transplanted immune cells attack the recipient’s body, causing tissue and organ damage. By suppressing these immune reactions, ATLGs significantly lower the incidence of GVHD (Finke J, et al‚ Lancet Oncot 2009;10(9)1855—64).
In solid organ transplantation (SOT), polyclonal antibodies are indicated either for the prevention of organ rejection or to suppress active, acute rejection reactions. The rejection of a transplanted organ is primarily caused by immune cells of the recipient that start attacking the grafted organ, because it is recognised as foreign. By suppressing these immune reactions, ATLGs limit organ damage and prevent graft loss (Kaden J, et al. Ann Transplant. Jan 10 2013;18:9-22).
ID-Number: ATM.00003-3.0
Name ›
Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Fax › Email › Website ›
Created by scientists for scientists, New England Biolabs is proud to be a world leader in the discovery and production of enzymes and reagents for molecular biology applications. Since our establishment in 1974, we have remained committed to developing highquality, innovative products that empower not only your research but also our own. Our profits have always funded an extensive research programme, which we believe is critical for staying connected to our customers and helping to drive scientific breakthroughs. From our founding principles to our unique corporate culture, NEB’s philosophy can be distilled down to three core values: passion, humility and being genuine.
Latest Innovation in Enzyme Technology
Our outstanding expertise in protein engineering and evolution has led to the creation of unrivaled enzymes and unique workflows in library preparation and target enrichment for the NGS space. These products set the benchmarks for optimal performance and ease of use in modern molecular biology laboratories. Moreover, NEB’s specialised offerings for alternative DNA assembly, isothermal amplification as well as novel reagents for CRISPR/Cas9-based genome editing make us a first-choice supplier for today’s molecular biologists.
Customised Solutions/GMP–grade & Lyophilisation
NEB’s customised solutions unit has been delivering tailor-made enzyme formulations and packaging solutions to biotech, pharma and diagnostic customers. Building on an extensive experience, our GMP-grade manufacturing capabilities offer a range of customised products at scale, enabling commercial customers and partners to use NEB’s world-class products in their specific applications and to support them in their efforts to access regulated markets. The recently established subsidiary NEB Lyophilisation Sciences combines expert knowledge in the design, development and manufacture of innovative enzyme solutions for ambient store products to meet our customers small- to large-scale lyophilisation needs.
THE BRIDGE TO YOUR SUCCESS
Customized Enzymes and Reagents from New England Biolabs
Largest selection of enzymes for genomic research
Research-grade and GMP-grade production
Large to small scale lyophilization capabilities
ISO 9001 and ISO 13485 certified
Formulations without components such as BSA, detergents or glycerol
NEB is dedicated to providing research products of the highest quality. Our integrated quality management systems are certified to meet the requirements according to the standards ISO 13485 and ISO 9001.
Social Responsibility & Sustainability
While our passion for science helps us to drive discovery, we continue to be guided by our responsibility to each other and our community. We continuously strive to promote ecologically sound practices and environmental sustainability in order to protect our natural resources. As an additional measure, NEB has received ISO 14001 certification, a quality standard for environmental management systems. We also recognise that we must work together to build a more equitable society and improve diversity, equity and inclusion in our workplace.
Basic and Applied Science
We believe that basic research and the cultivation of scientific knowledge is critical for us to stay connected with our customers and to drive scientific breakthroughs. At NEB, over 30 labs participate in research projects, which are aided by post-doctoral fellows and students in Masters and PhD programmes. NEB researchers have authored or co-authored over 1,450 publications to date. With a dual focus on basic and applied research, NEB’s culture is both collaborative and academic.
Scientific Customer Service
Our support model is unique as it utilises technical support scientists, scientist responsible for product development or manufacturing, and product line experts. As such, customers are supported by scientists and often experts in the product or its application.
New England Biolabs GmbH
The NEB subsidiary in Germany represents the service hub for Central Europe. From our location in Frankfurt, we serve scientists and industry customers in Germany and Austria and support our network of distribution partners across Europe.
For further information please visit our website at www.neb-online.de.
Areas of Activity › Annual Turnover › Nordmark Pharma GmbH
€140m
Founded in 1927, Nordmark is an internationally leading specialist for the development, manufacturing, and commercialisation of active pharmaceutical ingredients (APIs) and drug products of biological and biotechnological origin under GMP conditions. Headquartered in Uetersen near Hamburg (Germany), and family owned again after a management buyout from the BASF group in 2001, Nordmark today employs around 700 employees and generates revenues of around EUR 140 million.
Inspired by the organisation and high-quality standards of our former parent company, as an independent pharmaceutical enterprise, we successfully develop and produce biological active pharmaceutical ingredients and drug products through all stages of the value chain.
Nordmark Biotech, the biotechnological division of Nordmark, is a specialist for providing tailor-made solutions for the development and manufacturing of biopharmaceuticals from lab to production scale. In this context, we are able to offer expertise in both systems – microbial as well as mammalian – to our customers.
Services cover the entire value chain from process development to marketed drugs:
› Strain and Cell Line Development
› Microbial Fermentation – Upstream Process Development
› Mammalian Cell Culture – Upstream Process Development
› Downstream Process Development
› Formulation and Filling – Pharmaceutical Development
› Biomanufacturing under GMP Conditions
› Analytical Services
› Regulatory Service
› Process Transfer
› Market Supply
Nordmark Biotech connects flexible partnerships with a unique expertise and know-how in developing and delivering drugs to market. As a family-owned business we work with maximum care and attention and with fast and simple decision-making processes. We are focused on success – regardless of project size.
Nordmark can refer to a significant track record in the industry with different successful process development and manufacturing projects in various stages of clinical development as well as approved and marketed products for more than 40 international partners. With more than 90 years of excellence and commercial success, Nordmark is the ideal partner to bring your ideas to market.
Name ›
Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone
Email
Website › Social Media ›
Number of Employees › Founded (year) › Areas of Activity ›
Nova Biomedical GmbH
Hessenring 13A, Geb. G 64546 Mörfelden-Walldorf Hesse
Cell culture analysis, autosampler, upstreaming, automation, cell counter, glucose reference analyzer US-FDA in-vitro diagnostics, point-of-care testing, blood gas analysis, critical care, diabetology, emergency medicine
Innovation empowering life science
Nova Biomedical develops, manufactures, and commercialises analytical systems for cell culture and whole blood testing. The company is headquartered in Waltham, MA, USA. Worldwide, more than 1,500 people are employed by Nova, which operates direct subsidiaries in 11 countries and factory-trained distributors in more than 110 countries.
Our commitment to scientific innovation and product quality has made Nova Biomedical a world leader in the development of whole blood analyzers for clinical applications and cell culture/fermentation analyzers for biopharma for more than 40 years.
Cell Culture Analysis
Request for › Further Collaborations
Kidney disease screening & monitoring partners
GMP-compliant cell culture analysis made easy Nova offers the latest in maintenance-free cell culture analyzer technology – BioProfile ® FLEX2. FLEX2 provides fully automated analysis of key chemistries and gases, cell density, cell viability, and osmolality with one sample and a single data output stream in under 4.5 minutes. The full 16- test menu includes: Gluc, Lac, Gln, Glu, NH4+, Na+, K+, Ca++, pH, PCO2, pO2, total cell density, viable cell density, viability, cell diameter, and osmolality.
The system can be flexibly configured to meet diverse and changing needs with the optional and field upgradeable pH/gas, CDV and osmolality modules. sampling from 96-well plates, syringes, or a 24-position external “load-and-go” sample tray provides maximum workflow flexibility and efficiency for cell culture monitoring.
FLEX2 is the only cell culture analyzer designed for online sampling from micro-scale vessels through large-scale commercial manufacturing SIP/CIP systemsand integration with the ambr ® 15 and 250 cell culture systems. An optional Sample Retain Collection system automatically collects cell culture samples from the On-Line Autosampler and stores them in a refrigerated environment to enable further offline testing. IQOQ support can be offered by the local Nova representative.
BioPro fi le Analyzers for Fermentation
BioPro fi le 300 series analyzers offer a total of nine measured tests, including glucose, lactate, phosphate or glycerol, acetate, ammonium, pH, sodium, and potassium, plus calculated osmolality. The analyzer is offered in two versions: the BioPro fi le 300A which includes a phosphate assay, and the BioPro fi le 300B with glycerol testing. These systems offer measurement ranges speci fi cally suited to monitor bacterial and yeast cultures. A conversion kit is available for easy interchange between the 300 A and B versions.
BioProfile FAST CDV analyzer
BioProfile FAST CDV is a high-throughput, fully automated viable cell density and viability analyzer with a throughput of 45 samples per hour on 100µL of sample volume. The analyzer performs all sample dilutions internally, enabling cell culture samples up to 140e6 c/mL to be analysed without any external sample dilution. Cell culture samples can be analysed via the external 32 position load-and-go tray or via an innovative 96-well plate option.
BioProfile FLEX2 Basic Analyzers
FLEX2 Basic analyzers provide multiple test menus for chemistry analysis in cell therapy, gene therapy, vaccine development, and alternative foods applications. The FLEX2 Basic A test menu consists of Gluc, Lac, Gln, Glu, NH4+, Na+, K+, Ca++, pH, PCO2, pO2 with automatic dilutions and an extended range. The FLEX2 Basic B provides the same test menu with standard ranges. Flex2 Basic C offers an 8-test menu of Gluc, Lac, Na+, K+, Ca++, pH, PCO2, pO2 with standard ranges.
Glucose Reference Analyzer
Nova Primary Whole Blood Glucose Reference Analyzer
Nova Primary fills the need for a replacement to the discontinued YSI STAT PLUS 2300 Glucose and L-Lactate analyzer. Nova Primary uses a single, reusable glucose electrochemical sensor based on glucose oxidase and has a measurement range of 20-900 mg/dL. It uses a small, 25 µL whole blood or plasma sample and provides results in under 2 minutes.
Name ›
Address/P.O. Box ›
Postal Code/City › State
Contact Person
Telephone
Email
Website
Social Media
Number of Employees
Founded (year)
Areas of Activity
Omicron-Laserage Laserprodukte GmbH
Raiffeisenstrasse 5e
63110 Rodgau
Hesse
Natalie Stühler
+49-6106-8224-0 sales@omicron-laser.de www.omicron-laser.de F I I 99 1989
Laser, LED, Light Sources, Diode Lasers, Medical Lasers, Medical Systems, CW Light Sources, Customised Laser Systems, Photonics, Laser Development, Laser Solutions, Customised Light Sources, Biotech, Life Sciences, Microscopy, Spectroscopy
Flexible Laser & LED Light Sources for Industry & Science with 36 Months Warranty
Omicron-Laser has been developing, manufacturing, and distributing innovative laser and LED light sources since 1989 and is one of the leading manufacturers for demanding applications in biotechnology, microscopy, microlithography, medicine, and many more.
Based in Germany, Omicron is specialised in customised solutions in addition to its broad product portfolio. Product development and production comply with European and US guidelines and are conducted according to the ISO9001 and ISO13485 quality standards. Omicron offers CW light sources as well as high-speed modulated systems in the nanosecond and picosecond range, both as single and multi-wavelength solutions.
Important developments based on ISO 9001 and ISO 13485 include:
› the LightHUB® laser beam combiner series
› the LedHUB® high-power LED light engine
› the QuixX® picosecond pulsed diode laser
› the PDT medical laser system for cancer treatment
› the BrixXLAB multichannel desktop laser for laboratory applications
As the first highly integrated multimode high-power laser light engine on the market, the BrixXHUB Ultra is the perfect fit for applications in widefield laser illumination. The new device is a highly integrated multimode highpower laser light engine with up to 6 high-power BrixX lasers at its core, offering a wide range of wavelengths between 375 and 1550nm at up to more than 5 Watts per wavelength. This, combined with 6 analog and digital modulation inputs, provides unique flexibility to meet dynamic project needs. The system is designed for user-friendly operation and comes fully equipped with all essential accessories, enabling users to promptly
start their projects without any delay. In addition, its user-upgradeable design allows for easy customisation, enabling individuals to adapt to evolving project requirements effortlessly.
Flexible Multi-Wavelength Solutions:
LightHUB+®, LightHUB Ultra®, LedHUB® Omicron’s innovative LightHUB+® and LightHUB Ultra® laser light engines represent a new form of laser light sources for science, research, and industry based on the ultra-compact LuxX (LuxX+) laser series. The highperformance systems can be equipped with one to six (LightHUB+®) or seven (LightHUB Ultra®) laser modules of different wavelengths from UV to the near IR range and offer rapid analogue intensity modulation with up to 1.5MHz (3MHz and 250MHz digital) and digital full ON/ OFF modulation with a switching time of <1µs for each channel. The individual laser modules can easily be exchanged and added by the user. Hence the systems can be adapted to changing application requirements and are future-proof.
The Omicron LedHUB® is a high-power LED light source for biotech, industrial, and analytical applications. With up to 6 different wavelengths between 340 and 940nm it can be used in applications like widefield microscopy, optogenetics, chemical analysis, forensics, and many more. The modular principle of the LedHUB® provides the possibility to start with only one or two wavelengths initially and upgrade by further wavelengths at a later stage. The capability of rapid switching between wavelengths and high-speed analogue modulation of intensity is a key feature for demanding applications.
Name ›
Address/P.O. Box › Postal Code/City › State
Contact Person
Telephone
Email
Website
Social Media
Number of Employees
Founded (year)
Areas of Activity
PAN-Biotech GmbH
Am Gewerbepark 6
94501 Aidenbach
Bavaria
Miriam Falck
+49-8543-6016-30 info@pan-biotech.de https://www.pan-biotech.com/ I 86 1988
| Cell culture and Biosolutions (Media, Serum, Reagents, Buffer, WFI)
With a strategic location in the heart of Europe, PAN-Biotech serves as a gateway for global customers seeking to access the European biotechnology market.
Market Access | Distribution Hub | Partnership Opportunities
PAN-Biotech, a global leader in manufacturing sterile liquids and cell culture media, upholds stringent GMP standards and “Made in Germany” quality. It supports the entire product lifecycle – from development through commercialization – offering extensive, customized solutions in bio production, pharmaceutical applications and cell culture, with nearly four decades of industry dominance.
PAN-Biotech was founded in 1988 with a mission to produce top-quality biotech products and promote scientific discovery. The company set out to revolutionize biotechnology with innovative solutions that contribute to enhance human health and well-being.
› Vision: Pioneering Cell Culture.
› Mission: Development of serum-free media and serum-replacement solutions to enhance cell culture performance and reliability.
Latest Product Strategy:
PAN-Biotech, is actively advancing its capabilities and product offerings in the following key areas:
› Cell and Gene Therapy: Development of specialized media and reagents to support the growth and production of cells and genes for therapeutic applications, enhancing the efficacy and safety of cuttingedge treatments.
› Vaccine Production: Expansion into vaccine production technologies, providing the necessary tools and solutions for the rapid and efficient development of vaccines, including those targeting emerging diseases.
› mRNA Technology: Innovation in mRNA technology, including the development of optimized media and delivery systems, to support the burgeoning field of mRNA-based therapeutics and vaccines.
› Antibody Production: Enhancement of products and processes for the production of high-quality antibodies, catering to research, diagnostics, and therapeutic applications.
www.pan-biotech.com info@pan-biotech.de
Supporting the Development of Medical Products
PAN-Biotech plays a crucial role in the development and production of medical products, drugs, and vaccines. Our innovative solutions are designed to meet the demanding requirements of the pharmaceutical and biotechnology industries, providing the essential tools needed to drive progress in human health. To fully support the approval and certification processes of medical applications, PAN-Biotech has implemented a state-ofthe-art and industry-unique supporting process:
› Research and Development Stage: During the stage of research and development, the usage of standard RUO (Research Use Only) products is recommended. The PAN-Biotech catalog includes over 1,800 products, with 85% available in stock and ready for worldwide shipping within 2 days.
› Pre-Clinical Stage: It is highly recommended to swiftly switch from RUO to GMP-ready products during the pre-clinical stage to ensure compliance and quality consistency.
› Clinical Development and Commercialization: During clinical development (Phase 1 - 3) and for commercialization, it is essential to use products that meet GMP (EU Annex 1) quality standards. This ensures the highest level of safety, efficacy, and regulatory compliance for medical applications.
Conclusion:
Through its diverse offerings and commitment to innovation, PAN-Biotech empowers scientists and industry leaders to drive progress in biotechnology. By providing customized solutions and supporting sustainable practices, PAN-Biotech is at the forefront of advancing scientific discovery and improving global health.
Name ›
Address/P.O. Box › Postal Code/City › State
Contact Person
Telephone
Email
Website
Social Media
Number of Employees
Founded (year)
Areas of Activity ›
PharmaLex GmbH
Basler Straße 7 61352 Bad Homburg vor der Höhe Hesse
Melanie Ludwig 06211815-380 melanie.ludwig@cencora.com www.pharmalex.com
I 330 1994
Consulting, Outsourcing and Services in: Regulatory Affairs, Pharmacovigilance, Clinical Development, Market Access, Quality Management, Medical Affairs, Project Management
About Us
Needing a partner to launch products with confidence? Looking for an experienced service provider to bring the promise of your therapies to life? PharmaLex, a Cencora company, supports on the path to commercial success. Our services are aimed to deliver expertise to pharmaceutical and medical device companies throughout the product lifecycle. We navigate through the complex regulatory landscape and leverage our extensive knowledge and global presence to guide small and medium-sized companies through the complexities of product development and regulatory requirements. By offering scalable, tailored solutions, PharmaLex empowers companies to successfully bring innovative pharmaceutical and medical device products to market and thereby improving patient outcomes and advancing healthcare.
Key Service Areas for SMEs
Regulatory Affairs:
Comprehensive support in regulatory strategy, submissions, and communications with health authorities.
› Developing regulatory roadmaps that align with the company’s product development plans.
› Providing strategic advice on the best regulatory pathways to expedite market entry.
› Assisting with the preparation and submission of regulatory documents, including INDs, NDAs, MAAs, and 510(k)s.
Pharmacovigilance:
Safety monitoring, risk management, and compliance services to ensure patient safety and regulatory adherence.
› Setting up and maintaining robust pharmacovigilance systems.
› Conducting risk assessments and developing risk management plans.
› Managing safety data, including adverse event reporting and signal detection.
Development Consulting and Clinical Development: Guidance on product development, clinical trial design, and market access strategies.
› Designing and managing clinical trials, from earlyphase studies to post-market surveillance.
› Ensuring compliance with Good Clinical Practice (GCP) and other regulatory requirements.
› Offering statistical analysis and data management services.
Market Access:
Conducting health economics and outcomes research (HEOR) to support reimbursement and pricing strategies
› Developing medical communication plans to effectively convey scientific and clinical information to stakeholders
› Supporting the creation of medical and scientific publications
Quality Management:
Quality assurance, compliance, and commercialisation services to meet international standards.
Medical Affairs:
Medical writing, scientific communication, and strategic consulting to support clinical data and product launch.
Project Management and Outsourcing:
› Offering project management services to oversee product development timelines and ensure milestone achievement.
› Providing flexible outsourcing solutions to augment internal teams with specialised expertise.
Comprehensive services for the development and commercialisation of high-value compounds using our award-winning Plant Cell Fermentation (PCF ®) Technology.
Established in 1993, Phyton Biotech offers comprehensive process development and commercial manufacturing services for fermentation-based products at its GMP facility near Hamburg with more than 200.000 liters of installed bioreactor capacity. Best known for our award-winning and environmentally responsible Plant Cell Fermentation (PCF®) platform, we have expanded our profile into other cell systems, offering development and supply services for a wide array of products including phytochemicals, biopharmaceuticals, and other high-value compounds. This PCF ® technology coupled with our extensive experience allows Phyton Biotech to serve a variety of global markets, including pharmaceutical, traditional medicines, agricultural, food ingredients, natural health, and cosmetics industries.
Our PCF® technology
PCF ® promotes the natural processes of plant cell growth and biosynthetic pathway expression of plant material in a controlled and fully defined bioreactor environment. Starting material is sourced without any environmental impact and the optimal cell cultures are developed in-house. Selected cell lines are scaled up in stirred tank bioreactors without the sunlight requirement. Finally, Phyton Biotech’s specialised product recovery and downstream technology allows for the preparation of extracts and purification of molecules.
Utilising this cutting-edge technology, Phyton Biotech offers a time, risk, and cost balanced path to commercially viable production processes, adding sustainability, reliability, quality, and scalability to the supply chain.
Our unique capabilities address the entire development chain. Phyton Biotech maintains one of the world’s largest plant cell culture collections, allowing for the unique selection and sourcing of plant material. Subsequent cell line development, process development, downstream development, chemical processing, scaleup, and commercial GMP production in up to 75,000L bioreactors guarantees Phyton Biotech’s position as the global leader in PCF® Name
Specialty fermentation solutions
Phyton Biotech’s commercial-scale fermentation facilities can produce large volumes of high-quality fermentation-derived products (max. bioreactor size is 75,000L; more than 200,000L of installed capacity). We offer flexible production schedules and a range of fermentation vessel sizes to meet the needs of our clients. Our facilities are designed to meet the highest quality and regulatory standards, ensuring our clients receive the best quality products possible. Coupled with 30 years of experience in development and production this enables us to carry out other Specialty Fermentation projects beyond PCF® hand-in-hand with our customers – from first cells to scale-up and through to product recovery. We offer comprehensive services for the development and commercialisation of manufacturing processes for high-value compounds including small molecules and biologicals.
Our API business
Phyton Biotech operates two GMP-certified, FDA and EDQM inspected facilities in Germany and Canada with full in-house QA/RA and QC capabilities, and supplies substantial amounts of Paclitaxel and Docetaxel with full control over the entire upstream and downstream production process. By providing a safe, reliable, high-quality supply of finished Active Pharmaceutical Ingredient (API) product that meets USP and EP standards, Phyton Biotech is the largest global commercial provider of Paclitaxel and Docetaxel API via PCF® to a customer base of pharmaceutical manufacturers around the world.
In summary
Through our expertise and experience, Phyton Biotech continues to offer world-class development, supply, and commercial manufacturing solutions in an environmentally responsible and sustainable way through our PCF® and Specialty Fermentation services for a wide range of high-value fermentation-based compounds.
PlasmidFactory GmbH
Address/P.O. Box
Postal Code/City
State
Contact Persons
Telephone
Fax
Email
Website
Social Media
Number of Employees
Founded (year)
Areas of Activity
Meisenstr. 96
33607 Bielefeld
North Rhine-Westphalia
Dr. Dirk Winnemöller / Dr. Marco Schmeer
+49-521-2997-350
+49-521-2997-355
info@plasmidfactory.com www.plasmidfactory.com
54 2000
| Contract Manufacturing of plasmid and minicircle DNA in different quality grades for research up to GMP
| High Quallity Grade plasmid and minicircle DNA as starting material for GMP productions, e.g. of mRNA or viral vectors, also in gram scales
| In Stock Service for AAV Helper & Packaging Plasmids (pDG/pDP) and for further plasmids and minicircles (e.g. reporter genes)
| CGE Analysis of plasmid topology
| GMP quality for late clinical phase and market supply
Biological Patents
Collaborations
Request for
Further Collaborations
PlasmidFactory owns any relevant know-how, patents, and licences for plasmid and minicircle manufacturing
Fruitful long-term cooperations with renowned academic and industrial institutions in the fields of gene and cell therapy and vaccination
PlasmidFactory is always interested in working in long-term collaborations with pharmaceutical and biotech companies as well as academic insitutes that require plasmid or minicircle DNA for (pre-)clinical applications.
The better way to DNA!
PlasmidFactory is the leading contract manufacturer of plasmid and minicircle DNA and the driving force in the development of gene vectors for gene and cell therapy and genetic vaccination. PlasmidFactory’s research and development as well as the complete services are located in Bielefeld, Germany.
Customised plasmids and minicircles
PlasmidFactory’s individual manufacturing service is frequently used by researchers from the fields of transfection and drug delivery, virus production, nanobiotechnology, gene therapy, cell or tumour therapy, and RNA or DNA vaccination. The company offers the production of plasmid and minicircle DNA in several quality grades: Research Grade and ccc Grade qualities for research purposes and pre-clinical applications, High Quality Grade as starting material for, e.g., GMP production of RNA, viral vectors and CAR-T cells. GMP quality available in H1 2026.
In-Stock services
Our In-Stock products are deliverable immediately off the shelf – e.g. reporter genes (gfp, lacZ, luc), AAV Helper & Packaging plasmids (2-Plasmid-System, pDG/ pDP family, several serotypes; incl. ITRRESCUE® and ITRPROTECT, see below) or pEPI / pEpito plasmids (containing S/MAR elements).
Other services
On request, plasmid DNA linearisation as well as storage and logistics can be organised, supplementing the company’s service portfolio.
PlasmidFactory’s proprietary method for quantification of the structural diversity of plasmid DNA by means of capillary gel electrophoresis (CGE) is the only reliable method able to determine the stability of plasmid DNA, e.g. during storage.
Minicircle DNA
The small alternative
Minicircle – a safe vector system
Minicircles (MC) are circular DNA molecules that are generated e.g. by an intramolecular (cis-) recombination from a parental plasmid (PP). The difference between MC and standard plasmid vectors for gene therapy or nucleic acid vaccination is that the MC contains neither the bacterial origin of replication (needed only in bacteria for the amplification of plasmids in cell division) nor any antibiotic resistance markers or other selection systems to keep the plasmid in high amounts within the producer cell.
PlasmidFactoryˇ s ingenious & reliable
Minicircle
References
Bexte et al., 2024
Pommersberger et al., 2022
Monjezi et al., 2016
Schnödt et al., 2016
Hence, minicircles are the most promising tools to achieve both increased efficacy as well as regulatory requirements for future clinical applications.
PlasmidFactory is the exclusive owner of all relevant patents and IP in this field and provides service production of these supercoiled monomeric constructs, according to clients’ requirements.
Starting material for mRNA vaccines in large quantities
In particular, the High Quality Grade production of plasmid DNA as a starting material for the production of RNA vaccines has gained in importance, especially in the context of the COVID-19 pandemic, as RNA is a promising vaccine candidate for the prevention of certain virus infections, with the additional advantage of not integrating into the genome of the cell and thus remaining as a potentially effective molecule in a patient’s body in the long term.
PlasmidFactory has developed and established the process for the production of the corresponding plasmid DNA containing unstable polyA stretches.
PlasmidFactory’s ITRRESCUE® technology restores and preserves plasmids with fragile AAV inverted terminal repeats (ITRs), using NGS to verify and quantify intact sequences for reliable AAV packaging. Their complementary ITRPROTECT service safeguards the original ITRs during cloning and production, preventing degradation and ensuring fully functional AAV vectors.
Name ›
Address/P.O. Box ›
Postal Code/City › State ›
Contact Person › Telephone › Fax › Email › Website › Social Media › Number of Employees › Founded (year) › Type of Laboratory
Areas of Activity ›
ProBioGen AG
Herbert-Bayer-Str. 8 13086 Berlin Berlin
Dr. Alfred Merz (CEO)
+49-30-322-935-100 +49-30-322-935-400 info@probiogen.de cdmo@probiogen.de www.probiogen.de I Q
300 1994 S1, S2
l Biopharmaceutical development and GMP production facility
l Proprietary technologies for improving product characteristics and process efficiency
l Designer cell lines
l Vector platforms
Biological Patents › External › Collaborations Request for › Further Collaborations
ProBioGen holds numerous international patents on technologies to improve product quality/potency and enhance cellular productivity.
With many international companies and research organisations, e.g. Boehringer Ingelheim, Bayer, CRISPR, Novartis, etc.
ProBioGen works with biotech and pharma companies that develop (complex) therapeutic proteins and antibodies or viral vaccines and viral vectors.
Intelligent Biopharmaceutical Solutions
ProBioGen is a Berlin based CDMO, specializing in the development and manufacturing of biopharmaceutical active ingredients, viral vectors and vaccines through proprietary technologies to improve product quality and features. Combining state-of-the-art development services and intelligent product-specific technologies results in biologics with optimized properties. Rapid and integrated cell line and process development, comprehensive analytical development and GMP-compliant manufacturing is performed by a highly skilled and experienced team.
Unique Services
Cell line & process development for therapeutic proteins
› CHO.RiGHT® expression system
› DirectedLuck® transposase for efficient gene delivery & high titers
› Proprietary chemically defined (CD) media platform/ multiple suppliers
› Robust and economic platform processes
› Classic and intensified processes
› Reports to support investigational new drug (IND) filing
› Modular services and open source concept
(GMP) Manufacturing for therapeutic proteins
› Cell banking (MCB/WCB)
› Up to 1000 L Tox manufacturing
› 2x up to 1000 L GMP manufacturing
› Disposable, stirred tank bioreactors
Development services for various viral vectors
› Tailor-made solutions for the production of e.g. lentiviral and adenoviral vectors, AAV and MVA
› Suitable cell substrates for the propagation of various viral vectors in suspension processes using CD medium
› Robust upstream and downstream processing supported by comprehensive analytical tools
› Cost-effective non-cGMP production for preclinical development phase
(GMP) Manufacturing for various viral vectors
› Cell Banking (MCB, WCB) and Virus Banking (MSV/WSV)
› Up to 200L Tox manufacturing
Your Biologics. Elevated.®
› Up to 200L GMP manufacturing (up to biosafety level 2)
› Aseptic filling of drug product and diluent under GMP conditions
Analytics, bioassays & quality management
› Integrated analytical development
› Validation according to bioanalytical guidelines (EMA/ FDA)
› Stability studies in accordance with ICH Q1
› Wide range of cell based and binding activity assays
› Various cell based and instrumental analyses for content and identity testing of viral vectors and vaccines
Innovative Technologies
GlymaxX® ADCC enhancement & glyco-engineering
› Prevents antibody fucosylation
› Boosts ADCC cell-killing activity against tumors and infected cells
› Applicable to both novel and existing producer cell lines
› Allows adjustment of fucose, galactose, and sialic acid levels in glycoproteins
DirectedLuck® – Transposase system
› Proprietary transposase for efficient gene delivery
› Generates high-titer clones (up to 8 g/L)
› Superior heterodimer rates for bi-specific mAbs
Lenti.RiGHT® packaging and producer cell line
› GMP qualified starter cell bank based on HEK 293
› Efficient LV production in CD medium (107-108 TU/ml)
› No requirement of GMP-grade plasmid DNA or transfection reagent
› Straightforward purification of lentiviral particles for e.g. CAR-T therapies
AGE1.CR® Designer cell line & MVA viral vaccine
manufacturing platform
› Avian suspension cell line permissive for numerous human and veterinary viral vaccine strains
› GMP-compliant chemically defined media and scalable suspension processes
› Proprietary MVA strain, transgene expression design, and technology for rapid generation of recombinants
Name ›
Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Fax › Email › Website › Social Media › Number of Employees › Founded (year) › Type of Laboratory › Areas of Activity › External › Collaborations
Request for › Further Collaborations
PROGEN
Maassstrasse 30 69123 Heidelberg
Baden-Wuerttemberg
Ruth Roschatt
+49-6221-8278-0
+49-6221-8278-24 info@progen.com www.progen.com
I 40+
1983
S1 class laboratories, DIN ISO 13485 certification for the production of in vitro diagnostic kits and research reagents.
AAV gene therapy analytical tools and antibodies, antibodies and reagents for biomedical research, in vitro diagnostics, ELISA, antibody phage display technology, density gradient media
Strong network with industrial and academic institutions
PROGEN is actively seeking partners for the advancement and distribution of its gene therapy and antibody-based products & services.
Making Gene Therapy Better. Together.
PROGEN develops analytical tools to support research and development in the fields of gene therapy and life sciences. Our core expertise lies in Adeno-Associated Virus (AAV) analytics, where we provide standardised reagents and assays that help scientists characterise, quantify, and monitor viral vectors across all stages of therapy development, from discovery to quality control. We work with biotech and pharmaceutical companies, commercial manufacturers, and academic institutions worldwide. Our focus is on tools that improve reproducibility, simplify workflows, and meet regulatory requirements. By building on more than four decades of antibody expertise, we deliver reliable solutions for today’s challenges in viral vector characterisation while preparing for the needs of tomorrow.
Looking Ahead
Founded in 1983 in Heidelberg, PROGEN is one of Germany’s first biotech companies. Today, we operate globally as a subsidiary of R-Biopharm AG, with ISO 13485 and My Green Lab ® certifications.
We collaborate closely with scientists and industry partners to ensure our tools reflect real research needs and evolving regulatory expectations. Beyond supplying products, we provide technical expertise and maintain active collaborations with academic institutions, biotechnology companies, and pharmaceutical companies. PROGEN is open to partnerships to advance and distribute its products and services.
Our goal is to deliver reliable, consistent tools that enable safe and efficient therapeutic development in gene therapy and beyond.
Easy-to-Use Analytical Tools for Gene Therapy
PROGEN offers a comprehensive portfolio to support AAV vector characterisation, monitoring, purification, and assay validation throughout the gene therapy for reproducible capsid titer quantification across all major serotypes, with exfor rapid, equipmentfree detection of assembled capsids during production.
› Antibodies against AAV particles, capsid proteins, and replicase proteins, which are widely used for detection, in-process monitoring, and assay development.
› Reference standards and proteins, including empty, full, and Renilla-filled capsids and VP1/2/3 proteins, to support assay comparability and regulatory readiness.
› OptiPrep™️ iodixanol for efficient AAV purification and full/empty capsid separation.
Non-Viral Gene Therapy Tools
Alongside our AAV expertise, we also provide lipid nanoparticle (LNP) delivery kits, supporting the growing importance of non-viral approaches in gene therapy.
Analytical Tools for Every Gene Therapy, for Every Lab.
Contract research and development (CRO); cytotoxic (≤OEL5); BSL-1; BSL-2; fee-for-service business model; 2-4 weeks start up time; slim and reliable timelines; GLP-like quality standards; submission-compliant documentation
Areas of Activity
Biological Patents
External
Collaborations
Analytical characterisation; preformulation screening; formulation development; freeze drying cycle development; lyophilisation process and scale-up; technology transfer Several patents in freeze drying and formulation
| Network for seamless development from pre-clinic to fill/finish and market.
| Formulation specialist for DS and DP CMOs worldwide.
| Partnered with Bi-nex for CDMO services on mAb DS (cell line & process development, manufacturing).
| Local company representation in APAC and U.S.A.
| Credited laboratory for Wyatt Technology in Europe.
Request for
Further Collaborations
| Small biotechnology/mid-size pharma companies, large top players in pharma/biotechnology.
| From DSP development to early and late drug product phases up to life cycle management.
| Customised solutions for challenges in formulation, analysis or process.
ProJect Pharmaceutics is a leading independent European CRO specialised in formulation and manufacturing process development for injectables: biologics (rec. proteins, antibodies, fusion proteins), peptides, ADCs, cytotoxics, small molecules, generics, viral therapeutics, ATMPs, VLPs and other nanoparticular drug delivery systems. We apply innovative, quality-by-design based, rational concepts of pharmaceutical development according to ICHQ8 and other guidelines. We support our global customers in developing a consistently high-quality pharmaceutical product that is transferable, scalable and manufacturable under GMP conditions. ProJect Pharmaceutics is managed by experts with >30 years of experience in the pharmaceutical industry. In about 850 m2 we operate special laboratories for biologics, cytotoxics and a BSL-2 unit, equipped with dedicated industrial HOF pilot freeze dryers.
Protein
formulation
› Predictive formulation analytics: a QbD-based highthroughput approach for accelerated development
› Pre-formulation, early state & late phase formulation
› Liquid & lyophilised formulation (DoE-based)
High concentration protein formulation
› Low viscosity formulation for s.c. application
› UF/DF process development
› Syringeability evaluation
Cytotoxic small molecules
A deep understanding of the challenges when processing highly potent drugs, such as limited solubility in water and rapid degradation, paired with long-lasting experience and comprehensive know-how of lyophilisation from various organic solvents enables us to provide specific solutions for high potency & cytotoxic drugs.
Antibody-drug conjugates (ADCs)
› Predictive, high-throughput formulation development
› High-end freeze-drying technology
By combining protein formulation and process know-how with cytotoxic drug expertise the company holds unique assets to develop ADCs. On top we offer complementary formulation and process development of intermediate antibody & linker-payload bulk.
PROJECT PHARMACEUTICS
Peptide formulation
› Formulation and lyophilisation cycle development
Innovative liposome technology
› High encapsulation efficiency (hydro- & lipophilic APIs)
› GMP-compatible manufacturability with standard equipment
Viral-based therapeutics
› Lyophilised formulation and cycle development
In-use stability studies
› Evaluation of DP compatibility with IV line equipment
Freeze drying
› In vials, dual chamber systems, syringes, cartridges, bulk trays or bags, containers in nest&tub configuration
› Out of organic solvents
› Rational cycle development (robust, collapse-safe, cost & time efficient, tailored to the formulation)
› Bulk lyophilisation (solid or powder)
› SEM structural analysis of lyo cake
› Time lapse video & IR thermal camera monitoring
› Aseptic pre-clinical batch manufacturing
› Robustness & design space evaluation
› Smooth technology transfer to GMP
Process development and manufacturing
› DSP: Smart optimisation of UF/DF & purification steps targeting a common DS/DP formulation
As state-of-the-art development experts we are teamed up with state-of-the-art contract manufacturing experts to provide high-quality parenterals from pre-clinical to clinical and commercial scale.
Name ›
Address/P.O. Box ›
Postal Code/City
State
Contact Person
Telephone
Email
Website
Social Media
Number of Employees
Founded (year) › Areas of Activity ›
Promega GmbH
Gutenbergring 10
69190 Walldorf
Baden-Wuerttemberg
Dr. Caroline End +49 6227 6906-0
Promega_Info@promega.com www.promega.com
Promega – Empowering Scientific Progress from Idea to Impact Tools that Drive Discovery
Member of
Patents ›
| High quality reagents & kits for all types of DNA, RNA and protein analysis; cell-based & biochemical assays for analysis of cellular processes; MSI diagnostics; cell systems for therapeutic antibodies including LOT release assays.
| Integrated Systems including instruments, chemistries and personalised support that simplify the process of automating research in the lab.
| Custom manufacturing
| On-site Stocking
| Automation Support
| Tailored R&D Solutions
Promega holds hundreds of patents in the areas of:
| Bioluminescence
| Cellular Analysis
| Cell biology
| Drug Discovery
For over four decades, Promega has been advancing science by providing innovative tools for life science research, diagnostics, pharmaceutical development, and applied testing. With a portfolio of over 4,000 products, our technologies span core areas such as genomics, protein analysis, cellular biology, genetic identity, and molecular diagnostics. From PCR and qPCR to luciferase-based assays, cell-free protein expression, CRISPR analysis, and STR-based human identification kits – Promega solutions enable workflows across the molecular biology spectrum.
Where Science Meets Simplicity
We design technologies that make complex processes more efficient. Whether you’re quantifying gene expression, detecting protein interactions, isolating high-quality nucleic acids, or analysing metabolic activity – Promega’s smart assay systems and reagents save time and increase reproducibility. Our Maxwell® instruments automate DNA and RNA extraction, while GloMax® detection systems deliver reliable readouts for luminescent, fluorescent, and absorbance-based assays. Technologies like NanoBRET™️, HaloTag®, and HiBiT® support advanced cellular analysis and highthroughput screening.
Serving Science across Sectors
Promega products are trusted by scientists in academic research, pharma and biotech companies, clinical diagnostics, forensics, food safety, and environmental monitoring. Our solutions support research areas such as cancer biology, neuroscience, immuno-oncology, microbiology, epigenetics, and personalized medicine. Whether in early-stage basic research or regulated environments, Promega tools help transform ideas into insights.
Beyond the Bench: Tailored Solutions & Scientific Partnerships
Promega offers a wide range of services to meet specific customer needs – from small-scale customisation to large-scale collaborations. These include:
Custom Assay Development & R&D Services: Tailored solutions for unique scientific challenges.
OEM Partnerships: Seamless integration of Promega technologies into partner products and platforms. Regulatory Support & Quality Standards: Products available under ISO 13485, GMP, or RUO grade.
Global Distribution & Local Support: Available in over 100 countries with scientific and technical expertise close to our customers.
Rooted in Values. Growing through Responsibility.
At Promega, we believe science serves the greater good. We foster a culture of curiosity, authenticity, collaboration, and personal development. We actively support education, creativity, and inclusiveness – both inside and outside the laboratory. These values shape not only how we innovate, but also how we work with our customers, colleagues, and communities.
Sustainability: Measurable Action, Lasting Impact
Promega aligns its global operations with the UN Sustainable Development Goals and has been part of the UN Global Compact since 2010. We are on track to reduce our carbon intensity by 50% by 2030, having already achieved a 48% reduction since 2019. Over 75% of our electricity comes from renewable sources, with a goal of 100% by 2025. Our products are designed with reduced environmental impact, and many facilities meet high sustainability standards, including ISO 14001 certification.
Name ›
Address/P.O. Box ›
Postal Code/City › State
ProtaGene GmbH
Inselwiesenstr. 10
74076 Heilbronn
Baden-Wuerttemberg/NRW
Otto-Hahn-Str. 15, 44227 Dortmund
Im Neuenheimer Feld 582
69120 Heidelberg
Site Burlington: 4 Burlington Woods Drive Burlington, MA 01803, USA
Contact Person › Telephone › Fax
Email
Website
Social Media › Number of Employees › Founded (year) › Type of Laboratory › Areas of Activity ›
Dr. Roland Moussa; Michael Stump, Ph.D. +49-7131-74504-0 +49-7131-74504-299 contact@ProtaGene.com www.ProtaGene.com I
220
1997
Protein Analytical Laboratories (GMP-Compliant, Biosafety Level 2)
ProtaGene is a world-leading analytical CRO partner for developing biotherapeutics and advancing therapy medicinal products. For over 25 years, the group has worked alongside clients worldwide ranging from startups to top-ten pharmaceutical companies to bring medicines to market. They have been part of the story for novel blockbuster products, as well as rare and orphan drugs. ProtaGene is rooted in deep science and hands-on execution, which allows for an intelligent and agile approach to meet the needs of the increasingly complex medicines being developed today. Their experience is demonstrated best through their Biosimilar analytical strategies that cut years off creating the required analytical data package. They also operate the gold standard of gene safety testing methods (Integration Site Analysis), which has generated critical data for gene and cell therapy market authorisation. ProtaGene is the deep science partner for modern medicines and analytical development, empowering our partners to bring innovative therapies to market by supporting a broad range of cutting-edge modalities and complex formats, including:
› New Biological Entities
› Bi- and multispecific mAbs
› Fusion Proteins
› Antibody-Drug Conjugates
› Antibody-Oligonucleotide Conjugates
› Peptide-based Drugs
› Oligonucleotides (e.g. ASO, siRNA)
› mRNA-based (LNP) Vaccines
› Viral Vectors (e.g. AdV, LVV, AAV)
ProtaGene supports all phases of drug development by operating at every quality level, including GMP, GCP, GLP, and R&D, ensuring data meets rigorous regulatory standards while applying lean, agile processes to accelerate delivery. Analytical reports are regularly accepted by multiple regulatory authorities worldwide including
the FDA (USA), EMA (EU) and others, spanning all stages of development from scientific advice to phase I–III, and up to market authorisation. By means of standard and innovative analytics, customised and applied by our highly experienced teams within the FDA and EMA territories, we focus on delivering analytic excellence in advancing, de-risking and accelerating all stages of drug development.
ProtaGene provides you with the full range of analytical services from drug discovery and development to release testing and regulatory compliance under Biosafety Level 1 and 2 (BSL1/BSL2):
› Characterisation and Structural Analysis
› Physicochemical Testing
› Purity and Impurity Testing
› Bioassays and Potency Testing
› Stability and Forced Degradation Studies
› Analytical Method Development
› Method Validation
› GMP, GLP and R&D Testing
› Bioinformatics
Our analytical services for gene therapy-based products provide best-in-class molecular diagnostics and analysis services to ensure the safety of novel cell and gene therapies focusing on insertional mutagenesis and genotoxicity. Highly sensitive platforms and bioinformatics tools determine fusion sequences adjacent to known DNA or RNA fragments in minimal tissue samples down to the single-cell level. Applications include clonality and safety of (viral) vectors in gene therapy, on-target specificity of designer nucleases, immune repertoire studies in T cells and B cells, and next-generation sequencing (NGS). Drawing on our unique worldwide experience in gene therapy studies, bioinformatics, NGS, and associated regulatory demands, we help our customers by designing solutions entirely tailored to their needs.
Contract Development Manufacturing Services (CDMO) for biopharmaceuticals including monoclonal antibodies, biosimilars, small molecules and diluents.
Capabilities to process pre-fillable syringes (PFS), vials, and cartridges.
Our End-to-End CDMO Services
| Analytical services
| Method and process development
| Cold-chain logistics, including lowtemperature handling down to –70 °C
| Compounding
| Aseptic filling or filling with terminal sterilisation
| Visual inspection and secondary packaging
| GMP storage and GDP transport
Your Pharma CDMO for Aseptic Filland-Finish Services
PSM GmbH is a family-run German company that operates as a Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry, located in Schiffweiler in the state of Saarland in Germany.
From Clinical Development to Commercial Manufacturing
As an end-to-end CDMO, we provide services for the entire implementation process and lifecycle of your drug, from clinical phases to commercial GMP manufacturing.
Our portfolio includes method and process development, in-house analytical services, aseptic fill-andfinish services, visual inspection with CCIT, secondary packaging with serialisation, as well as GMP storage and GDP transport.
State-of-the-Art EU GMP Annex 1 Approved Facility
With our state-of-the-art facility, we are proud to be one of the first European CDMOs to have passed the inspection by the local authorities under the new EU GMP Annex 1. Our facility has been inspected and approved by the local regulatory authorities in 2024.
All the equipment, from fill and finish to secondary packaging, is designed to process all common ready-to-use primary packaging containers, including pre-fillable syringes up to 10 mL, vials up to 50 ml, and cartridges up to 10 mL, made of glass or polymer.
This flexibility enables us to offer fill-and-finish services for biopharmaceutical drugs like monoclonal antibodies, biosimilars, small molecules and diluents (e.g. WFI). Our current processes can accommodate batch sizes of up to 600 litres.
Member of
Highest Product Yields for Orphan Drugs
For very high-value biological drugs like monoclonal antibodies, we use the most sophisticated human-free robotic fill-and-finish technologies with isolator tech -
nology to minimise product loss throughout the entire processing cycle for batch sizes of up to 100 litres. Our services include the handling of low-temperature drugs of -70° C and the controlled thawing process of frozen API.
Your Benefits in Working with Us
Fast Decision-Making Processes: Flat hierarchies in our family-owned business ensure fast decision-making processes, making your project a success within the agreed timeline.
Focused Collaboration and Customised Solutions: We are approachable, easy to work with, and offer customised solutions to integrate your project requirements into our processes and equipment.
Agility and Flexibility: Changing requirements during a project are embraced rather than rejected.
Reliability and Transparency: We want to be your reliable partner and ensure the highest level of transparency in all processes relevant to your product.
Relationship-Based Decision-Making: We base our decisions not simply on short-term commercial aspects, but also on your product’s long-term success.
Our Mission
In order to support patients and improve their quality of life, we put passion into our daily work, focus on pharmaceutical excellence and use the latest fill-andfinish technologies and processes. We offer the most advanced, agile and, above all, GMP-compliant endto-end solutions for aseptic contract manufacturing.
psm-saar.de
Watch our video showcasing biopharmaceutical fill-and-finish processes.
Address/P.O. Box
QIAGEN Strasse 1
40724 Hilden North Rhine-Westphalia
John Gilardi +49 2103 29-0 pr@qiagen.com www.qiagen.com I
5,700 1984
QIAGEN – From Sample to Insight
Life faces many urgent challenges: combating cancer, diagnosing infectious diseases, ensuring public safety, and securing a reliable food supply. Meeting these challenges begins with unlocking the insights hidden in DNA, RNA, and proteins – the building blocks of life. That is where QIAGEN plays a vital role. As a global leader in Sample to Insight solutions, we provide the tools that help scientists and healthcare professionals turn biological material into valuable molecular information. Our portfolio spans sample technologies, assays, automation platforms, and bioinformatics, enabling customers to work with speed, accuracy, and confidence. Serving more than 500,000 customers in over 170 countries, QIAGEN supports both Life Sciences research and Molecular Diagnostics in clinical healthcare. Academic institutions, pharmaceutical and biotechnology companies, government agencies, and diagnostic laboratories rely on our technologies to accelerate discovery, guide treatment decisions, and improve public health.
Core areas of expertise
QIAGEN’s offering is anchored by five growth pillars: › Sample technologies that provide trusted solutions for nucleic acid collection, stabilization, and preparation.
› QuantiFERON, the leading blood-based test for latent tuberculosis infection, endorsed worldwide by healthcare authorities.
› QIAcuity digital PCR for precise quantification of nucleic acids in both research and clinical settings.
› QIAstat-Dx for syndromic testing, delivering rapid answers in infectious disease and beyond.
› QIAGEN Digital Insights to analyze and interpret complex genomic datasets with AI-powered, curated bioinformatics.
Making a difference
QIAGEN’s technologies address pressing challenges in science and medicine. They support research into cancer, infectious diseases, and personalized medicine, while enabling clinicians to detect pathogens rapidly
and identify patients who may benefit from targeted therapies. Beyond healthcare, QIAGEN contributes to forensics, food safety, and environmental testing.
Responsibility
Headquartered in Venlo, the Netherlands, QIAGEN brings together about 5,700 employees from 75 nationalities and operates 35 subsidiaries worldwide. In 2024, sales reached US$1.98 billion, with 89% coming from consumables, a sign of the stability and recurring strength of our business. We are also committed to operating responsibly, cutting Scope 1 and 2 emissions by 14% in 2024 and continuing to push for more sustainable sourcing and product design.
Outlook
The market for QIAGEN’s solutions is valued at around US$11 billion today and is expected to grow to US$13–14 billion by 2028. This growth is being driven by ongoing investment in research, broader use of molecular diagnostics in everyday healthcare, and the increasing need for bioinformatics tools to make sense of complex genomic data.
QIAGEN is ready to grow with these changes. Our strong consumables base gives us steady footing, while innovations in digital PCR, syndromic testing, and bioinformatics open new opportunities. Partnerships with pharmaceutical companies strengthen our role in precision medicine, where companion diagnostics are becoming more essential to targeted therapies. With our global presence and focus on sustainability, we are well placed to continue growing while helping advance science and improve healthcare worldwide.
Name ›
Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Fax › Email › Website › Social Media › Number of Employees › Founded (year) › Type of Laboratory ›
Areas of Activity
ReliaTech GmbH
Lindener Straße 15 38300 Wolfenbüttel
Lower Saxony
Dr. Markus Heine
+49-5331-8586-987
+49-5331-8586-989 orders@reliatech.de www.reliatech.de I Q
< 10 1999
S1, DIN ISO 9001:2015
Production of growth factors, cytokines, soluble receptors and antibodies
Cell culture (E.coli, Insect cells, HEK293, CHO)
Cell line development for research and preclinical use
Process development
Contract development Fill & Finish of cell culture components
Our story
Since its foundation in 1999, ReliaTech has developed into one of the leading European manufacturers of growth factors, cytokines, receptors, mono- and polyclonal antibodies for life science research and industry. Our biggest aim is to satisfy our customers with products of the highest quality. For this reason, close contact with our customers is very important to us. A short and reliable communication as well as fast reagent supply efficiently support our business.
Our products and services
Proteins for research and preclinical applications
› RUO - From development and production to formulation and quality control, our fully biologically active cytokines and soluble receptors are developed inhouse by experienced scientists. A product release is always based on clear specifications, such as purity, cell-based activity, stability and impurity profile. All products are available in customised filling sizes and quantities.
External › Collaborations
Request for › Further Collaborations
Collaborations with research institutions and industrial partners
We are open to further collaborations with Cell culture medium manufacturer, Biotechs, Academias and CDMOs
› Animal-free products - We are continuously expanding our portfolio of animal-free proteins, produced entirely without raw materials of animal origin. This innovative approach not only ensures the highest safety standards by eliminating the risk of animalderived contaminants, but also supports a more sustainable future and actively reduces animal suffering. With our animal-free solutions, we are shaping a cleaner, more responsible biotech industry.
› Monoclonal/Polyclonal antibodies – We develop our antibodies using highly pure antigens and purify them through advanced affinity chromatography, leveraging precise antibody-antigen interactions to consistently achieve over 95% purity. Each antibody undergoes a thorough quality validation to ensure exceptional specificity and affinity, guaranteeing reliable performance and versatility across diverse applications. We also provide biotinylated antibodies, perfectly suited for sensitive and specific analytical techniques.
Contract manufacturing
With our in-house system for transient and stable expression in different expression systems, including process development for cultivation and purification, we offer our customers a customised solution for the production of their protein of interest. The customised protein production is based on a flexible, modular system that allows for an individual selection of different service options depending on your specific needs.
Fill-and-Finish (F&F) service
We professionally fill your cell culture media or supplements according to your formulation. Thanks to our flexibility, we precisely fill even complex and sensitive media formulations, specialising in small to medium-sized batches – from µL to L scale. All our filling processes are carried out under stringent quality standards, ensuring high sterility and consistent product quality.
Bioassay service
We offer our extensive expertise in cell proliferation assays to check the biological activity of customer proteins or even the responsiveness of customer cell lines to a specific growth factor. This assay is frequently used as a first step to check the biological activity of a protein up to a validated assay with international standards.
Our quality promise
As an ISO 9001:2015 certified company, achieving the highest quality standards is very important to us. We are constantly working on improving our quality standards and optimising our service. We regularly derive our quality measures from the ICH guidelines and are guided by the specifications of our internal QP.
Name ›
Address/P.O. Box ›
Postal Code/City
State
Contact Person
Telephone
Fax
Email
Website
Social Media
Number of Employees
Founded (year)
Type of Laboratory
Areas of Activity
Rentschler Biopharma SE
Erwin-Rentschler-Str. 21 88471 Laupheim
Baden-Wuerttemberg
Dr. Latika Bhonsle-Deeng, Global Head of Communications +49-7392-701-0 +49-7392-701-300 communications@ rentschler-biopharma.com www.rentschler-biopharma.com
1,400 1872 S1
Contract development and manufacturing organization (CDMO) for biopharmaceuticals, including complex therapeutic proteins, mRNA and viral vectors
A world-class biopharmaceutical CDMO
Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO) focused exclusively on client projects. Rentschler Biopharma’s high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. Rentschler Biopharma is a family-owned company with about 1,400 employees, headquartered in Laupheim, Germany, and operations in Milford, MA, USA. In 2024, the company joined the United Nations Global Compact, emphasizing Rentschler Biopharma’s focus on sustainability.
Your trusted partner from concept to market
External
Collaborations Request for › Further Collaborations
Strategic collaboration with Vetter, headquartered in Ravensburg, Germany, for high quality aseptic filling and secondary packaging
Rentschler Biopharma offers bioprocess development and cGMP manufacturing solutions from concept to market for pharma and biotech companies in long-term collaborations and strategic collaboration settings.
The company offers process development and manufacturing of biopharmaceuticals, as well as related consulting activities, project management and regulatory support. Rentschler Biopharma is highly experienced in the development and cGMP manufacturing of monoclonal antibodies, designer proteins, and other therapeutic proteins in compliance with international standards (EMA/ FDA). Working collaboratively with its clients, Rentschler Biopharma provides customised solutions with optimized work packages for each development stage. State-of-the-art cGMP facilities and cell culture processes are leveraged for manufacturing for both, clinical studies and commercial supply. Consistent monitoring of the international regulatory landscape and in-depth understanding of the necessary regulatory documentation (CMC), ensures that each project is properly documented in accordance with international regulatory requirements. The company works in a strategic collaboration with Vetter for aseptic manufacturing & Packagin. The desired goal of the collaboration with Vetter is the alignment of manufacturing approaches that enable clients to bring their products to patients more easily and faster.
Bioprocess development
› Fast and efficient supply for multiple candidate screening
› Robust and scalable CHO cell lines for cGMP manufacturing
› Efficient cell culture and purification processes
› Well-established analytical methods
cGMP biomanufacturing
› Multiple stainless steel bioreactor lines, including a twin system with 2x 3,000 L
› Flexible single-use bioreactor lines up to 2,000 L
› State-of-the-art purification processes
› Guaranteed product quality and purity in accordance with cGMP guidelines
Rentschler Development Services
The company provides tailored service offerings for best-fit solutions for client projects. “Velocity” offers fast-track development for Phase I/II, “Flexibility” is for fully customized projects, “Liberty” offers standalone activities and work packages.
Our newly expanded, state-of-the-art Milford, MA site primarily focuses on the production of highly complex molecules for international clients and is fully operational. Thanks to a 22,000 square feet of manufacturing cleanroom space and four 2,000 L single-use bioreactors, we meet our clients’ changing needs by building design to accommodate future adaptions for scale and capacity.
As a world-class solution provider, we ensure optimum time-to-clinic and time-to-market by accelerating timelines to create competitive advantage for our clients. For seamless market approval, we consult and assist clients with regulatory queries, develop optimised strategies, and generate complete documentation for approval of clinical studies and market launch.
Name ›
Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Fax › Email ›
Social Media › Number of Employees › Founded (year) › Areas of Activity › Biological Patents › External › Collaborations
Request for › Further Collaborations
Richter BioLogics
Suhrenkamp 59
22335 Hamburg
Hamburg
Dr. Thilo Kamphausen
+49-40-55290-451
+49-40-55290-888
BusinessDevelopment@ richterbiologics.eu
I > 400 1987
Contract development and manufacturing organisation (CDMO)
Several patents on manufacture of proteins and pDNA (pART process)
Biotech and Pharma companies worldwide
Richter BioLogics offers CDMO services from gene to finished product. Our teams provide top level solutions to bring your product to market. Contact us for more details.
High class GMP-compliant microbial production of biopharmaceuticals –Plasmid DNA and Proteins
Richter BioLogics is a leading and expanding Germanybased contract development and manufacturing organisation (CDMO) specialised in a broad range of products derived from bacteria and yeasts. With a 35-year track record in cGMP manufacturing, Richter BioLogics provides its clients with a unique knowledge base in process and analytical validation, process performance qualification (PPQ) procedures, commercial production of therapeutic proteins, antibody-like scaffolds (e.g., VHH/ Nanobodies, Fab-fragments), bacterial vaccines, and plasmid DNA (pDNA) products.
Your product – our competence and dedication
Our focus is on our customers, their needs, timelines and quality requirements. Our seasoned, highly educated, and motivated teams support the global pharmaceutical and biotechnological industries with one-stop-shop services ranging from strain/process development to analytical development, manufacturing, QC testing and filling of finished product. In addition to our headquarters, we operate two GMP-compliant production sites with total bioreactor capacities of 2x 1,500L and 2x 300L to provide manufacturing solutions for large and commercial scales. Further space and connections exist to install more capacity as needed by the customer.
Quality is our DNA
Richter BioLogics consistently works to the highest standards of pharmaceutical quality as verified by major regulatory bodies including but not limited to EMA, FDA, PMDA, ANVISA, MFDS, and more, as well as by numerous customer audits. Throughout the company teams have excellent expertise in the development and cGMP-compliant production of biopharmaceuticals. To ensure efficient, timely and transparent work, we apply professional project management methods and an integrated Quality Management System. The quality system
at Richter BioLogics meets the strictest standards of quality in biopharmaceutical production.
Products and services
Our process development team possesses extensive experience in developing and optimising fermentation and purification processes. For initial strain development, a variety of proprietary E. coli expression systems are available to support strain selection. Small-scale models of existing processes provide helpful tools for trouble shooting, process characterisation, and validation and ensure a smooth scale-up to large-scale cGMPcompliant manufacture.
Additionally, our in-house QC testing covers development and validation of a variety of analytical methods (incl. biological assays), performance of stability studies, and characterisation of reference standards.
Richter BioLogics offers a full range of biopharmaceutical manufacturing services:
› Establishment of cell banks (MCB/WCB)
› In-house QC testing and release
› Stability studies according to ICH guidelines
› Strain and process development
› pART proprietary process– pDNA for different purposes at scales needed
› cGMP manufacturing for clinical phases I to III
› Commercial cGMP manufacturing
› Process validation and PPQ procedures
Thanks to the broad knowledge of Richter BioLogics’s experts and many decades of experience gained from different kinds of projects, Richter BioLogics works out tailor-made solutions for its customers worldwide, which include large pharmaceutical companies as well as advanced biotech companies.
We manage each of our customer projects individually and with the utmost dedication and flexibility - a guarantee for a successful and ongoing partnership.
The academic staff has many years of experience in the research and development of diagnostics
Founded (year) ›
Areas of Activity › Biological Patents › External › Collaborations Awards › and Certificates
1989
Development, production and marketing of diagnostics
ScheBo ®• Biotech AG holds many international patents in the above fields and owns a good intellectual property-position.
ScheBo ®• Biotech AG has academic alliances with several universities and university hospitals in Europe, the USA, Japan, Israel and Canada.
1993 – Hessian Innovation Award of the MBG
1998 – Hessian Innovation Award of the MBG
2002 – “Hidden Champion 2002”
2002 – “Innovationspreis der deutschen Wirtschaft“ (4 certificates)
2004 – Among the finalists for the “Innovationspreis der deutschen Wirtschaft”
Company profile
ScheBo®• Biotech AG is an innovative biotech company that is active in the fields of development, production and marketing of diagnostics. ScheBo ®• Biotech AG’s mission is to improve quality of health care by providing the best diagnostics with a focus on QUALITY, CLINICALLY RELEVANT INNOVATION and SIMPLICITY.
ScheBo ®• Biotech AG was founded by the biochemists and molecular biologists Ursula Scheefers-Borchel, PhD, and Hans Scheefers, PhD.
Subsidiaries
ScheBo ®• Biotech UK Ltd., founded: 1999
ScheBo ®• Biotech USA Inc., founded: 2001
The company
› is completely privately funded and independent, › operates internationally, › develops innovative diagnostics.
25 years of leading innovations
R&D and manufacturing led to the successful launch and sales of the following products:
1993 ScheBo ® • Biotech AG launched the world’s first non-invasive, cheap routine test procedure for monitoring the exocrine function of the pancreas. Today highlyregarded clinicians and medical text books regard the ScheBo ® • Pancreatic Elastase 1 ELISA, based on two monoclonal antibodies, as the “gold-standard” for noninvasive pancreatic exocrine function testing. ScheBo®• Biotech AG is world market leader for this FDA-cleared product. In 2013 the ScheBo ® • Pancreas Elastase 1 Quick™ test has been introduced as a point of care rapid test for the fast and reliable diagnosis/exclusion of Exocrine Pancreatic Insufficiency. Continuous innovation and strong customer focus have made ScheBo ® • Biotech AG a leading molecular diagnostic company.
Closing a gap
The ScheBo®• Tumor M2-PK™ EDTA-Plasma Test is the first test in the world which detects a metabolic state, specific to 11 cancer entities. The predictive value of Tumor M2-PK reflects tumour activity and aggressiveness. Thus, the ScheBo ® • Tumor M2-PK™ EDTAPlasma Test closes a gap in the clinical practice of cancer treatment management.
Fighting cancer, colorectal cancer screening
The ScheBo®• Tumor M2-PK™ Stool Test is the first test detecting pyruvate kinase in stool, an excellent biomarker for colorectal cancer screening. This test has a sensitivity of 85% and a specificity of 95%. In 2012, ScheBo ® • Biotech launched ScheBo ® • 2in1 Quick™ (M2-PK+Hb), a brand new innovative combined rapid test to simultaneously detect the enzyme biomarker M2-PK and human haemoglobin for improved colorectal cancer screening. By simultaneously testing for M2-PK and haemoglobin (Hb), both non-bleeding and bleeding colorectal cancers and polyps can be detected.
Name ›
Address/P.O. Box › Postal Code/City › State ›
Contact Person › Telephone › Email › Website › Social Media ›
Number of Employees › Founded (year) › Areas of Activity › Biological patent › External › collaborations
SciRhom GmbH
Am Klopferspitz 19 (IZB) 82152 Martinsried Bavaria
Dr. Jan Poth
+49-89-614241230 info@scirhom.com www.scirhom.com
I 9 2016
Preclinical and early clinical development of therapeutics with novel mode of action, treatment of autoimmune and inflammatory diseases, key inflammation pathways, iRhom2/TACE signal transduction biology
Comprehensive international patent portfolio
Hospital for Special Surgery, New York, expert academic collaborators, highly reputable Contract Research Organisations
SciRhom and its Vision
SciRhom is a pioneering biotech enterprise with the vision to translate advanced scientific findings into game-changing therapies for the treatment of autoimmune and inflammatory diseases.
Based on a decade of ground-breaking research by Prof. Carl Blobel, M.D., Ph.D., co-founder of SciRhom and Director of the Arthritis and Tissue Degeneration Program at Hospital for Special Surgery, New York, SciRhom is developing first-in-class antibodies against the cellular target protein iRhom2 for the selective inhibition of the inflammatory master switch TACE.
SciRhom’s Approach
TACE (TNFα converting enzyme or ADAM17) controls several major signalling pathways in health and disease, including TNFα, IL-6R, and EGFR signalling, and has therefore been considered a highly attractive target to block pro-inflammatory pathways. However, direct inhibition of TACE causes severe side effects, such as skin and intestinal lesions, since it leads to the blockade also of physiologically important and protective pathways. Very recently, iRhom2 (inactive Rhomboid 2, RHBDF2) was discovered as the exclusive key regulator of TACE for the disease-associated release of TNFα, IL-6R, and HB-EGF from immune cells. In contrast, the activation of TGFα as a crucial mediator of skin and intestinal barrier function is supported by both iRhom2 and its closely related family member iRhom1. SciRhom’s highly specific antibodies against only iRhom2 open the exciting opportunity to selectively and simultaneously target the iRhom2-mediated pro-inflammatory activities of TACE, while preserving its iRhom1-supported protective functions important for normal physiology. This new mode of action allows for a highly efficacious but safe treatment of various disorders, including major debilitating autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and lupus glomerulonephritis.
SciRhom’s Asset
SciRhom’s key asset is a series of first-in-class humanised monoclonal antibodies (mAbs) against iRhom2 with excellent physicochemical, pharmacokinetic, and pharmacological properties. Reflecting the simultaneous blockade of several disease-driving pathways and the restoration of immune-balancing mechanisms, our antibodies have proven superior efficacy over the current standard of care single pathway inhibitors Humira, Remicade, RoActemra, and Skyrizi in various disease mouse models. Further to the unique mode of action, our anti-iRhom2 antibodies promise a better tolerability and a real disease-modifying effect. The CMC development of the clinical candidate SR-878 and its toxicological assessment were successfully completed, and CTA approval of a first clinical study was obtained. Based on a recently closed series A financing round, SciRhom has entered SR-878 into clinical development with the goal to ultimately demonstrate clinical proof-of-concept in two indications. SciRhom’s antibodies are protected by four strong patent families that cover the antibodies themselves, their iRhom2 target epitopes, as well as their therapeutic use until 2039.
SciRhom’s Management
Our management team unites several decades of biotech and big pharma experience in advancing therapeutics into early clinical development and beyond, and consists of
› Jan Poth, Ph.D., Managing Director & CEO
› Jens Ruhe, Ph.D., Co-Founder, Managing Director & COO
Illustration of iRhom1/TACE and iRhom2/TACE complexes and their role in driving inflammatory processes (iRhom2/TACE) as well as protecting the skin & intestinal barrier (iRhom1/TACE and iRhom2/TACE)
Inhibiting iRhom2/TACE complexes by binding our antibody to iRhom2 simultaneously blocks a number of pathways driving inflammation, while the physiological effects, such as skin & intestinal barrier protection, are preserved through the activity of unaffected iRhom1/TACE complexes
Number of Employees › Founded (year) › Areas of Activity ›
SERVA Electrophoresis GmbH
Carl-Benz-Straße 7 69115 Heidelberg
Baden-Wuerttemberg
Dr. Marc Seidler
+49-6221-13840-0
+49-6221-13840-10
info@serva.de www.serva.de 45 1953
Laboratory (reagents, instruments), electrophoresis (precast gels, stains, markers, reagents and consumables, equipment); protein analysis (IEF, SDS PAGE, 2D, Western blotting)
Who we are
“SERVA Serving Scientists” is our mission to supply top quality products that meet the demands of the life sciences research community. The SERVA portfolio comprises fine biochemical reagents and products for the separation of biomolecules with a focus on electrophoresis specialties. All processes are subject to SERVA’s quality management system certified according to ISO 9001:2015.
The name “SERVA” has been well-known for more than 70 years. SERVA Electrophoresis GmbH was founded in 1998 as a mid-sized private-owned entity. As the successor of the former SERVA Feinbiochemica GmbH & Co KG originally established in 1953, the know-how and expertise in biochemistry and protein separation stay with us until today. The company is located in the heart of Heidelberg, a centre of excellence in life sciences research. Heidelberg is situated within the enlarged Rhine-Neckar metropolitan region, a multi-industrial area where many biotech companies, pharmaceutical, and chemical enterprises are based.
What we do: continuing product development in electrophoresis
Our strategy is to provide a comprehensive assortment of traditional as well as innovative specialties – all you need for your experiment. Well known in the community of Isoelectric Focusing (IEF) are the SERVALYT™️ carrier ampholyte buffers. At SERVA, we develop and produce special reagents for protein electrophoresis, e.g. precast gels (SERVALYT PRECOTES™️, FocusGel), markers, solutions, and stains. One of our latest and most famous technologies is “HPE™️” (High Performance Electrophoresis) – a workflow in protein analysis which combines horizontal conventional electrophoresis with superb resolution by applying a large gel format using a unique equipment (HPE™️ BlueHorizon™️ flatbed system). Based on requests from customers we have developed the complete workflow and protocols for various applications, e.g.:
› Isoelectric Focusing, analysing samples from food, plant, seeds, and diagnostics (e.g. urine, EPO)
› SDS PAGE 1D and 2D / DIGE Western blotting (proteomics, HCP coverage analysis)
› Fluorescent, colorimetric and chemiluminescent detection and documentation
SERVA ELECTROPHORESIS
But that’s not all. SERVA offers everything for common slab gel mini electrophoresis, calling it “PRiME TM” (Premium Resolution in Mini Electrophoresis) – precast gels, gel media, buffers, and blotting. Our equipment line called “BlueLine” supports electrophoretic separation and is exclusively available from SERVA and “made in Germany”. You have protocols in place that utilise products that are no longer available? Looking for replacement of “ExcelGel™️”, “PhastGel®”, or “Multiphor™️ II” or even an automated gel-staining device? No problem. We have the solution (and the products) to transfer those applications to state-of-the art technology utilising HPE™️
In 2025, LICORbio™️ strategically acquired SERVA Electrophoresis GmbH. The acquisition significantly broadens the electrophoresis offerings for both parties, allowing to deliver an end-to-end workflow with an expanded suite of products tailored to the evolving needs of proteomics researchers worldwide. The integration of SERVA’s proprietary technologies with LICORbio’s industry-leading imaging platforms will provide customers with complete workflow solutions from sample preparation and resolution to imaging and best-in-class quantification.
What we offer: service and support
–our application specialists are ready Our technical service department supports you with online services, videos, webinars, and workshops. Need assistance beyond the standard support? Our experts can help you to establish your workflow – e.g. antibody separation by IEF or 2D Western blot-based HCP analysis. From sample preparation to evaluation we provide confidential consultation for our customers – our know-how for your success.
Quality matters
Particularly in biotechnological production, compliance with quality standards is crucial for companies. SERVA offers qualification services (IOPQ) for our equipment line “BlueLine”. It is a unique service only available with us, carried out by our experts – from installation and operation quality assurance to process quality assurance within the framework of maintenance contracts, adapted to your needs at the silver, gold, or platinum level.
Evaluation of FFE-IEF-Separation. Fractions of MAP 7.6 after FFE-IEF separation on SERVA FocusGel pH 3-10 displays the narrow separation power of FreeFlow Electrophoresis
Odyssey product family of LICORbio™. Advanced documentation of NIR, visible fluorescence, RGB, and luminescence application of gels, blots or 96-well plates.
SERVA HPE™ BlueHorizon™ Flatbed Electrophoresis Chamber, with BluePower™ 3000 HPE™ PowerSupply
Name ›
Address/P.O. Box ›
Postal Code/City › State ›
Contact Person › Telephone › Fax › Email Address › Internet Website › Number of Employees › Founded (year) › Areas of Activity ›
Sirius Fine Chemicals SiChem GmbH
Fahrenheitstr.1
28359 Bremen
Bremen
Dr. Miriam Rittner
+49-421-2208-228
+49-421-2208-226
mrittner@sichem.de www.sichem.de 17 2001
l Tools for Life Sciences
l Custom syntheses
l Purification / (Enantio)separation
Sirius Fine Chemicals SiChem GmbH (SiChem) is a privately held company founded in 2001 in Bremen.
SiChem’s unique expertise is based on the synthesis of masked derivatives of compounds with biologically and pharmacologically increased bioavailability (prodrugs) that are usually not suitable for drug development. The masked drug candidates are successfully tested against several pathological conditions, for instance cystic fibrosis (CF), diarrhea, and inflammation. Some products have tested positively in animal and ex-vivo patient experiments.
Custom
synthesis / contract research
To complete complex projects for clients mainly from the biochemical, biomedical, and pharmaceutical sector requires concentration, flexibility, innovation, and also creativity. SiChem’s extensive experience in the area of custom synthesis / contract research helps to find optimum solutions for new tasks as well.
The SiChem team assists its clients competently until the agreed objectives are met, keeping in dialogue with them. Professional documentation is a matter of course.
SiChem’s chemical and technical know-how, which is constantly growing due to numerous custom syntheses from the pharmaceutical industry and biotech companies, is made available for new synthetic tasks and innovative research. Support is offered in the following areas:
› classical custom synthesis (building blocks and target structures) for medicinal research, pharmaceutical development, lead compound, and prodrug development from mg to kg scale.
› Synthesis of (API) metabolites (made synthetically or enzymatically) or stable labelled isotopes.
› FTE based research & development
Custom purification / enantioseparation
(www.prep4U.de)
SiChem offers comprehensive services around preparative HPLC:
› Purification of compounds (e.g. purification of APIs and intermediates, pesticides, natural produts / isolation of API impurities and metabolites
› Enantioseparation of racemic mixtures
SiChem has profound and longstanding experience in the area of preparative HPLC – regardless of whether it is 100mg or 100kg that needs to be separated and regardless of whether this is reversed phase (RP) or normal phase (NP). Columns of (almost) every size and various stationary phases from polar to nonpolar and chiral are available. For sensitive compounds, supercritical fluid chromatography (SFC) with CO2 as solvent is used. This technology makes a valuable contribution to the environment (Green Chemistry).
Tools for life sciences
SiChem synthesises fine chemicals and diagnostic tools for biochemical, biomedical, and pharmaceutical research. The core expertise is in the field of intracellular signaling, e.g. on derivatives of inositol phosphates. SiChem constantly develops new tools for R&D, especially photoactivatable and fluorescent compounds for which there is a fast growing demand.
The portfolio is complemented by innovative tools for click chemistry (Si-Click ®):
› clickable unnatural amino acids
› clickable dyes (Si-DYEs®)
› bi- and trifunctional clickable lipids
› clickable (PEGylated) tools
Name ›
Tentamus Pharma & Med Deutschland
GmbH, site Bad Kissingen
Address/P.O. Box › Postal Code/City › State › Telephone › Fax › Name ›
Columbiastraße 14 97688 Bad Kissingen
Bavaria
+49-971-78558-0
+49-971-78558-25
Tentamus Pharma & Med Deutschland
GmbH, site Karlsruhe
Address/P.O. Box › Postal Code/City › State › Telephone › Fax › Name
Am Hubengut 3
76149 Karlsruhe
Baden-Wuerttemberg
+49-721-957-919-500
+49-721-957-919-900
Tentamus Pharma & Med Deutschland GmbH, site Oldenburg
Address/P.O. Box › Postal Code/City › State
Telephone › Fax
Contact Persons
Email
Website › Social Media
Number of Employees › Founded (year) › Type of Laboratory › Areas of Activity ›
Würzburger Straße 3 26121 Oldenburg Lower Saxony
+49-441-350344-0
+49-441-350344-11
Dr. Christian Hummert info-tpmd@tentamus.com tentamus-pharma.de I I 100 2021 Contract laboratory for pharmaceutical and medical device analytics
Pharmaceuticals, medical devices, bio-analytics, in vitro analytics, instrumental analytics, cell and immune analytics, micro- and molecular biology, GMP laboratory
Tentamus Pharma & Med Deutschland GmbH (TPMD) is your Contract Laboratory for Pharmaceutical and Medical Device Analytics.
TPMD offers you the full range of testing for pharmaceuticals including cytostatics, narcotics and nitrosamines. We are able to determine element impurities according to ICH Q3D. We perform physical chemical analysis according to Ph. Eur., USP, JP, BP and support you in the whole process ranging from pre-clinical development to market batch release testing (e.g. clinical and pre-clinical samples, analytical method development and validation, stability studies, and release testing).
In respect to safety testing of medical devices, we offer a full range of accredited and ISO 10993 compliant analytics including chemical characterisation and residual ethylene oxide.
In the same context we focus on biocompatibility testing in vitro, offering a sophisticated test platform including the evaluation of cytotoxicity / genotoxicity / irritation to skin and eye / sensitisation / endotoxin and pyrogen analytics and microbial contamination (Bioburden)
Our microbiological department specialises on guideline-compliant purity testing of prokaryotic cell banks in combination with bacteriophage analytics.
In respect to molecular biology, we are perfectly equipped for qPCR analytics with respect to Ph. Eur. 2.6.7.
Within our department of cell & immune analytics, we focus on specialised cell models including the biological safety testing of eukaryotic cell banks (mycoplasma / adventitious agents in vitro / viruses, mycoplasma and more).
TPMD consists of three laboratory sites in Germany located in Bad Kissingen, Karlsruhe, and Oldenburg representing different areas of analytical services. We can handle biological samples up to biosafety level 2, narcotics and high-potency samples
Our laboratories are
› GMP-certified
› Registered with the FDA
› Accredited in accordance with ISO 17025
› Our microbiological laboratory is authorised to handle biosafety level 2 microorganisms (human and animal pathogens) and biosafety level 2 GMOs
› We have a license from the Federal Opium Agency of the German Federal Institute for Drugs and Medical Devices (BfArM) to handle various narcotic drugs.
› We offer batch certification and EU retests performed by qualified personnel.
› We hold a manufacturing license in accordance with section 13 of the German Drugs Act (AMG), which enables our qualified personnel to monitor pharmaceuticals testing and release products.
› We have a specially equipped cytostatic area in which we can safely process and analyse cytotoxic raw materials and narcotics
› We are specialised in analysing element impurities according to ICH Q3D
Name ›
Address/P.O. Box
Postal Code/City
State
Contact Person
Telephone
Email
Number of Employees
Founded (year)
Areas of Activity
Tosoh Bioscience GmbH
Im Leuschnerpark 4
64347 Griesheim
Hesse
Moritz Brüggemann
+49-6155-7043700
Info.tbg@tosoh.com www.tosohbioscience.de >50
1989
Supplier of chromatography instruments, media, HPLC and UHPLC columns
Application support in analysis and purification of biomolecules.
Tosoh Bioscience is an acknowledged global leader in the field of liquid chromatography with a focus on bioseparations. For more than 35 years, Tosoh Bioscience has been providing cutting-edge solutions to meet the needs of customers developing and producing new biologics, biosimilars, or biobetters, such as plasma products, monoclonal antibodies, recombinant proteins, vaccines, and oligonucleotides.
Our product portfolio encompasses analytical and preparative chromatography instruments and a comprehensive line of media and prepacked process development, HPLC, and UHPLC columns. These products are popular in the biotech and biopharmaceutical industry and are used in R&D, downstream processing, and quality control. Typical applications comprise the purification of therapeutic proteins in lab, pilot, and commercial scale, as well as their characterisation by HPLC or UHPLC.
Latest developments comprise prepacked columns for screening and method development of batch and continuous chromatography processes (SkillPak), Toyopearl Super A – a new Protein A resin for antibody purification, and a holistic multicolumn chromatography solution for DSP intensification, the Octave instrument. For analytical characterisation, we introduced a multiangle light scattering (MALS) detector and novel TSKgel size exclusion columns suited for native separation with MALS or mass spec detection, as well as several new hydrophobic interaction chemistries for ADC analysis.
Headquartered in Griesheim, Germany, in the Frankfurt/ Rhine-Main Metropolitan Region, Tosoh Bioscience’s European operations offer extensive technical support such as application development, on-site training and workshops. One of the services that stand out in the industry is the Tosoh Chromatography Workshop Series, providing a comprehensive background to the chromatographic purification of biomolecules.
Tosoh Bioscience is part of the Tosoh Group, a Japanese chemical and specialty products and materials group, founded in 1935, which comprises over 100 companies worldwide and a workforce of more than 13,000 people. Our brands TOYOPEARL® and TSKgel® are renowned for their quality and reliability. The stationary phases cover all common modes of liquid chromatography, including ion exchange, hydrophobic interaction, mixed mode, reversed phase, hydrophilic interaction, size exclusion and affinity.
Name
Address/P.O. Box › Postal Code/City
State
Contact Person
Telephone
Email
Website
Social Media
Number of Employees › Founded (year) › Type of Laboratory
Areas of Activity
TRIGA-S Scientific Solutions
Mühltal 5 82392 Habach Bavaria
Dr. Andreas Franke (Managing Director), Peter Glessner (Lead Sales & Marketing), Eugen Brenninger (Client Solutions Manager) +49-8847-695-78-0 info@triga-s.de www.triga-s.de
130+ 1998 Contract laboratory (BSL 2)
Services for Analytical and Clinical Performance Studies of In-Vitro Diagnostics (IVD), Companion Diagnostics (CDx) as well as Individual Services for IVD manufacturers and Pharma R&D:
| Contract Laboratory Testing and Application Work
| Sample Management and Processing
| Study Materials and Logistics
| Study Management and Monitoring | Biostatistics and Data Management
External
Collaborations Request for › Further Collaborations
Research institutes, clinics, contract development, and manufacturing organisations, and regulatory consultants
TRIGA-S seeks synergistic collaborations in the field of IVD development and pharmaceutical research
TRIGA-S:
Your Partner for In-Vitro Diagnostics and Pharma R&D
Fast, flexible, and tailored solutions for your research and development needs.
With over 25 years of experience, TRIGA-S is your trusted partner for in-vitro diagnostics. From feasibility studies to full clinical validation, we adapt to your needs with ISO 13485-certified S2 laboratories and GCP/ GCLP-qualified teams ensuring the highest quality and regulatory compliance.
How We Support IVD Development:
We specialise in the verification and validation of IVD products, guiding manufacturers through performance evaluations.
› Analytical performance studies: Validation of precision, sensitivity, specificity etc.
› Clinical performance studies: Planning, execution, and documentation in line with regulatory requirements.
› Feasibility studies: Initial feasibility testing and exploratory studies.
› Point-of-care simulation: Evaluating performance under realistic conditions.
How We Support Pharma R&D and CDx Development:
› Biomarker hypothesis testing.
› Rodent sample analysis (e.g., rats, mice) for exploratory studies.
› Custom collection kits and reference samples.
Customised Services:
Contract Laboratory Testing and Application Work:
› Analytical testing: Platforms for clinical chemistry, immunology, NAT, ELISA, and PCR.
› Custom Analytical Testing: Setup and operation of any analytical platform.
› Custom experiments: Validation and optimisation of diagnostic tests.
› Feasibility studies: Assessment of technical feasibility.
› Multiplex analyses: Measurement of multiple parameters from small sample volumes.
Sample Management and Processing:
Long-term storage at -80°C, -20°C, 2-8°C, RT, and
Sample processing: Aliquoting, pooling, dilution, and
Traceability: Modern LIMS for maximum transpar-
Kit assembly: Preparation and validation of collection kits. Reference and control samples.
› Global shipping: Coordination of sample transport with full traceability.
› Hazardous materials logistics: Safe transport of biological materials.
Study Management and Monitoring:
› Planning, coordination, and execution of analytical and clinical performance studies.
› Development of study plans / protocols, and reports.
› Site assessment, training, source data verification (SDV), and close-out visits.
› Regulatory support: Submissions to ethics committees and authorities, including IVDR/CFR guidance.
Biostatistics and Data Management:
Statistical consulting: Study design and sample size calculation.
Analysis plans and reports: Development of SAPs and SARs.
Data management: Setup and maintenance of EDC systems.
Why TRIGA-S?
› Regulatory expertise: IVDR-compliant services.
› Flexibility: No minimum order quantities – we handle even small projects.
› S2 laboratory: Safe handling of biologically demanding materials.
› Experience: Over 25 years in IVD development and ISO 13485 certification.
› Innovation support: Proof-of-concept analyses and assay optimisation.
Name ›
Address/P.O. Box ›
Postal Code/City › State ›
Contact Person › Telephone › Email › Website › Social Media ›
Number of Employees › Founded (year) ›
Areas of activity ›
Valicare GmbH
Eschborner Landstrasse 130-132 60489 Frankfurt on the Main Hesse Dr. E. Sons-Brinkmann +49-69-153-293-700/709 info@valicare.com www.valicare.com I > 100 2002
GMP Services for Pharma and Biotech with a special focus on Cell and Gene Therapies.
Valicare – Partner for strategic life cycle management in the GMP industry GMP regulations become more and more complex, challenging and time consuming. Lack of actual regulatory knowledge, human resources and short timelines are only some of the hurdles.
Valicare is not only a GMP service supplier but also a partner for strategic life cycle management in the GMP industry.
Knowing the business inside out, we support you efficiently from R&D to manufacturing of sterile medicinal products and cell and gene therapies, compliant to EU-GMP and Annex 1.
We enable seamless processes and offer sustainable solutions for any step of your GMP process from advice and guidance to practical on-site support.
About the company:
Valicare GmbH is headquartered in Frankfurt/Main since 2002 and a subsidiary of Syntegon Technology GmbH, a leading supplier of process and packaging technology and life cycle management. Valicare is ISO 9001:2015 certified and has a subsidiary (joint venture) in Turna, Slovakia. Around 120 experts work in GMP projects worldwide.
Multidisciplinary teams of engineers and scientists, experienced project managers, and senior GMP consultants support customers in the pharma, biotech, and medical device industries and manufacturers of cell and gene therapy products.
More than 5000 GMP projects have been successfully completed worldwide. Our approaches are always riskbased, and as ef ficient as possible.
Our services:
High-level GMP (and GxP) consulting support: › GMP, GAP, and target-performance analyses for every GxP topic and for quality systems according to DIN EN ISO 9001 and DIN EN ISO 13485
› Implementation or adaptation of GMP QA systems
› Structuring and moderation of workshops (risk analysis, risk assessment)
› Design and planning of GMP-compliant project work flows
› Definition of high-level process or project specifications (URS)
› GMP concepts for risk, change, or deviation management or validation strategies
› GMP for new and rebuild projects
› Documentation services (basic and demanding)
Risk-based, integrated quali fi cation and validation support in compliance with GMP, especially Annex 15.
Our services include, but are not limited to:
› Design review, plant-specific technical and process risk analyses
› Quali fi cation of equipment from laboratory to large machines and (clean) rooms, FAT, SAT, AFT
› Preparation of quali fi cation documentation and definition of test conditions
› Calibration and requali fi cation after modernisation, HMI upgrades after format change
› Quali fi cation and validation of biodecontamination processes in isolators as well as of inspection systems
› Validation of manufacturing processes, cleaning processes, analytical methods, and computer systems
Our passion: Accelerating GMP for cell and gene therapies
› Expert advice on the development, transfer, and implementation of straight and GMP-compliant ATMP manufacturing processes
› Our turnkey manufacturing concepts (valicare.tainer; cult.tainer), consisting of fully equipped GMP- and Annex 1 compliant cleanroom modules, enable aseptic process development and manufacturing of ATMPs, accompanied and supported in all GMP issues by our experts on-site.
Co-create & co-succeed to reduce time to market.
Vetter Pharma International GmbH
Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Email ›
Eywiesenstrasse 5
88212 Ravensburg
Baden-Wuerttemberg
Lars Hahn
+49-751-3700-0
EU and other international inquiries: info@vetter-pharma.com
US inquiries: infoUS@vetter-pharma.com
Website › Number of Employees › Founded (year) ›
Areas of Activity ›
Asia Pacific inquiries: info@vetter-pharma.com www.vetter-pharma.com
7,300 1950
Drug product development, aseptic clinical and commercial fill and finish, device assembly and packaging, analytical services, regulatory support, logistic services Name ›
We place heightened focus on your success as your strategic partner
We produce aseptically prefilled syringes, cartridges, vials and dual-chamber systems as a globally operating CDMO partner. We are a family-owned, independent company rooted in 75+ years of history. We do not manufacture our own drugs – we focus on providing highly skilled support and state-of-the-art manufacturing resources. We support our customers from the initial phases of clinical drug product development and filling to commercial manufacturing, device assembly and packaging, and lifecycle management. Over 80% of our active projects are biologics.
We are a reliable, responsive, and progressive partner
Our portfolio of services includes dedicated resources for clinical development and commercial manufacturing as well as assembly and packaging, and more. We provide tailored solutions to meet your product’s specific market needs.
Services
› Drug Product Development
Support in navigating key early decisions in your product’s evolution with scalability, quality and efficiency in mind.
› Aseptic Filling & Visual Inspection
Comprehensive expertise in manufacturing injectable drug products and related visual inspection systems.
› Device Assembly & Packaging
Strategic, technical and packaging support for patient-friendly combination products.
› Analytical Services
Robust, customizable testing methods for drug products including evaluation and quality verification.
› Regulatory Support
Support to achieve milestones related to compliance during clinical development, market authorization and beyond.
› Logistic Services
Cutting-edge solutions that maximize efficiency, transparency and precision of a vital supply chain.
Fast facts: Vetter-at-a-glance
› Headquartered in Ravensburg, Germany
› Commercial production sites in Ravensburg and Langenargen, Germany
› Dedicated clinical production facilities in Rankweil, Austria, and Chicago, USA
› Branch offices for Asia Pacific in Singapore, Japan, South Korea, and China
› More than 7,300 employees worldwide
› A leading specialist in the development, aseptic production, assembly and secondary packaging of prefilled drug delivery systems
› International expertise with regulatory authorities including FDA, EMA, PMDA (Japan), and RP (Germany)
› Service offerings for pharma and biotech firms of all sizes and locations
› Numerous patents including technologies for protection against tampering and counterfeiting
› Lyophilization (freeze-drying) and siliconization specialist
For more information, please scan the QR code.
Name ›
Address/P.O. Box › Postal Code/City › State ›
Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Email › Website › Social Media › Number of Employees › Founded (year) › Areas of activity ›
Dr. Julia Neugebauer +49-345-555-99-00 info@vivoryon.com www.vivoryon.com I 14 1997
Diabetic kidney disease, inflammatory and fibrotic disorders
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY) is a clinical-stage biotechnology company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases.
About VIVORYON
Driven by our passion for ground-breaking science and innovation, we strive to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins.
Building on our in-depth expertise in post-translational modifications, we develop medicines that modulate the activity and stability of proteins altered in disease settings. The mechanisms of action underlying our approach enable us to target a variety of disease areas where there is a high medical need.
Lead candidate VAROGLUTAMSTAT
We are developing a pipeline of orally administered small molecule inhibitors of glutaminyl cyclases, with our most advanced medicine in development, varoglutamstat (PQ912), having demonstrated a beneficial effect on kidney function in two independent Phase II studies in an elderly patient population. Varoglutamstat is being evaluated for the treatment of diabetic kidney disease (DKD), and has therapeutic potential to treat inflammatory and fibrotic diseases, neurodegenerative diseases and more.
Varoglutamstat targets the glutaminyl cyclases QPCT and QPCTL. These enzymes catalyse a specific posttranslational modification process known as pyroglutamate formation, which is the formation of a ring at the N-terminus of a number of different peptides and proteins. This post-translational modification changes the properties of the proteins and the modified proteins have been shown to play important roles in causing or promoting a number of different diseases. Blocking these enzymes to prevent the modifications enables an intervention early in the different pathologic pathways.
Varoglutamstat has not yet been approved by any regulatory authority, and its safety and efficacy have not yet been established.
Name ›
Address/P.O. Box › Postal Code/City › State
Contact Person
Telephone
Email
Website
Social Media
Number of Employees
Founded (year)
Wacker Biotech
Hans-Knöll-Strasse 3 07745 Jena Thuringia
Dr. Ilona Koebsch +49-3641-5348-0 info.biologics@wacker.com www.wacker.com/biologics
Wacker Biotech is the all-in-one expert CDMO partner for process development and manufacturing of advanced therapies and vaccines, as well as live microbial products (LMPs) and recombinant proteins based on microbial systems. Our advanced therapies capabilities span the full manufacturing value chain, from the production of plasmid and template DNA as a starting material for mRNA through the IVT of RNA to lipid nanoparticle (LNP) formulation.
Wacker Biotech is wholly owned by Munich, Germanybased Wacker Chemie AG, a publicly traded company founded in 1914 that has pioneered some of the modern era’s leading chemical and biochemical manufacturing advances.
Areas of Activity
| CDMO | Biologics | cGMP-Compliant Manufacturing | Process Development | R&D and Preclinical to Clinical and Commercial Drug Supply
Our Global Sites & Capacities
A pioneer in microbial production with decades of experience, Wacker Biotech consists of four complementary, state-of-the-art sites: Amsterdam (Netherlands), Halle and Jena (Germany) and San Diego (USA). Our sites have received approvals from all the major regulatory agencies, including EMA and the FDA. We have the capability to produce at diverse scales, with 10 GMP lines offering capacities ranging from 3 L for research-grade material up to 1500 L for high-quality clinical and commercial GMP supply.
Scientific Research Expertise
Complementing our bioprocess development and manufacturing experts at our four global sites is a team of more than 180 dedicated research scientists at our parent company’s R&D hub in Munich, including approximately 30 focused just on nucleic acids. This team continuously leads new technological innovations and manages more than 200 active and pending patents and 35 active academic and industry collaborations.
Our Track Record
We have led multiple programmes throughout the entire product lifecycle from feasibility runs to commercial manufacturing. Some of the released commercial products manufactured at our sites include Vaxchora ® , an attenuated oral cholera vaccine, and Spectrila®, an
injectable for treating acute lymphoblastic leukaemia via the protein enzyme asparaginase. We have managed more than 200 projects for our clients.
In Wacker Biotech, you have a flexible partner offering science-driven solutions and guidance from concept to commercialisation.
Products at a Glance
› pDNA -> RNA -> LNP
› Recombinant proteins (based on microbial systems)
› Live microbial products
› Vaccines (mRNA, protein, polysaccharide, live attenuated, inactivated)
E. coli strain for expression of insoluble proteins that has demonstrated a 20x increase in productivity
› LIBATEC ® – platform for producing live microbial products including live bacterial therapeutics in a monoseptic environment in both aeorobic and nonaerobic fermentation regimes
› PLASMITEC ® – platform for producing supercoiled/ linearised plasmid DNA (pDNA)
Name ›
Address/P.O. Box ›
Postal Code/City › State
Contact Person
Telephone
Fax
Email
Website
Number of Employees
Founded (year)
Areas of Activity
Waldeck GmbH & Co. KG
Havixbecker Str. 62
48161 Münster
North Rhine Westphalia
Saskia Rauner
+49-2534-970-0
+49-2534-970-258 info@waldeck-ms.de www.waldeck-ms.de ~ 75 1868 by Arnold Waldeck
Contract Manufacturing
| Long-standing experience in contract manufacturing and contract filling of liquid chemical and medical products.
Contract Filling
| Efficient filling solutions for small and medium batches of wet chemical products.
BLR-Products
| Best Liquid Reagents directly from our laboratory.
Waldeck
GmbH & Co. KG
Tradition Meets Innovation
Waldeck GmbH & Co. was founded in 1868 by Arnold Waldeck in Münster. The company initially specialised in pharmaceuticals and related products, serving scientific institutes and laboratories at the University of Münster.
Today, we specialise in contract manufacturing, filling and packing, focusing on custom solutions for liquid chemical and medical products in the life sciences sector.
Our many years of experience ensure reliable highquality contract manufacturing and filling services.
Modern production machinery and highly trained staff ensure consistently high product quality. Our facilities include an ISO Class 8 cleanroom and a dedicated filling area for solutions and liquids. We constantly strive to integrate innovative procedures and are continuously optimising our processes.
Contract Manufacturing
Waldeck is a service provider and partner for several aspects of contract manufacturing. The manufacture of wet chemical products is one of our core services, supported by extensive expertise, consistent product quality, and proven reliability. Our product portfolio encompasses a wide variety of laboratory products and organic solvents for a broad range of applications. In addition, we can also manufacture custom solutions to required formulations. By specialising in products for the healthcare sector, Waldeck provides particular benefits to customers in the medical and scientific sectors.
Our many years of experience guarantee outstanding solutions for a wide range of requirements.
Member of
From buffer and cell wash solutions, acids, alkalis and stain solutions to reagents and more, Waldeck ensures that all services maintain consistently high quality.
Contract Filling
Waldeck offers an efficient filling process, particularly for small-to-medium quantities.
Rather than large-scale industrial production, we offer contract filling of liquid chemical and medical solutions in batch sizes tailored to your requirements. We fill glass or plastic containers – including jars, jerrycans, cans, bottles and syringes – ranging from 2 ml to 25 l according to customer specifications. We can also produce one-off promotional products for you and help you meet short-term spikes in demand.
Waldeck processes a wide range of liquid chemical products – from hydrochloric acid and buffer solutions to silver nitrate, sodium hydroxide and other aqueous solutions.
Waldeck – Qualified to the Highest Standards
Regular certification of our business activities builds trust: trust in our suppliers and the confidence our partners place in us. That is why Waldeck has been certified in accordance with DIN EN ISO 9001 since 1995, and in compliance with DIN EN ISO 13485 since 2011.
For more information, please contact us!
Name ›
Address/P.O. Box ›
Postal Code/City › State › Contact Person ›
X-act Cologne Clinical Research GmbH
Rudi-Conin-Strasse 4 50829 Cologne North Rhine-Westphalia
Olivia F. Hoffmann, Sales & Marketing Manager
Jasmin Atarodi, Managing Director
Andreas Fichtner, Head Biostatistical Services
Ilka Strehlau, Head Clinical Data Management
Telephone › Fax › Email › Website › Social Media › Number of Employees › Founded (year) ›
Areas of Activity ›
+49-221-337716-0 +49-221-337716-33
business@x-act-cologne.com x-act-cologne.com I 35+ 1994
Clinical Data Management
Biostatistical Services
Medical Writing
Your Trusted Partner in Clinical Data Management & Biostatistics
From study planning to regulatory submission, we provide comprehensive support to ensure top quality and compliance. Our expert team offers tailored, efficient services that optimise processes, easing our clients’ workload. Committed to excellence and reliability, we support our clients in advancing medical research to deliver groundbreaking therapies globally. Let’s shape the future of healthcare together.
Company Overview
Type: Owner-managed CRO
Founded: 1994
Location: Cologne, Germany
Experience: 480 + successful studies (interventional Phase I – IV, non-interventional, medical device)
Team: 35 + seasoned and technology proficient team members contribute to the success of your project.
Biostatistical Services
› Consulting: Answering scientific questions with expert statistical advice
› Study Design: Sample size determination, inclusion of statistical input in protocols
› Randomisation: Customised randomisation plans and implementation
› Analysis Plans: Statistical Analysis Plans (SAP) with focused programming
› Data Mapping: SDTM and ADaM standards for study submission support
› Reporting: Comprehensive biostatistical reports for studies, publications, or dossiers
› CRF Design and Implementation: Aligned with CDSIC | CDASH standards
› Documentation: Creation of essential DM documents for project success
› Best Practices: Implementation of Good Clinical Data Management Practices
› Procedures: Supported by robust and harmonised SOPs
› Collaboration: Work closely with the clinical team and medical experts to review and clean data
› Reporting: Comprehensive status updates for clarity and transparency
Interested in our Services?
Contact us at:
business@x-act-cologne.com
Name ›
Address/P.O. Box ›
Postal Code/City › State ›
Contact Person › Telephone › Fax › Email › Website › Social Media ›
Number of Employees › Founded (year) ›
Areas of Activity ›
YMC Europe GmbH
Schöttmannshof 19 46539 Dinslaken North Rhine-Westphalia
Dr. Carsten Weber
+49-2064-427-0
+49-2064-427-222 info@ymc.eu www.ymc.eu I Q
50 (Europe) 485 (worldwide) 1993
| Glass Columns for Lab and Pilot Scale
| Prepacked Glass Columns
| Laboratory Services
| Preparative Liquid Chromatography
| Analytical Liquid Chromatography
Your resource for chromatography
As a research-driven chromatography specialist, YMC provides chromatographic solutions for compounds such as peptides and proteins, mAbs, and ADCs, as well as oligonucleotides from R&D scale through scale-up to production and final quality control in your lab. We supply innovative bio-chromatography resins and columns for preparative processes, as well as highly reproducible BioLC-(U)HPLC-columns for SEC, IEX, RP, & HIC.
Furthermore, YMC glass columns in laboratory as well as pilot scale are designed to meet bio-chromatographers’ demands. You can choose them empty as well as prepacked according to your requirements by YMC’s inhouse packing service. In addition, you can make use of on-demand services for application support, screening, analytical, or preparative method development. Trainings on different chromatographic topics complement the products and services.
Innovations
The most recent and interesting developments include:
› The new standard for columns for bio-purification suitable for self-packing: YMC PilotPLUS
› Macro-porous AEX resin for the purification of large biomolecules: MacroSep IEX Q
› Innovative solutions for BioLC: YMC-Triart Bio (U) HPLC columns, also available in bioinert hardware
The broad and continuously growing portfolio of stationary phases especially designed for the separation of biomolecules provides high flexibility for the chromatographer and ensures successful lab results, day after day. Additionally, the availability of particle sizes from analytical to preparative scale guarantees smooth and easy scale-up processes.
Worldwide availability and support
YMC products are available worldwide through a dedicated support network that guarantees qualified and meaningful practical assistance with regard to method development, method transfer, method validation, purification services, and custom column packing – locally, personally, and efficiently. It is not only product specifications that represent YMC quality, but also the positive energy and dynamics of our employees, who provide competent and consistent performance together with pronounced reliability even for the most difficult and demanding separations. The YMC network consists of highly focused product specialist teams to provide active support for chromatographers.
Regulatory Support
Since all YMC processes and working procedures are thoroughly monitored and documented, YMC resins and glass columns are fully compliant with requirements. Full technical documentation is available to show compliance with all applicable regulations.
Name ›
YUMAB GmbH
Science Campus Braunschweig-Süd
Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Email › Website › Social Media › Number of Employees › Founded (year) › Type of Laboratory ›
Areas of Activity ›
Inhoffenstr. 7
38124 Braunschweig Lower Saxony
Dr. Inga Hochnadel +49-531-481170-0 info@yumab.com www.yumab.com I 30 2012 S1, S2 | Fully human antibody discovery & lead development | Antibody Libraries | Engineering & Humanization | R&D services (CRO) | Partnered innovation
Request for › Further Collaborations
YUMAB seeks clients & partners for human antibody development in the biopharma, biotech, & diagnostic industries.
Accelerating Biotherapeutic Innovation
YUMAB is a German biotech company offering contract and partnered research for the development of therapeutic antibodies from target to optimised lead candidates. The company was founded in 2012 with the aim of providing state-of-the-art and next-generation recombinant antibody technologies to researchers from early start-ups to biotech and biopharma industry, helping them to bridge the gap between research innovation and therapeutic application. Since then, the company has evolved into a global player advancing biomedicine by accelerating the development of next-generation biotherapeutics.
Translating Innovation by Technologies
The YUMAB ® antibody platform provides access to challenging targets, supports all antibody drug modalities and accelerates the development of biotherapeutics by addressing the needs of manufacturing and clinical development through advanced protein engineering and lead optimisation technologies. The company delivers fully human and humanised therapeutic antibody candidates that are the closest to the natural human antibody repertoire.
Our highly diverse, fully human antibody libraries contain >1011 natural antibody sequences and specificities to all types of antigens. In addition, YUMAB can also access very broad immune repertoires from different immunised animal species (mouse, rat, rabbit, chicken, llama …), maximising epitope and functional diversity to identify the optimal drug candidate for each target and any modality. Our powerful in-vitro discovery technologies are efficient for rare and difficult target antigens and allow for the pre-design of functional and biophysical properties. Antibody candidates are identified rapidly within weeks. They are highly developable into all antibody drug formats including full-length IgG, Fab, scFv, bi- and multispecific, CAR, fusion proteins, and ADCs. Our advanced protein engineering technologies include in silico and experimental platforms that deliver lead candidates with desirable biophysical properties and lowest immunogenicity optimal for manufacturing and clinical development.
Therapeutic antibody discovery & development
From Target to Lead
Proven Success
Our antibody platform has been proven in over 400 projects with more than 140 customers and partners worldwide, and by several drug candidates in clinical development. In 2020, YUMAB spun out CORAT Therapeutics to bring its proprietary COVID-19 antibody drug into the clinic in just 11 months. The virus-neutralising antibody COR-101 is uniquely designed to treat patients with high viral loads by not inducing unwanted immune responses. In addition, YUMAB is involved in numerous collaborations to develop novel technologies such as AI-assisted discovery and development, target discovery on tumour samples, mammalian display or TCR-like antibodies (TCRm).
Trusted and Collaborative Partner
YUMAB offers customised service and partnering concepts to accelerate the translation of your research innovation into drug development, with affordable entry costs, flexible licensing options, and no additional thirdparty obligations. Our team of experts is committed to close communication with clients and partners, providing advice and guidance throughout the antibody discovery and early development process.
YUMAB at a Glance
Therapeutic antibody platform
› Fully human libraries for low immunogenicity
› Broad immune repertoires of different species including close to human germline humanisation
› Canine & feline antibody libraries for animal health
› Optimised in vitro selection for difficult targets
› Rapid discovery within weeks
Direct link to lead development
› Advanced antibody lead development & optimisation
› All antibody modalities, all disease areas
› Robust, adjustable process, high success rates
YUMAB® platform
› Fully integrated discovery & development platform from target to optimised lead
› Modular projects with flexible entry & exit points
Flexible services, collaborations & partnering
› Fee-for-service & flexible licensing options
› No technology access fee
› Collaborative development
The leading biotech magazine in German
Focus on Germany, Austria and Switzerland: |transkript reports on biotechnology and life sciences in German-speaking Europe – competent, networked, never boring. As a printed magazine or daily updated online at transkript.de
Economy. Technology. Life. 2025 in its 31
ISSN 1435-5272
Subscription: transkript.de
transkript.de
Profiles of Service Providers
Name ›
BioM Biotech Cluster Development GmbH
Address/P.O. Box › Postal Code/City › State
Contact Person
Telephone
Email
Website
Social Media
Number of Employees › Founded (year)
Areas of Activity
Am Klopferspitz 19a
82152 Martinsried, Munich
Bavaria
Prof. Dr. Ralf Huss
+49-89-899679-0 info@bio-m.org www.bio-m.org
29 1997
| Supporting start-ups regarding foundation and financing with specialised coaching, training, and mentoring programmes
| Start-up Incubator MAxL (Munich Accelerator Life Sciences & Medicine)
| Supporting biotech and pharmaceutical companies with an extensive network
| Connecting Bavarian life sciences companies with national and international companies, investors, and relevant stakeholders
| National and international trade fairs, conferences and exhibitions
| Seminars and workshops
| Company database
| Online job market
| News, press releases, annual report „Biotech in Bavaria“
Bio M – Biotechnology Cluster Management for Munich and Bavaria
Since 1997, BioM has been the central network organisation for the biotechnology sector in Munich and Bavaria, commissioned by the Bavarian Ministry of Economic Affairs. As a non-profit organisation, BioM supports the biotech community in a variety of ways with its extensive network. The cluster management connects Bavarian life science companies with relevant national and international partners.
Bio M – central point of contact
› non-profit organisation funded by the Free State of Bavaria
› supporting start-ups and SMEs through specialised and customised business support services since 1997
› bringing together the key life sciences actors in Bavaria
› attracting international investors and industrial partners
› coaching founders and founders-to-be
› preparing the ground for a thriving and sustainable biotech economy in Bavaria
› connecting Bavarian biotechnology world-wide
Bavaria: the place for the medicine of the future
BioM recognises the challenges of the medicine of the future and promotes the innovation process by identifying and connecting matching partners from science, industry, medicine, and finance. By organising individual partnerings with global and local companies as well as scientific institutions, we help companies to find the right contacts and to cooperate with leading organisations. In addition, BioM offers a variety of workshops and training courses on industry-specific topics and advice on funding opportunities for small and medium-sized enterprises.
Bio M for founders
Bio M supports Bavarian biotech companies at every stage of setting up their business. Therefore, BioM has developed a unique support programme tailor-made for aspiring start-ups and entrepreneurs in the life sciences sector. In total, BioM has supported more than 250 startup companies in over 25 years.
From idea to success:
› Start-up Coaching – hands-on support
› Mentor Circle – get inspired by experts
› Pitch Days – raise money for your project
› BioEntrepreneur Bootcamp – validate your business idea
› BioAngels Investors Network – find the right investor
› m4 Award – for academic teams to spin-off
› MAxL – BioM pre-seed and early start-up incubator
MAxL – Munich Accelerator Life Sciences & Medicine
MAxL is BioM’s unique start-up incubator and supports selected Bavarian pre-seed and early-stage start-up teams from the life sciences and healthtech sectors with well-targeted funding. On 900m2 MAxL offers exclusive high-end infrastructure and access to a vibrant start-up community and BioM’s extensive network.
News - Events - Jobs - CompaniesReport
In addition, Bio M offers comprehensive information on its website www.bio-m.org: current news, a company database, event information, a job exchange, and much more. Every year Bio M publishes the report “Biotech in Bavaria”, a compilation of current business figures and success stories of the Bavarian biotechnology and pharmaceutical industry with a comprehensive company list and detailed company profiles.
Address/P.O.
Employees
Areas of Activity
biomindz
Standortentwicklungsgesellschaft
Mainz mbH
Taunusstr. 59-61
55118 Mainz
Rhineland-Palatinate
Felix Wälder
+49-6131-126280
info@biomindz.com
https://biomindz.com
I 7 2023
Integrated local economic development:
| promote growth, start-up and settlement conditions
Campus development:
| support for life science and biotechnology companies interested in setting up or growing at the Life Science Campus Mainz
Network development and management:
| enabling access to the biotech ecosystem in Mainz
The Life Science Hub Mainz –for People’s Benefit
Over the years, Mainz has developed a global reputation as a successful life sciences and biotechnology hub and today provides an ideal environment for both fundamental and application-based research as well as businesses.
The hub’s primary emphasis lies on immunology and individualised medicine, with a strong focus on oncology and the use of mRNA technologies. In addition, it boasts particularly strong expertise in diagnostics and analytics as well as other life sciences and technologies of the future.
The hub’s goal is based on a socially relevant core: life science and biotechnology from Mainz improve the quality of life of people – everywhere.
biomindz – to support the biotech industry
in Mainz
The city of Mainz is making targeted use of this dynamic momentum. To enable start-ups and companies to successfully establish and grow in Mainz, the biomindz Standortentwicklungsgesellschaft Mainz mbH was founded as a municipally owned company.
The aim is to support the state capital of Mainz in maintaining its dynamic development and sustainably developing the location as a hotspot for biotechnology and life sciences in Europe. Name
| connecting start-ups and companies with international companies and startups, investors and other relevant stakeholders
| organisation of regular networking events
International PR and marketing:
| advertising and communication activities
| presence at national and international fairs, exhibitions and conferences
Our services
The company’s activities are divided into four key areas:
› Integrated local economic development to promote growth, start-up and settlement conditions.
› Development of the Life Science Campus to attract companies to settle in the vicinity of the university, university medical center and university of applied sciences.
› Network development, to connect the various players and strengthen the existing ecosystem at the location.
› PR and marketing to raise the profile and market the location internationally.
Our promise
In Mainz you can successfully research, found and grow sustainably – for people’s benefit!
More information
On our website (https://biomindz.com), you will find information on the prospects, strengths, and potential for life science and biotechnology in Mainz. In addition, the website provides an overview of all life science and biotechnology companies as well as R&D organisations and research institutions. It offers direct contact with various experts who may help you if you are interested in the life science hub Mainz.
Name ›
Address/P.O. Box › Postal Code/City › State
Contact Person
Telephone
Fax
Email Address
Internet Website
Social Media
Number of Employees › Founded (year) › Areas of Activity ›
BIOPRO Baden-Württemberg, the state agency for the health economy, connects science, industry, and care, empowers stakeholders, and positions Baden -Württemberg as a leading hub for innovation and collaboration in health.
A Unique Healthcare Ecosystem
Baden - Württemberg offers the entire value chain – from cutting - edge research to global sales. The region is home not only to innovative SMEs but also to global leaders like Roche, Boehringer Ingelheim, and Aesculap. Biotechnology, medical technology, and pharma are embedded in strong networks of university hospitals and research institutions, while suppliers and service providers thrive through collaboration. A high-performing healthcare system – with leading providers and excellent care – ensures rapid translation of innovation to patients.
Building Bridges
BIOPRO Baden-Württemberg brings together science, industry, policy, and networks to spark innovation and strengthen Baden-Württemberg as a hub of healthcare excellence.
› Enabling translation across the continuum – from basic science to product development and market access.
› Fostering entrepreneurship and start-ups and cultivating an innovation-driven mindset.
› Supporting companies on their path to market access – from regulatory pathways to business-model transformation.
› Improving the framework conditions for the health and life sciences industry.
› Driving innovation, digitalisation and sustainability across the healthcare system.
› Providing evidence-based information and strategic guidance to political decision-makers – so policies keep pace with innovation and real-world needs.
› Positioning Baden-Württemberg on the global stage as a leading healthcare ecosystem.
From Strategy to Action
› Clear, impactful communication: audience-specific messaging, storytelling, and actionable translation of complex topics.
› Strong networks: connections across research, industry, care, and policy; partnerships and consortia; forums and matchmaking – structured through the innovative governance of the Forum Gesundheitsstandort Baden-Württemberg.
› Smart knowledge management: curated sector intelligence, evidence-based briefs and horizon scanning, best-practice sharing to scale innovation.
Name › Address/P.O. Box › Postal Code/City › State › Email › Website › Social Media › Number of Members › Founded (year) › Areas of Activity ›
btS – Life Sciences
Studierendeninitiative e.V. btS e.V.
Jacobsenweg 61 13509 Berlin Berlin kooperationen@bts-ev.de https://bts-ev.de/ F I I
More than 1,100 members 1996
On a nationwide level, we organise biannual career fairs, the “ScieCons”, and we are running an online tool called “ScieMatch” to match talents with companies based on the cultural fit. At the local level, we organise excursions, company presentations, workshops, and various other events.
External › Collaborations
The success of our commitment to life science students is enabled by the support of our various partners, such as Thermo Fisher Scientific Inc., jobvector GmbH, A.S.I. Wirtschaftsberatung AG, BIOCOM AG, BIO Deutschland e.V., Gesellschaft für Virologie e.V., VBIO e.V. and Verband deutscher Studierendeninitiativen e.V.
Request for › Further Collaborations
btS is always interested in new partners and collaborations. There is a wide variety of possible projects and events you can be part of. Please feel free to contact us if you are interested.
The btS – Life Sciences Studierendeninitiative e.V. is a Germany-based student initiative that is active in 21 cities all over Germany. With various activities, btS creates an interface between students, universities, research institutes and companies. For this purpose, we organise career fairs, excursions, networking events, lectures, workshops and scientific symposia.
With more than 1100 members, btS is the largest student initiative in the life science sector. In addition to the large network of students, we are supported by alumni and associate members from both university and industry backgrounds.
We offer students the chance to realise their creative ideas and gain valuable experience for their personal development. In addition to the acquisition of key competences in areas such as project management, communication, time management, leadership and teamwork, our members get insights into various fields of work early on during their studies since we work together with many different partners from academia and industry.
Opportunities for partnering up with btS
Would you like to get in touch with highly skilled life science students? In this case, btS is the perfect partner for you! We offer a wide range of events, contributions to our career blog and newsletters as well as other cooperation opportunities. In addition to bringing you to the university, we are also interested in organising an excursion to your company. Those local events offer unprecedented insights for the participating students.
Member of
Another great chance to meet many life science students face-to-face is our career fair ScieCon. The fair is specifically targeted to students, graduates and doctoral candidates in the field of life sciences and offers a perfect link between industry and academic education. The ScieCon attracts students from local universities and from all over Germany. It offers companies a platform for self-presentation and recruiting new employees.
One of our latest achievements targets the need of companies to find graduates that share their company values and philosophy. Therefore, we have launched ScieMatch, a digital career matching platform that was awarded the Stifterverband’s Hochschulperle of the year 2021. Through our unique matching algorithm, we can bring talents to your attention that match with your company based on a high cultural fit. Other parts of the ScieMatch platform include job profile matching as well as a digital research group catalogue for students.
Do you want to ensure the long-term success of your life science company? Get the attention of the most committed life science students with a nationwide partnership with btS. Even a completely new format of cooperation is feasible.
DC Advisory’s global Healthcare team has extensive experience across a broad range of healthcare sub-sectors, with a track record in delivering results for clients, anywhere in the world.
Sub-sectors include: Care & Services
Healthcare IT & Supply Chain
Medtech & Life Sciences Pharma
DC Advisory is an international investment bank committed to making a difference. Part of Daiwa Securities Group Inc., we offer access to over 750 professionals in 24 locations throughout Asia, Europe, and the US. Across 11 industry-focused teams, we offer tailored, independent advice on M&A, debt raising and restructurings, private capital markets, secondary advisory, and access to unrivaled Asian investment knowledge.
Globally, DC Advisory has completed 80 Healthcare transactions since 2020. Selected notable transactions include:
› Isto Biologics, a portfolio company of Thompson Street Capital Partnes, on its majority stake sale to Keensight Capital
› Savanne Life Sciences on its majority investment in Franklin Biolabs
› Arlington Capital Partners and Riverpoint on the acquisition of CP Medical
› Blackstone on its acquisition of I`rom Group Co. Ltd
› Näder Holding on its €1.1bn debt financing to support buyback of shares from EQT
› Eurazeo on the sale of Peters Surgical to Advanced Medical Solutions Group plc
› Altor Equity Partners on the acquisition of VTU Group
› c-Lecta on the sale of a majority stake to Kerry Group
Key contacts
Martin Moser, Managing Director
Frankfurt am Main | Germany
Martin.Moser@dcadvisory.com
Dr. Wolfgang Kazmierowski, Managing Director
Frankfurt am Main | Germany
Wolfgang.Kazmierowski@dcadvisory.com
Andrew Murray-Lyon, Managing Director
London | United Kingdom
David Lyons, Managing Director
Dublin | Ireland
David.Lyons@dcadvisory.com
Joaquín Gonzalo, Managing Director
Madrid | Spain
Joaquin.Gonzalo@dcadvisory.com
Marzia Cormun, Director Milan | Italy
Marzia.Cormun@dcadvisory.com
Manish Gupta, Managing Director Chicago | United States Manish.Gupta@dcadvisory.com
Hector Torres, Managing Director Chicago | United States
Hector.Torres@dcadvisory.com
Rich Blann, Managing Director New York | United States
Richard.Blann@dcadvisory.com
Justin Balciunas, Managing Director Washington, D.C. | United States Justin.Balciunas@dcadvisory.com
Koki Kaita, Senior Managing Director Tokyo | Japan
l Collaborations with the scientific faculties on the Campus Martinsried l Munich Life Science Pitch Day with the High-Tech Gründerfonds Management GmbH l IZBrunch - Science meets Sciencs l Law Lab - law for biotech businesses
Hotspot for Life Sciences
The Innovation and Start-up Center for Biotechnology (IZB) with sites in Planegg-Martinsried and FreisingWeihenstephan near Munich is one of the leading biotechnology centres in Europe. The company Fördergesellschaft IZB mbH, founded in 1995, operates the IZB. The IZB hosts over 40 biotech companies with more than 700 employees across a 26,000 m² area. At the main site in Planegg-Martinsried, spanning 23,000 m², resident start-ups primarily focus on medical biotechnology. The IZB in Freising provides ideal conditions for founders in the life sciences sector.
Outstanding infrastructure
The IZB offers young companies a superior environment and infrastructure for realising their product and service ideas. Crucial for successful growth are S1 laboratories and office spaces that flexibly adapt to the companies‘ needs. Additionally, the IZB provides excellent infrastructure. At the Martinsried location, start-ups have access to modern conference rooms, a design hotel, the restaurants „The Bowl“ and „Seven and More“, as well as the Bio Kids kindergarten.
A strong network
Another vital success factor for IZB start-ups is the close proximity of both locations to cutting-edge research. On the Weihenstephan Campus, you’ll find the TUM school of Life Sciences of the Technical University of Munich, as well as the University of Applied Sciences Weihenstephan-Triesdorf. Adjacent to the IZB on the Martinsried/ Großhadern campus, you’ll find, among others, two Max Planck Institutes, faculties, and facilities of LMU, as well as the University Hospital of Munich-Großhadern. The close proximity of the scientific institutes around the Martinsried campus provides an enormous competitive advantage. Young scientists can benefit from incorporating scientific and research expertise into their own companies; short distances promote interaction and cooperation between biotech companies - in the face of globalisation, both factors are essential for successfully entering world markets.
The IZB fosters and supports this strong network through various measures: The Faculty Club offers an exceptional venue for founders and scientists to exchange ideas and know-how. With an array of event formats like the IZBrunch and the Munich Life Science Pitch Day, the IZB has established itself as a key meeting point in the industry, extending far beyond Munich.
IZB – in brief
› 26,000 m2 laboratory and office space for start-ups and growing companies
› Home for nearly 40 start-ups
› Business development support
› In-house estate management
› Center of an impressive research campus
› Access to an international network
› Flexible lab and office structures
› Close contacts with investment partners
› Joint location marketing
› Attractive, modern conference rooms, also for external booking
› IZB Residence CAMPUS AT HOME (42 Rooms)
› Faculty Club G2B
› Restaurants: SEVEN AND MORE and THE BOWL Food Lounge
› 2 day care centres (Bio Kids & Bio Kids2)
Visit us: Get our Newsletter:
Name ›
GKM Gesellschaft für Therapieforschung mbH
Address/P.O. Box › Postal Code/City › State
Contact Person
Telephone
Email
Website
Social Media
Number of Employees
Founded (year)
Areas of Activity
Lessingstraße 14
80336 Munich
Bavaria
Daniela Seidl
+49-89-209120-884
d.seidl@gkm-therapieforschung.de
www.gkm-therapieforschung.de
I Q
100 + 1981
Full-service CRO providing a comprehensive portfolio of CRO services for
| Clinical trials and non-interventional studies with pharmaceuticals
| Clinical and PMCF studies with medical devices
| Value dossier writing and consulting, health economic & outcome research
GKM – your full-service CRO
GKM is an independent, family-owned full-service CRO providing a comprehensive portfolio of CRO services since 1981. Our core competencies include studies with medicinal products, medical devices as well as early benefit assessment in the context of AMNOG and EU-HTA.
With over 1,100 clinical research projects completed and approximately 1.6 million patients across various indications involved, our highly experienced team consults and supports our clients throughout their national or international clinical projects deploying state-of-the-art technology and complying with the very latest standards.
As a mid-sized CRO, we are able to respond rapidly, efficiently and flexibly to your unique needs at every stage of your project. We are your strategic partner for the whole clinical development.
Key facts:
› Over 1,100 clinical projects
› Wealth of experience in a broad range of indications
› 100 + in-house professionals
› Outstanding personnel continuity
› High rate of academics and MDs
› Your strategic partner for the whole clinical development – from full-service packages to individual modular solutions
International coverage:
› DACH: 90 freelance CRAs
› World-wide: long term co-operations with our partner CROs
Competence:
› Clinical trials and non-interventional studies with pharmaceuticals
› Value dossier writing and consulting, health economic & outcome research
› Clinical and PMCF studies with medical devices
Services
› Concept & Design
· Medical & statistical consulting
· Feasibility analyses, sample size estimation
· Study design
· Definition of enrolment criteria, selection of adequate methods of measurement, patientrelevant endpoints
· Literature research, register searches
› Preparation & Material
· Study protocol / observational plan
· (e)CRF concept, patient information, informed consent form
· Questionnaires and PROs (electronic or paperbased)
· Regulatory & ethics
· Site recruitment, selection & contracts
› Realization & Support
· Data management & cleaning, query management
· EDC helpdesk
· Coding (performed by MDs)
· Interim analyses
· Clinical safety & medical surveillance (supervised by MDs)
· Training/consulting for and participation in oral hearings
Name ›
HealthCapital – Cluster Healthcare
Industries Berlin-Brandenburg
Address/P.O. Box › Postal Code/City › State ›
Contact Person › Telephone
Email
Website
Social Media
Areas of Activity › External › Collaborations
Fasanenstr. 85
10623 Berlin Berlin
Antonia Jung, Clustermanagement
+49-30-46302-463
healthcapital@berlin-partner.de www.healthcapital.de I #HealthCapitalBB
l Technology transfer between science and industry
l Initiation and support of networks
l Support for technology-oriented start-ups
l Funding support for innovative project concepts
l Providing and presenting regional life sciences information
l Building and coordinating of scientific and interdisciplinary networks
l Establishing contacts between experts from all disciplines
l Organisation of events and seminars, Public Relations work for the life sciences region
l Member of the Council of European Bioregions (CEBR)
l Member and contact point in Berlin for Enterprise Europe Network (EEN)
l Collaborations with European Life Science clusters and SMEs in several European projects and other activities
l Bio Deutschland
l Global Health Hub
The Berlin-Brandenburg BioRegion … … a Leading Hub for Life Sciences
The Berlin-Brandenburg region is one of the leading, international locations for life sciences. The area concentrates on clinical research via a dense and compact healthcare network, and boasts a state-of-the-art IT infrastructure. It is no coincidence that the region is Germany’s ‘health capital’ as it is home to both the German government, as well as the centre for healthcare industries.
The region’s distinction is anchored in its unique research and clinical landscape, as well as its ability to closely link the key players in the life sciences and healthcare. Biotechnology, in particular, is a strong driving force within the Berlin-Brandenburg healthcare industries cluster – HealthCapital – generating innovation and growth there and beyond. Through networking the pharmaceutical, diagnostics and medical technology sectors completely new fields of business are created. More than 300 biotechnology and 35 pharmaceutical companies are located in the German capital region. They include market leaders like Bayer, BERLIN-CHEMIE (Menarini), Daiichi Sankyo, Pfizer, Bausch + Lomb, Sanofi, and Takeda. Along with the sectors many small and mid-sized companies, they benefit from close cooperation, both with science and with more than 150 hospitals – above all, one of Europe´s largest university hospitals: Charité – Universitätsmedizin Berlin. Customers from research and industry have access to patient cohorts of urban and rural populations of about 180 ethnicities, covering all medical indications. The many technology parks and networks in the various branches of modern biotechnology create the excellent infrastructure and technological support that characterize the BerlinBrandenburg life sciences area. Focus of biotech activity within the region are biomedicine and diagnostics, therapeutics and regenerative medicine as well as industrial biotechnology.
… connected to the European Hotspots
Active cooperation in the networks of Europe’s BioRegions has played a central role in the internationalisation efforts in the region. The region is a member of the Council of European Bioregions (CEBR).
… offering Service and Support for Life Sciences in the Capital Region
The central contact and coordination office for all issues concerning life sciences in the German Capital Region is HealthCapital. At the interface of business, science and clinics, the HealthCapital cluster management drives networking and the technology transfer and supports companies interested in relocating to the region. Berlin Partner for Business and Technology and the Economic Development Agency Brandenburg (WFBB) are responsible for managing the cluster.
Meet us 2026 at
› RegMed Forum | February 19, Berlin, Germany
› bio:cap | June 9-11, Berlin, Germany
› BIO International Convention | June 22-25, San Diego, CA, USA
Name ›
Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Email › Website › Social Media › Number of Employees › Founded (year) › Areas of Activity ›
HOX Life Science GmbH
Wilhelm-Leuschner-Straße 68 60329 / Frankfurt a. M. Hesse
Dr. Michael Merli
+49-698700664-19 michael.merli@hox.de www.hox.de I I
70+ 2019 Human Relations & Business Consulting, Marketing Solutions, Life Science Career Companions & Academy
External › Collaborations
| btS – Life Sciences Studierendeninitiative e.V. | DKFZ Heidelberg
Just as HOX genes play a crucial role in embryonic development, at HOX Life Science we aim to make a vital contribution to the life science community. Since we ourselves are scientists with first-hand experience in the life sciences industry, we understand the language, needs, and requirements of our business partners and clients. Our motto is: “Scientists Supporting Scientists”.
HOX for Companies
Staffing, Recruiting & Employer Branding
Our holistic Human Relations Services Programme is tailored to the life science industry. To support and lighten the workload of internal HR, recruitment and staffing can be outsourced in full or in part, depending on actual needs. We will support you with customised solutions so that you can focus on your day-to-day operations even during peak times or staff shortages and still get in contact with many highly educated and experienced life science experts and specialists.
Candidates go through multiple steps in the candidate journey before they decide to apply to your company. We support you to improve the candidate experience along all touchpoints with your company as one part of our individually tailored employer branding strategy to position your company as an outstanding employer. With customised job ads and recruiting videos for social media and your webpage, we attract and retain suitable new employees for the long term.
Support in Marketing and Sales
We at HOX Life Science firmly believe that companies in the life science industry in particular need content-driven marketing concepts. This means that even when implementing the marketing mix, the focus should always be on the scientific content. After all, these are products that require clear explanations. Very often, advertising and selling life science products and pharmaceuticals involves observing special compliance rules.
According to our motto, “Scientists Supporting Scientists”, we offer marketing concepts tailored to the
life science industry along with the corresponding operational tools and measures. In joint sessions, we will develop the marketing strategy that meets the technical and scientific specifics of your product, and from there develop target-oriented marketing measures. We use intelligence to attract clients, not showmanship.
HOX for Experts
Job offers
At HOX, you can be sure that your expertise will be understood. We treat you as an individual and discuss your goals and wishes on a professional level. With our combined life science background and HR know-how, we support you honestly and competently in achieving your career goals. We maintain a strong partner network across:
› Pharma to biotech
› Food to chemistry
› Laboratory equipment & research products
› Diagnostics & medical technology
HOX Academy
Our online courses prepare scientists for careers in the life science industry:
› Business Administration: Understand the value chain of drug development, the role of marketing and sales, and career paths for scientists in pharma and biotech.
› Project Management: Learn Microsoft Project and apply real-world examples from the pharma and biotech industry to plan and manage projects effectively.
› Leadership: Many scientists aspire to leadership roles but are unsure about the required skills. Our course closes this gap by providing essential skills to guide your career towards management responsibilities.
Name
Address/P.O. Box
Postal Code/City
Contact Person
Telephone
Email
Social Media
Number of Employees
Founded (year)
Areas of Activity
iQ spaces Management GmbH
Neuer Wall 30 20354 Hamburg Hamburg
Vincent Wege, Jörg Hoffmann
+49-40-33468-3120 contact@iq-spaces.com www.iq-spaces.com I 8 2019
iQ spaces specialises in developing and renting high-tech laboratory, office, and research spaces tailored for the life sciences sector.
iQ spaces – Driving Innovation with Flexible Spaces
At iQ spaces, we understand the specialised needs of biotech and life science companies, thus we develop and let flexible laboratory, research, and office spaces that form the foundation for scientific discovery and breakthrough innovations.
Our facilities combine state-of-the-art infrastructure with modular layouts, providing the ideal environment for both established industry leaders and growing biotech firms.
Laboratory Solutions – Tailored to Your Growing Demands
We take pride in offering more than just spaces – we deliver highly specialised environments that cater to the technical and regulatory requirements of life sciences firms. From GMP-compliant labs to modular research and production facilities, we offer solutions that enable your teams to work efficiently and scale rapidly.
Each space is equipped with modular wet and dry labs, modern office setups, and scalable production zones, ensuring your operations are always supported with the right infrastructure.
Whether you’re in pharmaceutical R&D, medical diagnostics, or biomanufacturing, our laboratory solutions are fully customisable to your specifications.
A New Benchmark for Biotech in Berlin
Our new iQ space Berlin Center for Cell Therapies is a flagship 18,000 m² project developed with Charité and Bayer AG, supported by the Federal Government and the State of Berlin. Located on Bayer’s Nordhafen campus, this center will become a key hub for advanced gene and cell therapies. It includes GMP-ready labs, cleanrooms, and office spaces for start-ups and academic teams.
The center is designed to accelerate clinical translation by supporting early-stage ventures through access to production facilities, regulatory expertise, and translational know-how. Its goal: to strengthen Berlin as a leading biotech location.
Our other spaces:
› iQ space Potsdam, located in the heart of the Potsdam Science Park, offers research and office spaces tailored for high-demand users. Flexible layouts support lab, office, and documentation areas, while advanced building systems enhance energy efficiency.
› iQ space Munich North, in the Munich Airport Business Park, features customisable spaces for production, logistics, research, and offices. It combines modern infrastructure, efficient warehousing, and sustainable energy solutions.
Strategic Locations in Leading Science and Biotech Hubs
iQ spaces operates in life science clusters across Germany, offering facilities in proximity to academic institutions, industry peers, and innovation ecosystems. Our locations are chosen to promote synergies between research, commercialisation, and talent acquisition.
We eliminate the need for significant upfront capital investments by offering flexible leasing options, allowing companies to focus on what matters most: advancing science.
iQ spaces – Empowering Science
› Life science-focused: Tailored to meet GMP, GLP, and other regulatory standards.
› Flexible leasing: Expandable spaces that grow with your company’s needs.
› State-of-the-art infrastructure: Equipped with modular lab setups, advanced HVAC, and energy-efficient systems.
› Strategic locations: Proximity to top biotech clusters, academic institutions, and talent pools.
› Sustainability: Facilities designed to meet the highest environmental standards, crucial for future-proofing innovation.
| Supporting life science start-ups with state-of-the-art lab and coworking infrastructure in Goettingen and Munich
| needs-based approach and support for founders and researchers with comprehensive mentoring and accelerator programmes
| Supporting start-ups regarding foundation and financing with contacts and trainings
| Networking, interactive workshops and events
Our Accelerator Programme
Entrepreneurial Life Science
Accelerator with Fraunhofer AHEAD, Helmholtz Munich and H3 Health Hub
Life science made in Germany
With the non-profit, independent Life Science Factory, Sartorius aims to promote start-ups and attract founders from the life science sector. The Life Science Factory offers space and support for scientists willing to start up and young companies that want to take their first steps outside academic institutions. The goal is to mobilise the entrepreneurial spirit among researchers, identify future technologies, and support start-ups in the life science field to maximise the prospects for entrepreneurial success.
Location of choice for life science founders
In Göttingen in Lower Saxony, life science teams can research and realize their ideas on 3,300 square meters in a fully equipped S1-approved wet lab and in a fully equipped prototyping area including state-of-the-art equipment and full service. In the coworking space, flexible and fixed desks can be used to work together. The event space is a meeting place for founders and serves the exchange within the community. This infrastructure, embedded in a programme of mentoring and networking offers, guarantees young start-up teams a fruitful exchange and working in the midst of the life science community. Since the beginning of 2025, there has also been a Life Science Factory site in Munich. Here, startups also have access to fully equipped laboratories with state-of-the-art equipment and coworking and the access to the Life Science Factory programmes.
A vibrant environment for life science founders
Our curated community helps founders connect and collaborate with thought leaders, changemakers and industry experts. Our network understands entrepreneurship and the life science world. The constant interdisciplinary interaction within this ecosystem constantly stimulates new ways of thinking and solutions that redefine and stimulate our reality.
The Life Science Factory combines significant benefits for its users.
› Fast start in fully equipped infrastructure: Shared lab benches with state-of-the-art equipment and coworking space with flexible pricing models make it easy to get started. Your direct advantages:
In addition to the reduction of investments costs through fully equipped laboratories, the saving of costs for maintenance and the reduction of personnel costs, you profit from time savings and central services.
› Life Science Network: Contact with experienced entrepreneurs, top researchers and other relevant players in the life science sector and support through the Life Science Factory team.
› Know-how for entrepreneurs: Gain access to investors and learn fundraising strategies from successful entrepreneurs.
› Sandbox environment: Create and test prototypes in an isolated and fully equipped environment.
Name ›
Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Email › Website › Social Media › Number of Employees › Founded (year) › Areas of Activity › External › Collaborations
Life Science Nord Management GmbH
Steinhöft 5 20459 Hamburg Hamburg
Jan Phillip Denkers (PR & Communications Manager) +49-40-593-62-61-23 denkers@lifesciencenord.de www.lifesciencenord.de
I 20
2004 Cluster Management
| BIO Deutschland e. V.
| Council of BioRegions in Germany (AK-BioRegio)
| Council of European Bioregions (CEBR)
| Program “go-cluster”
| TransferAllianz e.V.
| Nordic Mentor Network for Entrepreneurship (NOME)
| MedTech Cluster Alliance D-A-CH
Together for Innovative Medicine
The Life Science Nord cluster in the federal states of Hamburg and Schleswig-Holstein embraces over 600 biotechnology, pharmaceutical, medical technology and digital health companies, clinics, and research institutes. More than 55,000 employees work in the industrial health economy.
Particular features of the cluster are the broad business base and the complete value chains from basic and applied research to clinical studies and the marketable end product. The outstanding, close cooperation between researchers, clinicians, and industrial partners in many fields is reflected in innovative products, projects, and technologies.
More than 300 Members, One Common Goal
The cluster management organisation Life Science Nord was set up by the Northern German federal states of Schleswig-Holstein and Hamburg to develop the cluster into a leading international life science network. The cluster agency Life Science Nord Management GmbH and the association Life Science Nord e.V. work as one together to achieve that goal.
More than 300 regional companies and institutions from the healthcare sector are active members of Life Science Nord. All members benefit from numerous competitive services and activities to promote regional networking, exchange experience and know-how, and jointly represent the life science sector of the two northernmost German federal states on a national and international level.
2024 Life Science Nord was awarded the GOLD label “Excel in Cluster Excellence” by the European Secretariat for Cluster Analysis (ESCA) for the fourth time in a row.
What Life Science Nord Offers
› Comprehensive support in initiating innovative projects, arranging contacts to experts, and providing know-how
› Fast and uncomplicated access to regional, national and EU funding programmes
› Admitting members to the network and helping them position themselves within the Life Science Nord cluster
› Extensive opportunities for collaboration within an international industry network
› Participation in leading international and national industry trade shows
› Providing data on business and technological capabilities in medical technology, biotechnology, and pharma in Northern Germany
› Comprehensive support and guidance for startups and investors.
› Providing the latest information on developments in business and science
› Organizing and hosting working groups, collaborative events, and networking activities
› Access to platforms on which the cluster players can exchange information and which support the dissemination of new developments in the cluster. This includes the online newsletter and the Life Science and online magazine, which can be read completely free of charge via the LSN website, as well as promoting cluster related news via social media.
Name ›
Address/P.O. Box ›
Postal Code/City › State ›
Contact Person › Telephone › Email › Website › Social Media ›
Number of Employees › Founded (year) › Areas of Activity ›
Lumis International GmbH
Giesebrechtstrasse 15 10629 Berlin Berlin Heike Schön
+49-30-235911-599 info@lumisinternational.com www.lumisinternational.com I
| Quality Management as a Service | Regulatory Consultancy for Medicines | Regulatory Consulting for Medical Devices
| Legal and Data Representation
Lumis International GmbH provides consulting services to small and mid-sized medical device and biopharmaceutical companies when outsourcing their clinical activities.
We offer services in the following areas:
› Regulatory support medicines: preparing, organising, and follow-up of scientific advice meetings with national authorities and EMA. Applying for orphan drug designation with EMA and supporting the application as Small Medium Enterprise (SME)
› Regulatory support for Medical Devices: CE marking, Technical File preparation, Conformity Assessment, Audit preparation, Notified Body Selection
› Oversight Project Management: vendor selection and management, clinical trial oversight management, Implementation of Project Management tools
› Quality management as service: analysis and establishment of complete quality management systems to enhance our client inspection readiness, Vendor and site audits
Jointly with our customers, we develop tailored solutions to optimise their clinical product development programs. We collaborate with a network of experienced subject matter experts, cooperation partners and consultants for the best services in the different areas. Small to midsize pharmaceutical and medical device companies often face the challenges of limited human resources. Thus, outsourcing clinical trials is the common way to proceed with clinical development. Moreover, the survival of such companies is frequently dependent on successful, timely completion of one or two critical clinical trials at limited budgets. Thus, high efficiency in managing clinical vendors is crucial, while the safety of patients and the quality of clinical data must not be compromised.
Especially during first clinical investigations, it is not easy for companies to decide which activities to outsource and which to perform in-house. Thus, each activity should be evaluated in advance:
› for its strategic importance
› for the main reasons to outsource, e.g. cost savings, access to clinical and/or regulatory experience
› for related risks and benefits, e.g. increased complexity of project and oversight management, access to opinion leaders
Lumis’ experts support the development and implementation of effective risk-based management systems for sponsors to ensure efficient and active monitoring and evaluation of vendor performance. We apply Key Performance Indicators to oversee the progress of clinical investigations. Moreover, the integration of a shared governance model is vital for success, by guaranteeing that the sponsor and vendor share one vision and have common goals. We optimise the interaction between sponsor, CROs and vendors by mastering different corporate cultures and expectations, so that your company will smoothly advance your drug development. Our experts have been creating successful partnerships between sponsors and CROs/vendors for over 20 years.
Platform for national and international stakeholders from science, industry, policy, society and regulatory authorities, Entrepreneurship Education for GCT, European GCTMapping, Technology Transfer, Information hub for GCT ecosystem via Newsletter, Linkedin, Website, etc.
A national task: Shaping the Medicine of the Future
Gene and Cell-Based Therapies (GCT) are key technologies that shape the healthcare of tomorrow. They do more than alleviate symptoms – they target the genetic root causes of disease. This gives them immense potential to transform healthcare and offer new hope to patients with severe and rare conditions for which no treatments currently exist. To unlock this potential, the Federal Ministry of Research, Technology and Space has launched the National Strategy for Gene and CellBased Therapies.
The national hub for GCT: The National Network Office GCT Germany
The National Network Office GCT Germany was founded as part of the National Strategy for Gene and Cell-Based Therapies (GCT). Acting as the central hub, we bring together national and international stakeholders from science, industry, policy, society and regulatory authorities. Our mission is to build a vibrant GCT community by providing independent information and fostering connections across all sites. By uniting the expertise and activities of stakeholders from every sector, we create powerful synergies that drive innovation and shape the medicine of the future.
Visibility, Networking & GMP-Facilities: The GCT-Atlas
The GCT-Atlas is the first comprehensive matchmaking platform for the GCT ecosystem. Started in Germany, it now expands to the European community – linking people, expertise, and infrastructure across borders. With just a few clicks, you can explore different layers – from clinics and research centers to e.g. patient organizations, GMP-facilities, industry, and investors. By overlaying them, the GCT-Atlas helps you match partners, expertise, and information tailored to your needs.
Member of
GeneNovate: Empowering Innovators and Entrepreneurs in Gene and Cell Therapies
Through Germany’s first nationwide entrepreneurship program, we empower top talents in medical and basic research to develop strong entrepreneurial skills and turn innovation into impact. By uniting local expertise and excellence in this highly innovative and forwardthinking field we are facilitating a new era of collaboration: Experienced guest speakers and top-notch mentors are guiding our participants along their journey. The national GeneNovate Network includes regulatory experts, TTOs, patent attorneys, VCs, business angels and many more. The GeneNovate Investors’ Day is a networking event that brings together translationally oriented project teams, international start-ups, investors, and experts from academia, industry, and politics. Its aim is to showcase the latest developments in gene and cell therapies and to identify promising investment opportunities.
Become visible, connect and join our national network GCT Germany!
Name ›
Address/P.O. Box ›
Postal Code/City
State
Contact Person
Telephone
Email
Website
Social Media
Number of Employees
Founded (year)
Areas of Activity
nova-Institut GmbH
Leyboldstraße 16 50354 Hürth North Rhine-Westphalia
Vanessa Kleinpeter +49-2233 4601400 contact@nova-institut.de www.nova-institute.eu I 50 1994
Research institute and science-based consultancy in the field of Renewable Carbon:
| Technology and Markets, | Economy and Policy, | Sustainability, | Communications
nova-Institute has been working in the field of sustainability since the mid-1990s and focuses today primarily on the topic of renewable carbon cycles (recycling, bioeconomy and CO2 utilisation/ CCU).
As an independent research institute and an internationally recognised think tank, nova supports in particular customers in chemical, plastics and materials industries with the transformation from fossil to renewable carbon from biomass, direct CO2 utilisation and recycling.
Scientific Expertise for a Climate-Neutral Future
Both in the accompanying research of international innovation projects and in individual, scientifically based management consulting, a multidisciplinary team of scientists at nova deals with the entire range of topics from renewable raw materials, technologies and markets, economics, political framework conditions, life cycle assessments and sustainability to communication, target groups and strategy development.
A team of 50 experts from various disciplines are working together on the defossilisation of the industry and for a climate neutral future. The members of the team at nova represent a wide range of academic and professional backgrounds, including materials science, policy, economics, chemistry, biology, environmental science, biotechnology, physics and communications.
Services of nova include in-house workshops, comprehensive reports, Life Cycle Assessments (LCAs), technology and market research, policy screening or communication plans – science based and independent.
Networking and Collaboration
nova-Institute offers extensive networking opportunities within the chemical and materials sector. With strong national and international connections in renewable carbon, sustainability, and the circular economy, nova enables partners to benefit from a broad professional network. The institute hosts four renowned conferences and several online nova webinars each year, providing platforms for knowledge exchange and visibility. Further networking options include a business directory of Renewable Carbon Companies, various newsletters including the daily Renewable Carbon News and the monthly nova newsletter, as well as an active LinkedIn community.
At nova, we bring our unique expertise to help your business make the transition to a climate-neutral future. Our focus areas include feedstocks, technologies, the intersection of economy and policy, sustainability, communications and strategy development. For this goal nova’s departments – technology & markets, economy & policy, sustainability, communications and the office of the Renewable Carbon Initiative – work closely and in an interdisciplinary approach to provide science-based advice to navigate your journey towards the defossilisation of the chemical and materials industry.
More information at: www.nova-institute.eu – www.renewable-carbon.eu
Name ›
Technical University of Munich (TUM), Campus Straubing for Biotechnology and Sustainability
Address/P.O. Box › Postal Code/City
Contact Person
Telephone
Email
Social Media
Number of Employees
Founded (year)
Areas of Activity
Petersgasse 5
94315 Straubing
Bavaria
Prof. Dr. Volker Sieber, Rector of TUM Campus Straubing +49-9421-187-0
info@cs.tum.de
https://www.cs.tum.de/en/
I I
400 2017
Biogenic Materials, Chemical Biotechnology, Data Science and Optimization, Economics and Sustainable Policy, Management and Sustainability, Renewable Energies, Sustainable Chemicals and Processes
Member of
Professors of TUMCS are members in several research or industrial associations and editorial boards. Some of the most relevant are e.g. the Royal Society of Chemistry, DECHEMA, the American Economic Association, the European Society of Operational Research and the Sachverständigenrat Bioökonomie Bayern.
The TUM Campus Straubing for Biotechnology and Sustainability (TUMCS) is an Integrative Research Institute of the Technical University of Munich (TUM). The mission of TUMCS is to enable the transformation of the economy and society towards sustainability. This mission is pursued by a profound interdisciplinary research and training in sustainable bio- and circular economy. Research and development of new technologies and concepts will only be successful when done interdisciplinary and combining different disciplines of natural sciences, engineering, and social sciences. Likewise, the transformation requires new professional profiles with the ability to think and act across the boundaries of disciplines. The special situation and unique selling point of TUMCS is that it bundles and connects the cross-cutting expertise and experts in the relevant fields of biotechnology, chemistry, economics, management, material science, process engineering and social sciences and places them under one roof.
Develop sustainable production processes
A strong research focus at TUMCS is on development and utilization of biotechnology for the conversion of renewable resources and renewable energy. The researchers work on fundamental concepts towards enhanced enzymatic and microbial systems (biochemistry, biocatalysis, bioinformatics, synthetic biology, etc.) to develop sustainable production processes for a wide range of basic and fine chemicals, fuels, materials, and pharmaceutical precursors.
To provide a platform to cooperate with external partners and industry, a Biofoundry was started as a virtual central unit at TUMCS. The SynBiofoundry@TUM offers a high-throughput technology platform to develop and optimize biotechnological production processes for academia and industry, integrating bioinformatics and machine learning approaches.
A Bio Scale-up Center Straubing is being established
TUMCS is embedded in a region dedicated to the use of biogenic raw materials and renewable energy. In the port of Straubing industrial area, a special zone has been reserved for the settlement of bioeconomy related companies.
The new Bio Scale-up Center Straubing, which is in the Technology and Start-up Center at the port, is intended to close the gap between laboratory and demonstration scale. The latest research results can be tested in the technical center and then transferred to demonstration scale. Placing the BioScale-up Center at this innovation hub was a strategic decision to further strengthen Straubing’s bioeconomy ecosystem. Creating synergies with TUMCS, the port is building its activities around driving innovation in the bioeconomy. Important facilities here are the Technology and Start-up Center, offering laboratory and office space, as well as developed building plots at an area reserved for bioeconomy companies.
Resident companies include CASCAT GmbH, MicroPyros GmbH, Microbify GmbH, Bayernhof BioTec, ADM, Fraunhofer IGB BioCat and Biofibre GmbH. The site is supported by BioCampus Straubing GmbH, a service provider, which fosters networking, start-up support and infrastructure development. A first-of-its-kind infrastructure project currently under construction is the BioCampus MultiPilot, a publicly accessible demonstration facility for scaling industrial biotech processes up to 25 m³.
Name ›
Wuesthoff & Wuesthoff
Patentanwälte und Rechtsanwalt PartG mbB
Address/P.O. Box › Postal Code/City › State › Contact Person › Telephone › Email › Website › Social Media › Number of Employees › Founded (year) ›
Areas of Activity ›
Schweigerstrasse 2 81541 Munich
Bavaria
Dr. Hendrik Wichmann +49-89-621-800-0 wichmann@wuesthoff.de www.wuesthoff.de I 120 1927 | Drafting IP rights | IP prosecution | Challenging IP rights | Defending IP rights | Litigation | IP strategy | Portfolio Management | Plant variety rights
You invent
Intellectual Property (IP), especially patents, trademarks, and designs, is usually the most valuable asset of companies in the biotechnology and pharmaceutical industry. For start-ups, IP rights are often the decisive factor in the next round of financing; for large companies, the IP-pipeline guarantees success in the longterm future; and for technology transfer centres, IP is the essential basis for the successful commercialisation of an innovation. Inventions in life sciences often have the potential to change the market or even open up a new market segment. At the same time, inventors may be confronted with challenges such as how to best protect early developments in a highly competitive field or particular exceptions from patentability.
We protect
Our Life Sciences team is committed to understanding your invention with all its implications and applications, transforming it into a solid platform for your business, and accompaning you throughout the entire commercialisation process. We support you against your competitors and fight for the best possible outcome with passion. The client’s success is our success.
Our background
Our team consists of scientists holding PhDs in the fields of biochemistry, chemistry, and biology. We are particularly happy that each of our patent attorneys completed his/her scientific training in a different life sciences specialisation, including antibody therapeutics, cell biology, DNA repair and organic/inorganic chemistry. In addition to our scientific expertise, we are legally certified as German and/or European Patent Attorneys with many years of experience. This allows us to offer you the best suited expert for your invention, or, if applicable, an efficient and goal-oriented team of experts for your case.
Our activities
Our activities range from evaluating invention reports, drafting, and prosecuting patent applications before the EPO and the German Patent and Trademark Office to nullity and infringement proceedings before German courts. Of course, we also provide support regarding FreedomTo-Operate Analyses (FTO) and Supplementary Protection Certificates (SPCs). Our clients include universities and highly recognised research institutes (tech transfer offices), start-ups, SMEs, and global players.
Contact us
We are happy to support you with our proven expertise and experience in all phases of the development of your products or services. Just reach out to us for a non-binding initial consultation with one of our experts.
